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Investigations into the Development of Epothilones as Antibody-Drug Conjugate Payloads 
Hunter David Imlay 
 
Cytotoxic natural products represent a class of cancer drug candidates that have remained 
largely untapped as payloads in the antibody-drug conjugate (ADC) therapeutic modality. The 
epothilones, a class of exquisitely cytotoxic natural products and their synthetic analogs, are a 
prime example, and our work has focused on the development of epothilones as ADC payloads. 
Strategies toward this goal have included total synthetic efforts toward four structurally distinct 
epothilone analogs equipped with linker functionality and structural modifications designed to 
improve metabolic and chemical stability. In addition, we have pursued the synthesis of octreotide-
epothilone conjugates, structures designed to target epothilones into cells that overexpress 
somatostatin receptors 2 and 5. Biological evaluation via in vitro cellular assays revealed one of 
our epothilone analogs as a promising epothilone-inspired ADC payload. Synthetic efforts toward 
these goals will be discussed. 
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CHAPTER 1: Introduction 
 Advances in cancer treatment over the last century have transformed this family of diseases 
from a near-certain death sentence into a treatable and often curable condition. Central to cancer 
treatment efforts and highly intertwined with organic chemical synthesis as a discipline is the broad 
field of cancer chemotherapy. From early studies examining the effects of nitrogen mustard on 
hematologic tumors to the current arsenal of synthetic small-molecule, natural-product, and 
biologic-based therapeutics available for cancer treatment, the progress achieved in this area is 
difficult to overstate. 
 The Leighton group has for many years been interested in the development of cytotoxic 
natural products as cancer therapies. Natural products and their derivatives account for 33 percent 
of drugs that received FDA approval between 1981 and 2014, demonstrating their importance as 
a class.1 Perhaps no molecule so clearly demonstrates the potential of natural products in cancer 
treatment as the blockbuster drug paclitaxel, a secondary metabolite originally isolated from the 
bark of Taxus brevifolia (Pacific yew) (Figure 1.1).2 Still, many natural products with promising 
biological activity remain unexploited in the clinical setting, and our lab has expended 
considerable effort in addressing some of the barriers to clinical use. 
 
Figure 1.1: Paclitaxel (Taxol). 
 One area in which the Leighton group has made significant strides in natural product 
development is through innovations in synthetic methods that allow for economical, scalable, and 





















based strain-release allylation and crotylation chemistry, we have developed asymmetric allylation 
and crotylation methodologies for the highly controlled installation of polyketide stereotriad and 
stereotetrad motifs. Such motifs are common in cytotoxic polyketide natural products, and we have 
leveraged our methodologies to accomplish efficient total syntheses of cytotoxic natural product 
analogs of spongistatin 1,7 epothilone B,8 and dictyostatin9 (Figure 1.2) in the last several years. 
 
Figure 1.2: a) spongistatin 1; b) epothilone B; c) dictyostatin. 
In contrast to our methodology development, a relatively new area of focus for our lab has 
been the investigation of polyketide natural products for use in antibody-drug conjugates (ADCs). 
ADCs are an example of the targeted delivery paradigm in cancer chemotherapy, and they 
represent a potential alternative method for deployment of cytotoxic natural products that have 
otherwise failed to gain clinical approval. We have investigated strategies to accomplish this goal 
in the context of spongistatin 1, dictyostatin, and epothilone B, as referenced above, and our efforts 
toward the goal of further development of epothilone analogs for ADC incorporation represent the 
focus of this work. New innovations in this area along with their historical context both within and 























































1.1 Overview of antibody-drug conjugates (ADCs) 
1.1.1 Definition and anatomy of ADCs 
 ADCs represent a highly promising and active area of research in cancer therapy. An 
example of the “magic bullet” theory initially proposed by Paul Ehrlich in the early 1900s,10 ADCs 
function by selectively delivering a cytotoxic payload to specific types of cells, typically tumor 
cells but also including cells of the tumor stroma,11 that overexpress cell surface antigens relative 
to healthy cells. Binding of the antibody to its target antigen leads to internalization of the ADC-
ligand complex, and subsequent release of the drug into the cell results in cell death.12 A secondary 
pathway implicated in certain drug and tumor types is the bystander effect by which internalized 
active drug is released from dying tumor cells during lysis and can enter neighboring tumor cells 
by passive diffusion across the cell membrane, exerting a secondary cytotoxic effect.13 In addition 
to their targeting abilities, ADCs also combine the cytotoxicity of highly potent small molecule 
drugs with the favorable pharmacokinetic properties of antibodies, including long plasma 
circulation times.13 This modality creates opportunities for the exploration of cytotoxic payloads 
that produce unacceptable systemic toxicity administered alone but that may enjoy more success 
in the context of an ADC. 
 ADCs are composed of three distinct components: a monoclonal antibody (mAb), chemical 
linkers, and cytotoxic payloads (Figure 1.3). Monoclonal antibodies are selected to bind 
overexpressed tumor cell surface antigens on tumors of interest. Early efforts in the development 
of ADCs utilized murine antibodies, but these were found in many cases to induce 
immunogenicity, leading to failure of the drug candidates. This issue was largely solved by the 
development of humanized mAbs.14 Chemical linkers fall into two broad categories: cleavable and 
non-cleavable. Cleavable linkers contain chemical functionality designed to lead to the 
 4 
fragmentation of the mAb-payload linkage upon exposure to certain chemical environments, 
including acidic, reductive, and enzymatic cleavage mechanisms. Non-cleavable linkers do not 
contain built-in cleavable functionality and instead rely on lysosomal or endosomal degradation to 
liberate the payload from the mAb.15 
 
Figure 1.3: ADC diagram showing constituent parts: humanized mAb, linker, and cytotoxic payload. 
 An important observation concerning ADC structure is the typical methods of linker 
attachment and the resulting heterogeneity of ADC therapies. Historically, linkers have typically 
been added via attachment to native lysine residues (amino group) or cysteine residues (sulfhydryl 
group liberated by reductive pretreatment of the mAb).12 The drug-antibody ratio (DAR), while 
theoretically a parameter that should be maximized for maximal delivery of payload, is limited by 
the aggregation and plasma clearance of ADCs that contain too many linker-payload moieties.16 
As such, the DAR must be optimized to a lower number, resulting in a statistical distribution of 
distinct ADCs within a therapeutic treatment. Indeed, each of the four currently-approved ADC 
therapies is composed of a heterogeneous mixture.17 
1.1.2 Characteristics of a successful ADC payload 
 For a cytotoxic drug to be a promising payload for an ADC therapy, it most importantly 
must exhibit high cytotoxicity, in the low nM to sub-nM range.18 The amount of drug able to reach 










expressed, tumor penetration of the ADC, intracellular trafficking, and ADC half-life. Indeed, it is 
estimated by theoretical calculations that only approximately 1 percent of administered drug 
reaches its intracellular target.14 As a result, the small amount of drug that acts on its desired target 
must exert a sufficiently powerful effect to produce the desired response of cell death. 
 
Figure 1.4: a) maytansine; b) DM1, the maytansinoid payload utilized in ado-trastuzumab emtansine, 
with extended linker functionality shown in red. 
A second requirement for a cytotoxic agent to be used as an ADC payload is the existence 
of a validated linking strategy (Figure 1.4). The nature of ADCs requires conjugation of the drug 
to the linker-mAb moiety via a covalent chemical linkage. Such a linkage can be achieved through 
either elaboration/extension of a functional group of the drug molecule to provide a functionality 
for attachment, or through direct attachment via a functionality on the natural payload. Necessarily, 
the presence of extended functionality must not significantly decrease cytotoxicity of the payload. 
Development of successful linking strategies can be achieved through SAR studies that identify 
modifiable regions of the molecules, an example of which can be seen in the development of ado-
trastuzumab emtansine, an ADC discussed in the following section.19 Currently, four ADCs are 











































1.1.3 Currently-approved ADC therapies and current pipeline 
 The first ADC to receive FDA approval was gemtuzumab ozogamicin (Mylotarg), which 
utilizes an anti-CD33 mAb, the DNA minor groove binder calicheamicin, and an acid-cleavable 
hydrazone linker (see Figure 1.5 for all approved ADCs). The therapy was fast-tracked for 
approval in 2000 for the treatment of acute myeloid leukemia (AML) for a subset of patients20 but 
was removed from the market in 2010 due to failure to demonstrate efficacy.21 However, later 
clinical studies involving additional patient stratification and changes to dosing regimens led to its 
reapproval in 2010 for a wider subset of AML patients.22 
 The second approved ADC therapy was brentuximab vedotin (Adcetris), which utilizes an 
anti-CD30 mAb, the tubulin destabilizer monomethyl auristatin E (MMAE, an analog of 
dolastatin-10), and a peptide cleavable linker cleaved by cathepsin B.23 The therapy was approved 
in 2011 for treatment of CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large 
cell lymphoma (ALCL). It has also shown success in clinical trials in combination with standard 
chemotherapy.24 
 
Figure 1.5: Currently-approved ADCs: a) gemtuzumab ozogamicin (Mylotarg); b) brentuximab vedotin. 
(Adcetris); c) ado-trastuzumab emtansine (Kadcyla); d) inotuzumab ozogamicin (Besponsa); multiple 






















































 Ado-trastuzumab emtansine (Kadcyla) represents the third approved ADC therapy, and it 
utilizes an anti-HER2 mAb, the tubulin destabilizer DM1 (a maytansinoid, also known as 
emtansine), and a non-cleavable linker. The therapy was approved in 2013 for HER2-positive 
metastatic breast cancer. Notably, Kadcyla was the first ADC therapy approved for a solid tumor 
indication.19 
 Finally, the latest ADC to gain clinical approval is inotuzumab ozogamicin (Besponsa), 
which utilizes an anti-CD22 mAb, an acid-labile hydrazone linker, and calicheamicin (also used 
in gemtuzumab ozogamicin).25 It was approved in 2017 for the treatment of relapsed or refractory 
B-cell precursor acute lymphoblastic leukemia (ALL).13 
 The relatively small number of approved ADCs belies the extensive attention this 
therapeutic modality is currently receiving, with over 60 ADCs under clinical investigation as of 
2019.13 ADCs are being pursued for a variety of cell surface targets, along with a variety of 
payloads with distinct mechanisms of action, including tubulin destabilization, DNA 
intercalation/crosslinking, and topoisomerase inhibition. However, tubulin stabilizers, including 
taxanes and epothilones, remain notably absent. We feel this absence provides a unique 
opportunity to contribute to the field of ADC payload development. Epothilones, in particular, 
have caught our attention for the last several years, and they will be the focus of the next section. 
1.2 Overview of epothilones 
1.2.1 Discovery and biology of the epothilones 
 Epothilones A and B (Figure 1.6), the two major naturally occurring epothilones, were 
initially isolated by Reichenbach and Höfle in 1987 from Sorangium cellulosum myxobacteria.26 
Originally investigated as antifungals, the compounds were also tested against a panel of cell lines 
at the National Cancer Institute and found to be highly active.26,27 In 1995, a team at Merck 
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identified the epothilones as sharing the tubulin-stabilizing mechanism of action and binding site 
of taxol, sparking renewed interest in the family of molecules.28 Both epothilones A and B 
demonstrated comparable activity to taxol in cell lines and an increased ability to induce tubulin 
polymerization in vivo, with epothilone B the more powerful of the two.  
 
Figure 1.6: Natural epothilones A and B, with standard numbering scheme shown on epothilone B. 
 
When compared against taxol in cancer cell lines, the epothilones had comparable activity 
in many cell lines but retained activity in multi-drug resistant (MDR) cell lines, indicating their 
potential as an alternative to taxol.29 Other promising properties of the epothilones include their 
enhanced water solubility compared to taxol, potentially negating the need for co-administration 
with side effect-inducing solubilizing agents;28 and their relatively simple structure compared to 
taxol, implicating total synthesis as a potential method for production of epothilone-based drug 
candidates. 
1.2.2 Early total synthetic efforts toward the epothilones 
 Following the publication of the absolute stereochemistry of the epothilones by Höfle in 
the mid 1990s,26 a flurry of total synthetic efforts toward epothilones were initiated, with early 
activity dominated by Nicolaou, Danishefsky, and Schinzer. Danishefsky and coworkers 
developed a creative approach to the total synthetic efforts in their use of a stereospecific B-alkyl 









































1.1).30 They utilized two distinct strategies for ring closing. The first involved macrolactonization 
to effect the transformation, achieved through unmasking of the acetal-protected aldehyde and 
subsequent aldol addition of t-butyl acetate, followed by ester deprotection and lactonization 
(Scheme 1.1c). The second and more unique strategy utilized macroaldolization to construct the 
 
Scheme 1.1: a) Danishefsky retrosynthetic strategies; b) example of aldolization strategy as applied to 












































PG = Ac (for R = H) or 






















































 C2-3 bond stereoselectively (Scheme 1.1b). Epoxidation of the C12-13 double bond occurred 
after ring closing using DMDO.31 Through this work, Danishefsky and coworkers became the first 
group to achieve the total synthesis of epothilones A and B. 
 The Danishefsky group continued to innovate in this area, including the application of 
RCM methodology to close the ring at the C12-13 bond. Using this strategy, they successfully 
synthesized epothilones C and D. 
The initial Nicolaou strategy toward the epothilones involved major disconnections at the 
lactone bond and the C12-13 olefin, with bond formation implemented by esterification and ring-
closing metathesis, respectively (Scheme 1.2).32 Using this strategy, they successfully 
accomplished the total synthesis of both epothilones A and C, although with a roughly equal 
mixture of Z/E isomers arising from closure of the C12-13 olefin (Scheme 1.2b). Later efforts 
focused on ring closing by macrolactonization (Scheme 1.2c), with construction of the C12-13 
olefin occurring by Wittig olefination, which was used to accomplish the synthesis of epothilones 
B and D. As in the case of olefin metathesis, mixtures of Z/E isomers were formed during the 
construction of the C12-13 bond.33  
 Schinzer and coworkers independently developed a disconnection strategy identical to that 
of the Nicolaou group to synthesize epothilone A and C, with major disconnections occurring at 
the lactone and C12-13 bonds and ring closing occurring via RCM and epoxidation occurring post 
ring closing.34 Their syntheses of epothilones B and D relied on macrolactonization for the ring 
closing step, and they utilized a modified version of Danishefsky’s B-alkyl Suzuki coupling to 
establish the C12-13 olefin geometry.35 Although their general disconnection strategies were  
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Scheme 1.2: a) Nicolaou retrosynthetic fragments as utilized in the RCM strategy; b) example of RCM 
strategy as applied to epothilone A/C; c) example of macrolactonization strategy (with not shown Wittig 
construction of the C12-13 bond) to epothilone B/D.27 
comparable, the two groups developed distinct methods to achieve the necessary precursors for 
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Scheme 1.3: a) Schinzer strategy toward fragment coupling of epothilone A/C utilizing esterification and 
RCM; b) fragment coupling for epothilones B/D utilizing B-alkyl Suzuki coupling, aldol, and 
macrolactonization. 
Total synthetic efforts occurring since this early work are numerous and have been 














































































strategies, a complete breakdown of which is beyond the scope of this work. Particular strategies 
relevant to the Leighton group’s total synthesis efforts toward the epothilones will be detailed in 
upcoming chapters. 
1.2.3 Clinical trials of epothilones and their analogs 
 Although initial indications during the investigation of epothilones as anticancer agents 
were promising, and with at least ten natural and synthetic epothilones clinically investigated to 
date, only one epothilone has advanced to clinical use. Ixabepilone, the lactam analog of epothilone 
B, received FDA approval in 2007 for the treatment of advanced and metastatic breast cancer.36 
Epothilone B, the only other epothilone to reach phase III in any cancer indication, was 
investigated for the treatment of ovarian cancer but failed to demonstrate higher efficacy than the 
standard of care.37 Iso-fludelone, a fluorinated analog that is discussed extensively in Chapter 3 
and showed promise in early investigations, has been in a Phase I trial for solid tumors since 2011 
and remains active to date (clinicaltrials.gov) (Figure 1.7).  
 
Figure 1.7: a) ixabepilone; b) iso-fludelone 
Utidelone (UTD1), a genetically engineered epothilone analog of undisclosed structure 
under development by Beijing Biostar Technologies, Ltd., completed a phase III trial in December 
2018 for breast cancer indications in combination with capecitabine with promising outcomes, but 































examples, successful transfer of epothilones to the clinic has been rare despite the attention given 
to the development of epothilones and the large number of epothilones currently in clinical trials. 
The epothilones remain largely unexplored as ADC payloads, and we see this reality as a potential 
approach to capitalize on the desirable properties of the epothilones where they have failed as 
small molecule drugs.  
1.3 Previous Leighton group efforts toward linker-equipped cytotoxic natural products 
1.3.1 Total synthesis of linker-equipped dictyostatin and spongistatin analogs 
 The Leighton group has long been interested in pursuing the total synthesis of polyketide 
natural products using efficient, economical, and scalable methods, both as a motivation for 
developing novel methodologies and to establish total synthesis as a viable method for industrial 
production of this class of natural products. To this end, we have pursued the total synthesis of 
zincophorin, dictyostatin, epothilone B, and spongistatin 1, among others.7–9,39 More recently, 
however, our interest has expanded beyond the use of polyketide natural products as small 
molecule drugs to include their potential as ADC payloads, which we first investigated in the 
context of the microtubule-stabilizing natural product dictyostatin. To establish a validated linker 
strategy for conjugation to an antibody, we pursued a “methyl extension” strategy, by which a 
methyl group on the natural product structure, hypothesized to be solvent exposed when the 
molecule is bound to its intracellular target, is elaborated into a functional alkyl chain.9 
 























dictyostatin analog A dictyostatin analog B
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The general strategy of extending an alkyl group instead of a more easily-modifiable 
heteroatom-containing functional group was inspired by the often-critical contributions of 
heteroatoms to ligand binding and hydrophobicity. We hypothesized that extending a well-selected 
alkyl group would minimize such drastic changes and provide a viable linker strategy. In work 
spearheaded by former Leighton group member Dr. Stephen Ho, we achieved the synthesis of two 
methyl-extended analogs of dictyostatin (Figure 1.8). As is detailed further in Chapter 2, two 
linker-equipped analogs largely retained the potency of the parent compound across several human 
cancer cell lines, encouraging further exploration of this strategy. 
 An alternative but similar approach to a linker extension strategy employed in the Leighton 
group was explored in the total synthesis of spongistatin 1 analogs. In work completed by former 
Leighton group member Dr. Makeda Tekle-Smith, with contributions from several others, the C15 
acetyl group was extended with two distinct azide-terminated alkyl and aryl chains to produce 
linker-equipped analogs.7 Gratifyingly, all analogs maintained the low- to sub-nanomolar 
cytotoxicity characteristic of the parent compound across several human cancer cell lines (Figure 
1.9). 
 
Figure 1.9: Spongistatin 1 ring-modified analog extension with GI50 values ranging from 0.06-0.15 nM 



























A: R = CH3
B: R = p-C6H4CH2CH2N3
C: R = CH2C(Me)2CH2CH2N3
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1.3.2 Total synthesis of epothilone B and linker-equipped epothilone B 
 
In work that became the inspiration for much of the contents of this dissertation, the 
Leighton group sought to employ the methyl extension strategy demonstrated in our linker-
equipped dictyostatin analogs in the context of the epothilone B scaffold. We took inspiration from 
novel methodologies developed during earlier work in our lab toward the efficient synthesis of 
epothilone B,40,41 as well as a recently published crystal structure of epothilone B bound to 
tubulin42 to pursue the total synthesis of a linker-equipped analog extended at the C6 methyl 
position. The C6 methyl group was chosen for modification due to its apparent solvent exposure 
in the bound conformation of the molecule.  
 
Figure 1.10: Epothilone B methyl extension with GI50 values ranging from 1-2 nM for Analog A and 0.9-
1.9 for Analog B in PC3 and A549 cells, compared to 1.7-2.1 nM for epothilone B.8 
We achieved the total synthesis of a linker-equipped epothilone B analog, with the C6 
methyl group extended into a chloride-capped n-butyl chain.8 The linker was then sequentially 
elaborated into azide, amine, and finally acetamide and alkyl ether amide functionalities to mimic 
potential attachment to an ADC linker via an amide bond (Figure 1.10). In the epothilone example, 
the methyl-extended analogs largely retained the potency of the parent compound against PC3 and 
A549 cell lines, further validating the methyl extension strategy as a viable method for linker 






































1.4 New Leighton group efforts toward epothilone ADC payload development 
1.4.1 Identification of acid-degradation pathway as epothilone vulnerability 
 In pursuing the development of an epothilone as an ADC payload, we have sought to 
address potential vulnerabilities of the epothilone molecule to degradation in the context of a 
targeted delivery therapy. We became aware of one such vulnerability that arose in the 
investigation of an aziridinyl epothilone-folate conjugate investigated by BMS and targeted to the 
folate receptor.43 In this work, the researchers studied degradation pathways of their synthesized 
drug candidate to optimize formulation of the drug. They found that, among other pathways, a 
prominent degradation pathway was a unique unimolecular cleavage mechanism that proceeded 
through an allylic carbocation intermediate, stabilized by the extended conjugation of the thiazole-
containing side chain. Notably, this degradation pathway occurred in the mildly-acidic pH range, 
leaving us concerned that it could be a potential downfall of any standard epothilones we 
synthesized for this purpose. (See Chapter 2 for a more in-depth discussion of epothilone acid 
sensitivity.) 
 In addition to the specific issue of mildly-acidic degradation, extensive research into 
epothilones as small molecule drugs has produced a variety of analogs with increased cytotoxicity 
and more favorable pharmacokinetic profiles, such as ixabepilone and iso-fludelone. We sought 
to capitalize on this accumulated knowledge to synthesize linker-equipped compounds that might 
prove more favorable than analogs based on the natural epothilones. 
1.4.2 Design and efforts toward synthesis of structurally-modified epothilone analogs 
 Our efforts toward the development of a linker-equipped epothilone analog began with 
investigations into a novel total synthesis of a linker-equipped ixabepilone analog, the clinically 
available lactam analog of epothilone B. Ixabepilone is commercially produced through a 
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semisynthetic process that involves late-stage modification of the macrolactone to produce the 
macrolactam.44 We sought to utilize the general disconnection strategy as developed in our lab’s 
earlier work on the total synthesis of a linker-equipped epothilone B, with major fragment 
couplings occurring through amide formation and RCM at the C9-10 bond (Scheme 1.4). In the 
course of our efforts, we developed a novel strategy for introduction of the amine functionality 
necessary for amide bond formation. We also developed a third-generation synthesis of the 
epothilone polypropionate fragment, utilizing the latest in our lab’s silicon-based strain-release 
crotylation methodology. Although fragment synthesis was successful, final steps in fragment 
coupling and post coupling modifications, notably hydrogenation of the C9-10 olefin after RCM, 
proved problematic and unsolvable. For an in-depth discussion of our efforts toward a linker-
equipped ixabepilone analog, see Chapter 2. 
 
Scheme 1.4: Transformation of ixabepilone fragments to ixabepilone analog target. 
 Considering the lessons learned during our ixabepilone efforts, we then sought to 
synthesize a linker-equipped analog of iso-fludelone, a fluorinated epothilone analog developed at 
































profile.45 Reasons for pursuing a linker-equipped version of this analog included a known synthesis 
of the parent compound that mimics our desired fragment coupling strategy (lactone formation and 
RCM at the C9-10 position) as well as unsaturation of the C9-10 bond in the parent compound 
(Scheme 1.5). The C9-10 unsaturation (and resulting lack of requirement to hydrogenate this bond) 
would act as a safeguard against the difficulties we observed in pursuing the analogous 
hydrogenation of the C9-10 bond in our ixabepilone efforts, giving us a higher probability of 
producing an active compound. As expected, our efforts proceeded smoothly, and we achieved our 
target molecule. For an in-depth discussion of our efforts toward a linker-equipped iso-fludelone 
analog, see Chapter 3. 
 
Scheme 1.5 Transformation of iso-fludelone fragments to iso-fludelone analog target. 
 Following our successful synthesis of a linker-equipped iso-fludelone, we became 
interested in pursuing more novel substitutions specifically aimed at stabilizing the macrolactone 
bond. Although extensive SAR studies have been completed on nearly all portions of the 



























position. We envisioned the incorporation of fluoride moieties in this vicinity, both as a 
replacement for one or more of the protons on the parent methyl group or a single fluoride as a 
replacement for the methyl group as a whole. Our goal in pursuing these substitutions was to 
capitalize on the high electronegativity of fluorine, with the hope that the incorporation of electron-
withdrawing substituents at the C16 position would increase the stability of the lactone bond. In  
 




























































an effort to probe the general viability of our fragment coupling strategy, we elected to maintain it 
in our efforts toward these two analogs (Scheme 1.6). 
 We began with efforts toward a trifluoro analog, with all C16 methyl hydrogens replaced 
with fluorides. The central challenge of this synthesis was establishing the appropriate geometry 
around the trisubstituted side chain olefin. We eventually employed a unique substrate-directed 
monolithiation strategy to achieve the correct geometry, and the synthesis proceeded smoothly 
afterward to produce a ring-closed analog. Notably, the trifluoro substitution proved beneficial in 
the RCM step, suppressing formation of an undesired side product and biasing the reaction toward 
the desired product. Efforts toward the synthesis of our C16-fluoro substituted analog are ongoing, 
but progress thus far has been promising. We have achieved the synthesis of an advanced 
intermediate of a retrosynthetic fragment, with only four additional steps necessary to complete 
the fragment. Potential issues we foresee include undesired reaction of the side chain olefin in 
RCM, epoxidation, and hydrogenation steps arising from deletion of the C16 methyl carbon and 
modified electronic properties due to direct attachment of the fluoride to the conjugated system. 
For an in-depth discussion of our efforts toward fluoride-containing epothilone analogs, see 
Chapter 4. 
1.4.3 Conjugation of linker-equipped analogs to somatostatin mimics 
 Aside from our total synthetic efforts toward useful linker-equipped epothilone analogs, 
we have also been interested in a more direct investigation of such analogs in a targeted delivery 
context. To this end, we have explored the conjugation of two of our linker-equipped analogs 
(epothilone B and iso-fludelone) to octreotide, a synthetic octapeptide analog of the hormone 
somatostatin, that can induce internalization upon binding to its cell surface receptors.46 For each 
analog, we have synthesized three conjugates, each utilizing a different linker. Two of the linkers 
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are used in approved ADCs and include the non-cleavable Kadcyla linker and the cathepsin B-
cleavable Adcetris linker. We also utilized a PEG24 linker that could in theory allow the epothilone 
payload to reach its binding site on the interior of the microtubule without release from octreotide, 
as well as an octreotide-bivalent DM1 conjugate. While these efforts were synthetically successful, 
preliminary biological results obtained from cellular assays have thus far not been promising. 
 
Figure 1.11: Examples of octreotide mono- and bivalent drug conjugates (see Chapter 5 for the full 
structure of abbreviated conjugate components). 
 Related to our main conjugate efforts, we also pursued the synthesis of octreotide-targeted 
microtubule-interacting tethered drug dimers to explore potential synergism of drugs proximally 
bound to microtubules. In these efforts, we utilized the drug DM1 as a payload because it has 
precedent as a successful payload and binds to the microtubule exterior (Figure 1.11). With the 
hope of better understanding some of the cellular trafficking patterns of our synthesized 
conjugates, we also developed an amine-reactive di-yne tag for use in imaging techniques 
developed in the Min lab at Columbia. For an in-depth discussion of our octreotide-epothilone 













































1.5 Summary and Outlook 
 Natural products, and particularly microtubule stabilizers, represent a largely-untapped 
source of potential ADC payloads that could lead to a wider diversity and implementation of this 
therapeutic modality. In parallel, incorporation of highly cytotoxic natural products into the ADC 
modality represents an opportunity for further investigation of such natural products that have 
failed to gain clinical approval as small molecule drugs. The epothilones, a promising class of 
highly cytotoxic microtubule stabilizers that have enjoyed relatively little clinical success despite 
the considerable attention they have received over the last three decades, are ideal candidates for 
such ADC development efforts. Extensive previous work toward the total synthesis, structure-
activity relationship elucidation, and biological evaluation of many epothilone analogs, as well as 
our lab’s past efforts toward a linker-equipped epothilone B analog, provide a solid foundation for 
further development of linker-equipped epothilone analogs for antibody conjugation. 
 Herein, we report our efforts toward the total synthesis and biological evaluation of four 
distinct linker-equipped epothilones designed for increased chemical stability in mildly acidic 
conditions, as well as incorporation of epothilones into targeted delivery constructs. Specifically, 
we focus on our total synthetic efforts toward linker-equipped ixabepilone, iso-fludelone, a C16 
trifluoromethyl-substituted analog, and a C16 fluoro-substituted analog, along with cellular 
cytotoxicity assays for the synthesized compounds. We also report the synthesis of a series of three 
octreotide-epothilone B conjugates and a series of three octreotide-iso-fludelone conjugates based 
on established and novel linker techniques with subsequent biological evaluation, as well as a 
bivalent octreotide-DM1 conjugate with associated synthetic innovations and an amine-reactive 
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CHAPTER 2: Progress toward synthesis of linker-equipped ixabepilone analogs 
2.1 Introduction 
2.1.1 Metabolic and chemical instability of the epothilones 
 Early efforts in the development of epothilones as taxane replacements, led primarily by 
researchers at Bristol-Myers Squibb (BMS), resulted in the discovery that the epothilones as a drug 
class lacked the necessary activity in xenograft and allograft murine models to serve as 
chemotherapeutic agents when administered at their maximum tolerated doses. They were, 
however, more effective if administered via slow infusion, leading to the hypothesis that the lack 
of activity arises from metabolic instability.1 Further investigation found that metabolic instability 
was a result of esterase-mediated lactone hydrolysis (Figure 2.1) by esterases in murine plasma, 
which was supported in part by a decrease in cytotoxicity of the drug following an incubation 
period in murine plasma.2  
 
Figure 2.1: Epothilone B, with problematic lactone segment shown in red. 
Although human plasma has reduced esterase activity compared to murine models and did 
not demonstrate similar degradative activity against epothilones,1 concerns about both analogous 
esterase activity occurring in the human liver during drug circulation and inability to utilize murine 

















epothilones as cancer therapies. These concerns led to the exploration of epothilone analogs 
designed to overcome the observed metabolic instability. 
 
Figure 2.2: BMS-753493, a folate-epothilone conjugate investigated for targeted delivery and 
degradation pathways. 
 In addition to metabolic instability, chemical instability of the epothilone macrolactone has 
been observed. Researchers at BMS investigated an aziridinyl epothilone-folate conjugate targeted 
to folate receptor-expressing tumor cells that showed high in vitro efficacy (Figure 2.2).3 However, 
chemical instability led to difficulties in drug formulation, which prompted a rigorous early-stage 
campaign to elucidate degradation pathways of the drug candidate, with the hope that insights 
gained could be used to minimize degradation through formulation optimization.4 Various 
degradation pathways at low and high pH in aqueous media were observed, including aziridine 
hydrolysis and carbonate ester hydrolysis, respectively. Of particular interest in the context of 
targeted delivery was a macrolactone ring opening event that was observed at near neutral to mildly 
acidic pH (7.5-5), conditions present in the physiological environment. Further experiments by 
BMS and Jumaa et al.5 suggested that this ring opening proceeds via a unimolecular solvolytic 


















































Figure 2.3: Solvolytic macrolactone cleavage mechanism as discovered by BMS and Jumaa et al. 
Evidence for this mechanism includes the observation of epimeric secondary alcohols as 
degradation products (stereochemistry would be retained in a hydrolytic mechanisms involving 
nucleophilic attack of water/hydroxide at the carbonyl carbon) (Figure 2.4a), apparent 
incorporation of 18O at the lactone alkoxy position when incubated in 18O-enriched water (this 
product is proposed to arise through reversibility of the solvolytic mechanism, allowing for ester 
re-formation after carbocation trapping) (Figure 2.4b), and lack of a kinetic isotope effect when 
incubated with D2O (a secondary or solvent kinetic isotope effect would be expected in a typical 
hydrolytic mechanism) (Figure 2.4c). The observation of this macrolactone cleavage in a neutral 
to mildly acidic environment in the context of a targeted conjugate indicates a need to address this 
degradation pathway. An epothilone-equipped ADC would likely be susceptible to the same 


















































Figure 2.4: (points of interest shown in red) a) presence of epimeric secondary alcohols in degradation 
product; b) incorporation of 18O into macrolactone; c) rate-determining step in traditional ester hydrolysis 
mechanism in D2O, in which secondary or solvent kinetic isotope effect would be observed. 
2.1.2 Identification and FDA approval of ixabepilone as a cancer therapy 
 In their efforts to develop an epothilone analog stable to esterase activity, BMS synthesized 
a series of lactam analogs through their semisynthetic approach (as discussed in detail in section 
2.1.3).6 In general, they found reduced activity of the lactams compared to the lactones. However, 
ixabepilone, the lactam analog of epothilone B, showed only slightly reduced activity, with 
activities comparable to those of paclitaxel against HCT-116 cells and in tubulin polymerization 
assays (Figure 2.5). In addition, it showed a 100-fold decrease in susceptibility to esterase cleavage 
relative to the natural epothilones.1 
In vitro cytotoxicity of ixabepilone was found to be high against a panel of 21 paclitaxel-
sensitive or paclitaxel-resistant cancers, with IC50 values of 1.4-35 nM).7 The data also suggested 
the ability of ixabepilone to evade major paclitaxel resistance mechanisms (MDR pump-mediated 
efflux, ß-tubulin mutations, and ßIII-tubulin isoform overexpression).8 Ixabepilone was found to 
act in a manner identical to epothilone, causing cell cycle arrest in the G2-M phase transition.7 
Moreover, the concentration of ixabepilone required to cause cell cycle arrest was found to 
correspond to the concentration required for cell killing, indicating this pathway is the major 





















































Figure 2.5: Lactam epothilone analogs investigated by BMS; all analogs besides Epo B-lactam were 
found to have IC50 values ranging from 65->200 nM in HCT-116 cells, or exhibited poor performance in 
tubulin polymerization assays. Epo B-lactam demonstrated an IC50 of 3.6 nM in the same cell line.7 
In addition to the demonstrated attenuating effect of the lactam motif on susceptibility to 
esterase degradation, we also suspect that this structural modification would increase the chemical 
stability of the macrocycle in the context of drug conjugates. This hypothesis is consistent with an 
understanding of the nature of the carbon-nitrogen bond. The electron-donating nature of the 
lactam nitrogen should destabilize the transition state required for formation of the allylic 
carbocation intermediate necessary in the unimolecular lactone hydrolysis mechanism (Figure 
2.6). The improved metabolic stability of ixabepilone relative to epothilone B makes it a promising 
target to pursue for antibody conjugation. However, pursuing this line of research requires a supply 
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Figure 2.6: Disfavored pathway required for carbocation intermediate formation by solvolytic pathway. 
2.1.3 Semisynthetic approach for industrial production of ixabepilone 
 In the course of their efforts to develop a scalable and economical synthesis of ixabepilone, 
BMS developed a semisynthetic approach wherein the epothilone B macrolactone was opened via 
formation of a palladium π-allyl species followed by addition of an azide moiety (Scheme 2.1).6 
The azide was reduced via a Staudinger reduction utilizing PMe3, and the resulting amine 
functionality was coupled to the carboxyl group using standard EDCI amide coupling conditions 
to form the macrolactam. This approach was telescoped into a one-pot procedure, and impressive 
overall yields of 20-25% for the process were achieved. Because culturing and extraction of 
epothilone B from Myxococcus xanthus is well-established and was utilized heavily in the BMS 
discovery campaign,9,1 this strategy was an acceptable process for pharmaceutical scale-up. 
 














































































45 °C, 1 h
65-70%
1) PPh3, THF
45 °C, 14 h, then
28% NH4OH, H2O
45 °C, 4 h
2) DPPA, NaHCO3, DMF





 While a semisynthetic approach may be appropriate for the single lactone to lactam 
modification, in large part due to the innovative chemistry BMS developed to effect the 
transformation, a similar strategy is unlikely to be successful in introducing additional 
modifications. Implementation of a drug as an ADC payload requires a validated linker strategy 
(see Chapter 1 for an in-depth discussion) for linker incorporation, and such a structural 
modification arising from a semisynthetic approach is to our knowledge unprecedented and 
difficult to imagine (outside of the aziridine epothilone class). The Leighton group’s previous work 
has focused in part on developing efficient and scalable total synthetic strategies for generating 
linker-containing natural product fragments,10,11 including in the epothilone class, creating a 
promising method for accessing linker-functionalized molecules. Thus, we feel efforts to produce 
a linker-functionalized lactam analog of epothilone B should utilize a total synthetic approach. 
2.1.4 Total synthetic approaches to epothilone lactam analogs 
 Two major total synthetic efforts for lactam analogs of epothilones have been described by 
Danishefsky and coworkers12 and Schinzer and coworkers,13 respectively. Danishefsky and 
coworkers targeted the synthesis of (R)- and (S)-(12,13)-desoxy analogs of ixabepilone. In the 
course of their work, they also epoxidized the (S)-(12,13)-desoxy analogs to give the analog now 
known as ixabepilone. Their disconnection strategy relied on a B-alkyl Suzuki coupling of vinyl 
iodide A with olefin B, and macrolactamization to afford the desired product (Scheme 2.2). 
Installation of the amine functionality required for amide formation was accomplished through an 
azide substitution of the alcohol of opposite configuration utilizing Thompson’s procedure.14 
Issues with Schiff base formation and interaction with the C3 ketone during the subsequent 
Staudinger reduction of the azide, resulting in an 18% yield for this step, were resolved through 
masking of the relevant ketone as its corresponding methyl enol ether during this step. This strategy 
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allowed for sequential Staudinger reduction of the azide and Boc protection of the resulting amine 
in good yield. Unmasking of the C3 ketone, followed by asymmetric Noyori hydrogenation, Boc 
deprotection, and HATU-mediated amide coupling gave the macrolactam. Subsequent 
deprotection gave the desired product. The same strategy was used to produce both desoxy EpoB 
epimers. The (S) epimer was epoxidized with DMDO to produce ixabepilone. (Scheme 2.3) 
 
Scheme 2.2: Key fragment coupling steps as employed in the Danishefsky synthesis of (12,13)-desoxy 
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Scheme 2.3: Final ring-closing and elaboration into ixabepilone. 
 Among the analogs tested, ixabepilone was found to have the highest cytotoxicity in the 
base leukemia cell lines. The (12,13)-desoxy analog of ixabepilone showed a decrease in activity 
of approximately one order of magnitude compared to the epoxide-containing species. The 
epimeric desoxy analog demonstrated an even further decrease in potency compared to ixabepilone 
(Figure 2.7). These results were consistent with the BMS studies. 
 










































































































dEpoB Aza-EpoB (ixabepilone) 15-epi-aza-dEpoBAza-dEpoB
Me Me Me Me
 38 
 
Scheme 2.4: Fragment coupling, ring closing, and final steps employed in the Schinzer epothilone lactam 
synthesis. 
The Schinzer synthesis focused on two lactam analogs of epothilone D: one with a 
secondary lactam comparable to ixabepilone, and one with a tertiary lactam with methyl 
substitution on the lactam nitrogen.13 The retrosynthetic approach, which mirrors the early 
ixabepilone total synthesis efforts by BMS, involved coupling of amines C and D to carboxylic 
acid E to generate amides F and G, followed by ring-closing metathesis to close the ring at the 
C12-13 olefin (Scheme 2.4). Notably, the reaction proceeded in a 1:1 ratio of Z:E olefins, which 
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Figure 2.8: Schinzer epothilone analogs.13 
 
In biological assays, macrolactams J (Aza-dEpoB) and K (Me-Aza-dEpoB) significantly 
underperformed against their macrolactone counterparts, with J showing only modest activity 
(IC50 of 464 nM in KB-31 cells, 285 nM in KB-8511 cells) and K showing essentially no activity 
(Figure 2.8). The only modest activity of J is consistent with previously discussed results, 
suggesting that ixabepilone is the most promising epothilone lactam analog to pursue. 
2.1.5 Linker-equipped ixabepilone analog design 
 The Leighton group’s linker-equipped ixabepilone synthetic strategy incorporated our  
group’s “methyl extension” approach, as successfully demonstrated in dictyostatin and epothilone 
B and detailed in Chapter 1 (Figure 2.9).10,11 The success of this strategy in the epothilone B system 
and the comparable potency and mechanism of action of epothilone B and ixabepilone suggest it 
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 40 
 
Figure 2.9: Successful application of our methyl extension strategy a) epothilone B and b) dictyostatin. 
2.1.6 Linker-equipped ixabepilone fragment coupling strategy 
In designing our disconnection strategy for ixabepilone, we set out to plan a synthesis that would 
be more efficient and more convergent than the Danishefsky12 and Schinzer13 total syntheses of 
lactam epothilone analogs. To this end, we sought to utilize the main disconnections as 
demonstrated by Sinha and coworkers15 in their total synthesis of epothilone B, generating 
 













































































retrosynthetic fragments 2.1 and 2.2. This strategy would utilize fragment coupling via amide 
formation followed by ring closing metathesis, with final steps yielding the desired compound 
(Figure 2.10).  
Although the amide coupling was expected to proceed without issue, there was concern 
regarding the success of the ring-closing metathesis. This strategy was demonstrated in the natural 
epothilone macrolactone class by Sinha and coworkers, though a mixture of E/Z isomers was 
observed when the RCM was attempted with the epoxide already installed, along with formation 
of a seven-membered ring side product (Scheme 2.5). In addition, there is no precedent for using  
 
Scheme 2.5: Inefficient RCM of (12,13)-unsaturated epothilone precursor, with reactive and formed 
bonds shown in red. 
a RCM to close a lactam analog at this position in the epothilone scaffold. Previous experiments 














































desoxy form) resulted in almost exclusive formation of seven-membered ring product. While 
specific reasons for preferential side product formation are uncertain, it can possibly be attributed 
to increased steric strain present in the transition state of the 16-membered ring formation created 
by conformational changes imposed by the rigidity of the amide bond. 
Despite these possible complications, we decided the relatively straightforward synthesis 
of amine fragment 2.1 justified our efforts to attempt this approach. We also hoped that the 
presence of the epoxide would bias the reaction toward the desired pathway, although a clear 
rationale for this hope was absent. Obvious advantages of this strategy include fragment coupling 
of only two fragments and minimal post-coupling modification. To this end, we also sought to 
improve upon our previous syntheses of the polypropionate fragment of epothilone B, as detailed 
in sections 2.3.2 and 2.3.3. 
2.2 Synthesis of amine fragment 
2.2.1 Synthesis of alcohol intermediate 2.15 
 Our proposed synthesis for amine fragment 2.1 took advantage of known chemistry from 
the Sinha15 synthesis for a number of key steps, including installation of the two olefins in their 
desired geometries and installation of the desired stereochemistry at the amine-bearing carbon 
(derived from an alcohol of opposite configuration). We elected to install the epoxide moiety pre-
fragment coupling, as discussed in section 2.1.6, using Sharpless conditions known for a different 
diastereomer.15 Finally, our strategy for amine incorporation mirrors that of Danishefsky et al. in 
their total synthesis of ixabepilone,12 though occurring at an earlier stage of the synthesis (Scheme 
2.6).  
To synthesize alcohol 2.15, we began by using known chemistry from Sinha et al. to access 
allylic alcohol 2.6. This sequence began with E-selective Wittig olefination of commercially 
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available aldehyde 2.3 with commercially available stabilized ylide 2.4 to give aldehyde 2.5. 
Aldehyde 2.5 was allylated using Brown allylation conditions to give homoallylic alcohol 2.6 in 
high yield and 95% ee, followed by TBS protection with TBSOTf to give silyl ether 2.7. Silyl ether 
2.7 was oxidatively cleaved to produce aldehyde 2.8, which was then subjected to Wittig 
olefination with stabilized ylide 2.9, to produce methyl ester 2.10. Methyl ester 2.10 was doubly 
reduced with DIBAL-H to produce homoallylic alcohol 2.11. 
 
Scheme 2.6: Implementation of synthetic strategy known for opposite enantiomer to produce allylic 
alcohol 2.11. 
At this point, the synthesis diverged from known work to produce diastereomers of known 
compounds. Homoallylic alcohol 2.11 was epoxidized using Sharpless conditions to generate 
epoxide 2.12. Epoxide 2.12 was tosylated to produce tosylate 2.13, which was then reduced with 















































































Scheme 2.7 Further elaboration to produce synthetic intermediate 2.15. 
2.2.2 Transformation of alcohol 2.15 into amine 2.1 
 Our strategy for installing the amine functionality relied on an alcohol substitution process 
intended to invert stereochemical configuration at the alcohol-bearing carbon. To accomplish 
substitution, a procedure from Thompson et al. was utilized involving DPPA and DBU.14 Alcohol 
2.15 was treated with these azide substitution conditions, resulting in secondary azide 2.16. 
Secondary azide 2.16 was reduced to its corresponding amine fragment 2.2 by Staudinger 
reduction. The iminophosphorane intermediate required treatment with concentrated NH4OH to 
effect hydrolysis (Scheme 2.8). 
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2.3 Previous work toward synthesis of linker-equipped polypropionate fragment 
2.3.1 Development of methyl extension strategy in dictyostatin system 
 The Leighton group became interested in a methyl extension strategy for linker 
functionalization as a way to avoid potential issues commonly encountered in linker 
functionalization. Traditional strategies often involve functionalization of a heteroatom-containing 
functional group for attachment; however, as these functional groups are frequently involved in 
critical binding interactions in the target binding site, modification risks disrupting these 
interactions.16 Late-stage linker functionalization of these groups can also be synthetically 
challenging. In contrast, alkyl extension of a solvent-exposed methyl group, incorporated in early 
stages of the molecule synthesis, would avoid these issues. A linear alkyl chain would have 
minimal steric difference from a methyl group in the vicinity of the natural product scaffold, and 
it would not disrupt potentially essential interactions. 
 The methyl extension strategy was first investigated in the Leighton group in the context 
of our total synthesis of dictyostatin.  Using the NMR and computation-based binding model 
advanced by Curran and Snyder17 (and eventually refuted by a crystal structure published by 
Sánchez-Murcias, Gago, and Díaz18), we identified the C6 methyl group as a promising candidate 
for linker extension. Our total synthesis utilized an example of our strain-release crotylation 
methodology to install the linker alkyl chain, terminating in a chloride for later functionalization. 
The C6 methyl-extended azide analog proved to have cytotoxicity comparable to dictyostatin, 
providing a promising proof of concept for this strategy. A triazole analog, generated through 
cyclooctyne-azide copper-free click chemistry,19 showed lower but still promising cytotoxicity 
(Figure 2.11). The C6 methyl group was later revealed to be buried in the binding pocket in a 
crystal structure of dictyostatin co-crystallized in its tubulin binding site by Sánchez-Murcias, 
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Gago, and Díaz, which could explain our observations of decreasing cytotoxocity as steric bulk 
was increased. 
 
Figure 2.11: Methyl-extended dictyostatin analogs. 
 
2.3.2 Development of methyl extension strategy in epothilone system 
 Buoyed by the promising, if not fully conclusive, results in the linker-equipped dictyostatin 
synthesis, we set out to synthesize a methyl-extended linker-equipped epothilone B and validate 
its cytotoxicity. We took advantage of a crystal structure of epothilone A bound in the taxane 
binding site of an (αβ-tubulin)2-RB3-tubulin tyrosine ligase complex16 to identify C6 as a suitable 
solvent-exposed methyl group for linker extension. 
The Leighton group’s early work with epothilone B resulted in the development of a unique 
tandem silylformylation/Tamao oxidation of an internal alkyne to install the stereotriad of the 
conserved epothilone polypropionate fragment, which was optimized on a model substrate20 and 
later refined for synthesis of the epothilone fragment.21 In approaching the synthesis of a linker-
equipped epothilone B analog, the conditions for the initial model substrate optimization 
performed the most efficiently, and these conditions were employed in the synthesis of a linker-
equipped fragment (Scheme 2.9).11 Although this sequence produced relatively low yields and 
only moderate dr, the step was early enough in the synthesis to allow for generation of large 
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 47 
 
Scheme 2.9: Tandem silylformylation/Tamao oxidation for generation of polypropionate fragment 
stereotriad. 
2.3.3 A new route to a linker-equipped epothilone polypropionate fragment 
 Following the development of our second generation allylsilylation and crotylsilylation 
methodologies, as developed by former Leighton lab members Drs. Makeda Tekle-Smith, Kevin 
Williamson, and Linda Suen-Lai,22,23 we became interested in utilizing this methodology in a third-
generation synthesis of the epothilone polypropionate fragment. Advantages of this strategy 
include a more straightforward silylformylation sequence without the need for pre-silylation of the 
substrate, and added versatility in our starting materials. 
 In unpublished work completed by former Leighton post-doctoral fellow Dr. Liang-An 
Chen, olefination of aldehyde 2.17 was accomplished by treatment with the ylide of phosphonium 
salt 2.18 to produce olefin 2.19. Using our one-pot hydroformylation/crotylation methodology 
with our second-generation chiral diamine ligand, the hydroformylation and crotylation of olefin 
2.19 was accomplished in an impressive 78% yield and 22:1 dr, with 50:1 olefin regioselectivity, 
generating the fragment stereotriad 2.20. TBS protection and acetal deprotection was 
























20 mol % NaH
hexane, 60 °C
i. 2 mol % Rh(acac)(CO)2
   1000 psi CO, PhH, 60 °C
ii. 2,3-dimethylhydroquinone
    O2 (1 atm), quinuclidine•HCl
    AgF, PhCN, 60 °C 44% from starting material
7:1.3:1 dr
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addition by the enolate of ester 2.22, resulting in a 3:1 mixture of separable isomers to give alcohol 
2.23. Substrate-directed reduction of alcohol 2.23 with Me4NBH(OAc)3 generated diol 2.24. Diol 
2.24 was subjected to a one-pot mono TES protection and DMP oxidation to give ketone 2.25. 
Treatment with excess TESOTf resulted in ester deprotection to give carboxylic acid 2.26 (Scheme 
2.10).  
 
Scheme 2.10: Steps toward a new synthesis of polypropionate fragment 2.2. 
 At this point, we became concerned about the possible steric consequences of the bulky 
TBS group existing in close proximity to the site of ring-closing metathesis. Global HF•pyridine 
deprotection of 2.25 to give diol 2.27 followed by a double TES protection21 gave the doubly TES-



































































































Scheme 2.11: Final steps in the synthesis of polypropionate fragment 2.2. 
2.4 Fragment coupling, synthetic challenges, and analog synthesis 
2.4.1 Fragment coupling and ring-closing metathesis 
 With both fragments in hand, we continued in our efforts to complete the synthesis of a 
linker-equipped ixabepilone analog. Using the standard EDCI coupling conditions with extensive 
precedent for use in the epothilone system, amide coupling of amine fragment 2.1 with carboxylic 
acid fragment 2.2 resulted in amide 2.28 in 63% yield. To effect ring-closing metathesis of amide 
2.28, we chose Grubbs 2nd generation catalyst because of its previous use in the epothilone system. 
In early epothilone total synthesis work by the Danishefsky group, they found that both Schrock 
metathesis catalysts and Grubbs 1st generation catalyst failed to close the ring at the C9-10 olefin. 
They attributed this failure to the steric bulk of the polypropionate region, supported by the success 
of ring closing in model substrates with much of the steric bulk omitted from this region.24 As 
became evident from the later Sinha syntheses, the higher activity of Grubbs 2nd generation catalyst 
was necessary to close the ring at this position.15 When we attempted to close our amide substrate, 
we were discouraged, though not altogether surprised, to observe formation of the seven-
membered ring byproduct in amounts roughly equal to that of the desired product and several other 
minor side products, with a low average yield of ~30% for the desired macrolactam 2.29 (Scheme 
HF•pyridine
































2.12). Clearly, while the presence of the epoxide allowed for recovery of some desired product 
and represents an improvement over the desoxy version that produced only trace amounts, the 
yield was still lower than we had hoped. Undeterred, however, we persevered in an attempt to 
complete the final stages of the synthesis. 
 
Scheme 2.12: Fragment coupling and ring-closing metathesis. 
2.4.2 Deprotection, C9-10 olefin reduction, and synthetic challenges 
 Deprotection of macrolactam 2.29 also proved to be challenging. The standard HF•pyridine 
conditions used by our group and others resulted in degradation of the starting material to form 
unknown byproducts (Figure 2.12a). The specific degradation pathway(s) at work were difficult 
to determine. Reaction workup involves filtration through a silica gel plug, and degradation 
products seemed to stick to the column. Indeed, flushing the plug with 100% EtOAc and 10% 
MeOH in CH2Cl2 failed to yield degradation product for further analysis, so we turned to other 




























CH2Cl2, 0 °C to r.t.
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occurring to give diol 2.30 without decomposition and purification achievable without column 
chromatography (Figure 2.12b). 
 
Figure 2.12: Attempts at deprotection of the macrolactam with a) HF•pyridine and b) CSA in MeOH. 
The next step, reduction of the C9-10 olefin, was attempted by treatment with TrisNHNH2. This 
reagent has been used to good effect by our group and others to reduce the C9-10 olefin in the 
epothilone system.11,15 However, this reagent also unfortunately led to product degradation in the 
ixabepilone system (Figure 2.13). We considered attempts at selective catalytic hydrogenation of 
the double bond as an alternative, but with a limited supply of our late-stage intermediates, we 
abandoned this step, with compelling precedent that reduction of the alkene may be unnecessary 





























































Scheme 2.13: Failure of TrisNHNH2 hydrogenation of the C9-10 olefin. 
2.4.3 Azide analog synthesis 
 In previous studies of epothilone analogs, there are examples in which unsaturation at the 
C9-10 position is known to have little effect on the overall cytotoxicity of the molecule. These 
include the iso-fludelone system (covered in depth in Chapter 3) and clinical candidate KOS-
1584.25 Inspired by these examples, we decided to test an analog of our C9-10 unsaturated 
compound in the hope that it might exhibit high cytotoxicity despite its unsaturation at this 
position. To that end, we synthesized an azide analog through treatment of diol 2.30 with NaN3 to 
displace the linker chloride, resulting in azide 2.31 as an analog for testing (Scheme 2.14).  
 
Scheme 2.14: Epothilone lactam synthesis with C9-10 unsaturation. 
2.4.4. Cytotoxicity assays of analog 2.31 
 Biological testing of azide 2.31 against PC3 and A549 cancer cell lines, performed by our 





























































this observation is the presence of unsaturation of the C9-10 olefin. Although there are epothilone 
analogs that demonstrate potent activity with saturation at this position, possible differences in 
structural conformation induced by the lactone to lactam substitution could account for the lack of 
activity in this example. Mistakes in stereochemical assignment at the lactam and epoxide 
positions are possible but unlikely based on conventions for the methodologies used to introduce 
them (Sharpless asymmetric epoxidation and Thompson’s procedure for azide substitution). 
Table 2.1: Results of cytotoxicity assays of analog 2.31 in PC3 and A549 cell lines against paclitaxel, 
epothilone B, and ixabepilone. 
 
2.5 Summary and outlook 
 Motivated by the current semi-synthetic approach to the industrial production of 
ixabepilone and its lack of feasibility for incorporation of a linker for antibody conjugation, we 
herein report the first total synthesis of a linker-equipped ixabepilone analog using a RCM 
approach unprecedented in the lactam system. Our strategy focused on improving the simplicity, 
scalability, and convergence of the synthesis over previous total syntheses of lactam epothilone 
analogs while also incorporating a linker for functionalization. We were successful in our synthesis 
of both retrosynthetic fragments. Synthesis of the amine fragment was inspired by known routes 
for epothilones, which were altered to incorporate necessary diastereomeric changes to ensure 


































fragment utilized the latest and most robust example of our strained silane methodology to produce 
the desired fragment efficiently and in low step count. 
 Challenges with the synthesis began with ring-closing metathesis and continued into the 
following two steps. Ring-closing metathesis, while successful at generating product, proceeded 
in low 25-30% yield of desired product with significant byproduct formation. HF•pyridine 
deprotection and TrisNHNH2 reduction both resulted in starting material decomposition. 
Deprotection was eventually achieved using CSA, but the issue of olefin reduction remained 
unsolved, with the possibility of exploring selective catalytic hydrogenation methodologies in 
future work. It is unclear why these reactions, straightforward in the epothilone system, failed in 
the ixabepilone system. The most promising, although still highly speculative, explanation 
involves a conformational strain induced by the amide bond as compared to the more freely-
rotating ester bond in the epothilone system, which could render the molecule more susceptible to 
degradation pathways. 
 A successful total synthesis of a linker-functionalized ixabepilone would likely need to rely 
on a different retrosynthetic approach that avoids ring-closing metathesis to construct the C9-10 
bond. Future efforts should look to the Danishefsky total synthesis of ixabepilone as inspiration 








2.6 Experimental procedures and characterization 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were purified 
by passage through an activated alumina column. Thin-layer chromatography (TLC) was carried 
out on glass backed silica gel TLC plates (250 µm for analytical and 1000 or 2000 µm for 
preparative) from Silicycle; visualization by UV light, cerium ammonium molybdate (CAM), 
phosphomolybdic acid (PMA), p-anisaldehyde stain, or potassium permanganate (KMnO4) stain. 
HPLC analysis was carried out on an Agilent 1200 Series using a Chiralpak OD-H (250 x 4.5 mm 
ID) column. Diasteriomeric ratios for all compounds were determined by 1H NMR analysis of the 
unpurified reaction mixtures. 1H NMR spectra were recorded on a Bruker AVIII 400 (400 MHz) 
and AVIII 500 (500 MHz) spectrometer and are reported in ppm, relative to residual protonated 
solvent peak (CDCl3, 7.26 ppm) unless otherwise indicated. Data are reported as follows: 
(bs=broad singlet, s=singlet, d=doublet, t=triplet, q=quarter, m=multiplet, dd=doublet of doublets, 
ddd=doublet of doublet of doublets, ddt=doublet of doublet of triplet, td=triplet of doublets; 
coupling constant(s) in Hz; integration). Proton decoupled 13C spectra were recorded on a Bruker 
AVIII 400 (100 MHz) and AVIII 500 (125 MHz) spectrometer and are reported in ppm from 
CDCl3 internal standard (77.16 ppm) unless otherwise indicated. High-resolution mass spectra 
were obtained from the Columbia University Mass Spectrometry Facility on a Waters XEVO 
G2XS QToF mass spectrometer equipped with a UPC2 SFC inlet, electrospray ionization (ESI) 
probe, atmospheric pressure chemical ionization (APCI) probe, and atmospheric solids analysis 
probe (ASAP). Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR 
spectrometer. Optical rotations were recorded on a Jasco DIP-1000 digital polarimeter. Buffered 
silica gel (pH 7.00) was prepared as follows: A 1000 mL round bottom flask charged with silica 
 56 
gel (250 g) and 25.0 mL of pH 7.00 buffer solution (potassium dihydrogen phosphate/sodium 
hydroxide, Fluka Analytical) was stirred on a rotary evaporator under atmospheric pressure 
overnight. 
SAFETY STATEMENT. No unexpected or unusually high safety hazards were encountered. 
2.6.1 Preparation of 2.1 
 
To a suspension of activated powdered 4 Å molecular sieves held between -30 and -20 °C 
in CH2Cl2 (3 mL) was added (+)-DET (37 µL, 0.22 mmol) and Ti(iPrO)4 (52 µL, 0.17 mmol), and 
the resulting mixture was stirred for 10 minutes. To the mixture was added tBuOOH (0.235 mL, 
1.29 mmol), and the mixture was stirred for 30 minutes. To the mixture was added dropwise 2.11 
(339 mg, 0.861 mmol) in CH2Cl2 (3 mL). The resulting mixture was stirred for 4 h at a temperature 
held between -20 and -30 °C. To the mixture was added 10% w/v NaOH solution in brine (3 mL), 
and the resulting biphasic mixture was stirred vigorously and allowed to warm to room temperature 
over 2 hours. The layers were separated, and the aqueous layer was extracted with CH2Cl2 (1 x 4 
mL). The organic layers were combined, dried over Na2SO4, and concentrated. The resulting 
residue filtered through a pH 7 buffered silica gel plug, eluting with 40:60 EtOAc:hexanes to give 
2.12 (319 mg, 0.777 mmol, 90% yield, 10:1 d.r.) as a clear colorless oil. 
OR [α]D21 -9.3 (c 1.0, CHCl3) 























1H NMR (500 MHz, CDCl3) δ 6.93 (s, 1H), 6.50 (s, 1H), 5.79 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 
5.20 – 5.07 (m, 2H), 4.34 (t, J = 6.5 Hz, 1H), 3.69 (dd, J = 12.3, 4.5 Hz, 1H), 3.56 (dd, J = 12.3, 
8.0 Hz, 1H), 3.12 (t, J = 6.1 Hz, 1H), 2.69 (s, 3H), 2.49 (ddt, J = 14.9, 7.0, 1.4 Hz, 1H), 2.24 (ddt, 
J = 14.8, 7.1, 1.4 Hz, 1H), 2.09 (dd, J = 8.3, 4.9 Hz, 1H), 2.01 (d, J = 1.4 Hz, 3H), 1.98 – 1.79 (m, 
2H), 0.89 (s, 9H), 0.04 (d, J = 23.9 Hz, 6H) 
13C NMR (101 MHz, CDCl3) δ 164.7, 152.9, 141.5, 132.8, 119.5, 118.5, 115.6, 76.7, 63.7, 62.4, 
57.9, 35.4, 33.9, 25.9, 19.3, 18.3, 13.8, -4.5, -4.9 




















































































































































































 To a room temperature solution of 2.12 (318 mg, 0.777 mmol) in CH2Cl2 (6 mL) was added 
TEA (0.119 mL, 0.855 mmol). The resulting solution was cooled to 0 °C, and pTsCl (163 mg, 
0.855 mmol) was added at once. The resulting mixture was stirred at 0 °C for 1.5 hours, then room 
temperature for 1 hour. The mixture was diluted with CH2Cl2 (6 mL) and washed with H2O (1 x 6 
mL). The layers were separated, and the aqueous layer was extracted with CH2Cl2 (2 x 4 mL). The 
organic layers were combined, dried over Na2SO4, and concentrated. The resulting residue was 
purified by silica gel chromatography, eluting with 10:90 ® 20:80 EtOAc:hexanes to give 2.13 
(363 mg, 0.644 mmol, 83% yield) as  a clear colorless oil. 
OR [α]D21 -9.0 (c 1.0, CHCl3) 
IR (thin film, cm-1) 2954, 2928, 2891, 2856, 1642, 1598, 1505, 1472, 1446, 1362, 1252, 1189, 
1177, 1096, 1075, 1020, 959, 835, 814, 778, 667, 555 
1H NMR (500 MHz, CDCl3) δ 7.78 – 7.70 (d, 2H), 7.34 – 7.29 (d, 2H), 6.95 (s, 1H), 6.52 – 6.43 
(m, 1H), 5.69 (ddt, J = 17.2, 10.3, 7.1 Hz, 1H), 5.12 – 5.01 (m, 2H), 4.29 (td, J = 6.4, 0.9 Hz, 1H), 
4.00 – 3.86 (m, 2H), 2.91 (t, J = 5.9 Hz, 1H), 2.70 (s, 3H), 2.49 – 2.38 (m, 4H), 2.24 (ddt, J = 14.9, 
7.4, 1.3 Hz, 1H), 2.01 (d, J = 1.3 Hz, 3H), 1.84 (t, J = 6.2 Hz, 2H), 0.88 (s, 9H), 0.03 (d, J = 21.1 
Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 164.6, 152.9, 145.1, 141.0, 132.7, 131.7, 130.0, 128.1, 119.6, 
119.4, 115.9, 76.5, 72.0, 59.4, 58.9, 35.2, 33.0, 25.9, 21.8, 19.4, 18.3, 13.9, -4.5, -5.0 

















































































































































































































 To a 0 °C solution of tosylate 2.13 (3.24 g, 5.75 mmol) in THF (58 mL) was added dropwise 
a 1 M solution of Super-H in THF (11.5 mL, 11.5 mmol). The resulting mixture was warmed to 
room temperature and stirred for 3 hours. The mixture was cooled to 0 °C and MeOH (0.7 mL) 
was added dropwise. The mixture was concentrated and then suspended in Et2O (40 mL). The 
mixture was washed with sat. NH4Cl (1 x 20 mL). The layers were separated, and the aqueous 
layer was extracted with Et2O (2 x 10 mL). The organic layers were combined, dried over NaSO4, 
and concentrated. The resulting residue was filtered through a silica gel plug, eluting with 20:80 
EtOAc:hexanes to give 2.14 (1.93 g, 4.90 mmol, 87% yield) as a clear colorless oil. 
OR [α]D21 -14.1 (c 1.0, CHCl3) 
IR (thin film, cm-1) 3078, 2954, 2928, 2891, 2855, 1640, 1504, 1470, 1447, 1379, 1360, 1253, 
1182, 1073, 1032, 1004, 921, 888, 835, 776, 728, 670, 605, 571 
1H NMR (400 MHz, CDCl3) δ 6.93 (s, 1H), 6.50 (s, 1H), 5.93 – 5.68 (m, 1H), 5.19 – 5.05 (m, 
2H), 4.32 (dd, J = 7.1, 5.9 Hz, 1H), 2.85 (t, J = 6.1 Hz, 1H), 2.70 (s, 3H), 2.33 (ddt, J = 14.5, 6.7, 
1.5 Hz, 1H), 2.25 – 2.16 (m, 1H), 2.03 (d, J = 1.3 Hz, 3H), 1.92 (ddd, J = 13.7, 7.1, 6.2 Hz, 1H), 
1.79 (dt, J = 14.1, 6.0 Hz, 1H), 1.26 (s, 3H), 0.89 (s, 9H), 0.04 (d, J = 19.6 Hz, 6H) 
13C NMR (101 MHz, CDCl3) δ 164.6, 153.1, 141.6 133.7, 119.4, 118.0, 115.6, 76.8, 61.7, 60.0, 
38.1, 36.0, 25.9, 22.3, 19.3, 18.3, 13.8, -4.5, -4.9 





























































































































































































To a 0 °C solution of epoxide 2.14 (1.93 g, 4.90 mmol) in THF (49 mL) was added a 
dropwise a 1M solution of TBAF in THF (7.84 mL, 7.84 mmol). The reaction was stirred 1.5 hours 
at 0 °C, then 1.5 hours at room temperature. The reaction was diluted with Et2O (30 mL), and H2O 
(30 mL) was added. The layers were shaken and separated, and the aqueous layer was extracted 
with Et2O (3 x 15 mL). The organic layers combined, dried over Na2SO4, and concentrated. The 
resulting residue was purified by silica gel plug, eluting with 40:60 EtOAc:hexanes to give 2.15 
as a clear colorless oil (1.25 g, 4.47 mmol, 85% yield). 
OR [α]D21 -4.21 (c 1.0, CHCl3) 
IR (thin film, cm-1) 3391, 3079, 2976, 2922, 2855, 1640, 1056, 1443, 1379, 1328, 1270, 1185, 
1152, 1055, 1024, 918, 880, 730 
1H NMR (500 MHz, CDCl3) δ 6.93 (s, 1H), 6.59 (d, J = 1.4 Hz, 1H), 5.78 (ddt, J = 16.3, 10.6, 7.0 
Hz, 1H), 5.19 – 5.03 (m, 2H), 4.41 (ddd, J = 7.7, 4.7, 2.3 Hz, 1H), 3.05 (d, J = 2.7 Hz, 1H), 2.93 
(dd, J = 8.0, 4.4 Hz, 1H), 2.68 (s, 3H), 2.36 (ddt, J = 14.6, 6.8, 1.4 Hz, 1H), 2.22 (ddt, J = 14.6, 
7.2, 1.5 Hz, 1H), 2.07 – 1.96 (m, 4H), 1.76 (dt, J = 14.3, 8.1 Hz, 1H), 1.28 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 164.8, 152.8, 141.4, 133.4, 119.2, 118.1, 115.8, 76.1, 62.3, 59.9, 
38.0, 34.4, 22.1, 19.2, 14.4 






































































































































































 To a 0 °C solution of 2.15 (533 mg, 1.91 mmol) in toluene (19 mL) was added dropwise 
DPPA (0.575 mL 2.67 mmol) followed by DBU (0.399 mL, 2.67 mmol). The resulting solution 
was stirred at room temperature for 12 hours. The mixture was diluted with EtOAc (20 mL) and 
washed with H2O (1 x 15 mL), sat. NaHCO3 (1 x 15 mL), and brine (1 x 15 mL). The organic layer 
was dried over Na2SO4 and concentrated. The resulting residue was purified by silica gel 
chromatography, eluting with 2.5/97.5 ® 10:90 EtOAc:hexanes to give 2.16 (408 mg, 1.34 mmol, 
70% yield, 20:1 d.r.) as a light yellow oil. 
OR [α]D23.2 -115.8 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3077, 2977, 2921, 2851, 2465, 2095, 1640, 1503, 1442, 1378, 1231, 1246, 
1182, 1130, 1102, 1030, 995, 960, 918, 877, 823, 733, 662, 608, 563, 538, 482, 447 
1H NMR (500 MHz, CDCl3) δ 7.02 (s, 1H), 6.56 (d, J = 1.6 Hz, 1H), 5.87 – 5.73 (m, 1H), 5.23 – 
5.08 (m, 2H), 4.29 – 4.15 (m, 1H), 2.91 (dd, J = 7.8, 4.2 Hz, 1H), 2.71 (s, 3H), 2.35 (ddt, J = 14.6, 
6.9, 1.4 Hz, 1H), 2.21 (ddt, J = 14.8, 7.2, 1.4 Hz, 1H), 2.11 (d, J = 1.4 Hz, 3H), 1.98 (ddd, J = 14.0, 
9.7, 4.2 Hz, 1H), 1.68 (ddd, J = 14.4, 7.8, 4.8 Hz, 1H), 1.31 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 165.0, 152.1, 136.6, 133.4, 122.4, 118.2, 117.1, 68.8, 61.3, 60.7, 
38.1, 32.7, 22.3, 19.4, 14.5 




toluene, 0 °C to r.t.
12 h



































































































































































 To a room temperature solution of 2.16 (121 mg, 0.397 mmol) in THF (4 mL) was added 
PPh3 (209 mg, 0.795 mmol). The resulting solution was stirred at 45 °C for 12 hours. The mixture 
was cooled to room temperature, and 5N NH4OH in H2O (1.1 mL) was added dropwise. The 
resulting mixture was stirred at 45 °C for 4 hours. The mixture was concentrated, and the resulting 
residue was purified by silica gel chromatography, eluting with 1:20 ® 1:10 MeOH:CH2Cl2 to 
give 2.1 (90 mg, 0.323 mmol, 81%) as a clear colorless oil. 
OR [α]D23.0 -14.4 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3296, 3075, 2962, 2919, 2851, 1706, 1640, 1504, 1442, 1377, 1337, 1264, 
1181, 1128, 1058, 1027, 995, 958, 916, 870, 810, 728, 668, 641, 605, 563, 529 
1H NMR (400 MHz, CDCl3) δ 6.90 (s, 1H), 6.57 – 6.45 (m, 1H), 5.79 (ddt, J = 17.3, 10.3, 7.0 Hz, 
1H), 5.21 – 5.02 (m, 2H), 3.66 – 3.51 (m, 1H), 2.87 (dd, J = 7.2, 4.7 Hz, 1H), 2.67 (d, J = 1.4 Hz, 
3H), 2.33 (ddt, J = 14.5, 6.8, 1.5 Hz, 1H), 2.20 (ddt, J = 14.6, 7.2, 1.4 Hz, 1H), 2.02 (d, J = 1.3 Hz, 
3H), 1.76 (qdd, J = 14.2, 7.5, 5.3 Hz, 2H), 1.54 (d, J = 34.9 Hz, 2H), 1.26 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 164.6, 152.9, 142.9, 133.5, 119.0, 117.9, 115.6, 61.8, 60.1, 57.9, 
38.0, 34.3, 22.2, 19.2, 14.8 








































































































































































2.6.2 Preparation of 2.31 
 
 To a 0 °C solution of 2.1 (29 mg, 0.10 mmol) in CH2Cl2 (0.5 mL) was added EDCI (24 
mg, 0.12 mmol) and DMAP (15 mg, 0.12 mmol). The resulting mixture was stirred at 0 °C for 
15 minutes, followed by dropwise of addition of a solution of 2.2 (55 mg, 0.095 mmol) in 
CH2Cl2 (0.5 mL). The resulting mixture was warmed to room temperature and stirred for 3 
hours. The mixture was concentrated, and the resulting residue was filtered through a pH 7 
buffered silica gel plug, washing with 20:80 EtOAc:hexanes  to give product 2.28 (49 mg, 0.066 
mmol, 63% yield) as a colorless oil. 
OR [α]D22.7 -25.1 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3333, 3075, 2954, 2914, 2876, 1725, 1685, 1506, 1459, 1414, 1378, 1294, 
1238, 1182, 1090, 1004, 915, 853, 736, 676, 571, 406 
1H NMR (500 MHz, CDCl3) δ 6.92 (s, 1H), 6.49 (d, J = 1.4 Hz, 1H), 6.32 (d, J = 8.1 Hz, 1H), 
5.95 – 5.70 (m, 2H), 5.20 – 5.09 (m, 2H), 5.10 – 4.95 (m, 2H), 4.69 (q, J = 6.6 Hz, 1H), 4.31 – 
4.18 (m, 1H), 3.81 (t, J = 4.0 Hz, 1H), 3.50 (t, J = 6.6 Hz, 2H), 3.04 (dt, J = 7.9, 4.1 Hz, 1H), 2.89 
– 2.76 (m, 1H), 2.69 (d, J = 1.4 Hz, 3H), 2.51 (dd, J = 15.6, 3.1 Hz, 1H), 2.38 (ddt, J = 14.6, 6.8, 
1.4 Hz, 1H), 2.27 – 2.17 (m, 2H), 2.14 – 2.06 (m, 5H), 1.87 – 1.62 (m, 4H), 1.48 (ddt, J = 13.1, 




































13C NMR (126 MHz, CDCl3) δ 217.0, 170.4, 164.5, 153.0, 140.5, 137.9, 133.4, 120.0, 118.2, 
116.2, 115.3, 75.9, 75.5, 61.2, 59.9, 55.2, 53.3, 52.1, 45.2, 44.7, 42.0, 38.1, 33.3, 31.7, 26.3, 25.5, 
24.2, 22.2, 21.1, 19.4, 18.5, 16.2, 7.3 (d, J = 6.2 Hz), 5.6, 5.2 































































































































































































































































































 To a room temperature degassed solution of 2.28 (100 mg, 0.119 mmol) in toluene (100 
mL) was added Grubbs second generation catalyst (29 mg, 0.036 mmol). The mixture was 
heated to reflux and stirred for 2 hours with dry nitrogen bubbling through the solution. The 
mixture was cooled to room temperature and filtered through a pH 7 buffered silica gel plug, 
washing with 30:70 EtOAc:hexanes. The resulting solution was concentrated, and the resulting 
residue was purified by pH7 buffered silica gel chromatography, eluting with 20:80 → 30:70 
hexanes:EtOAc to give 2.29 (32 mg, 0.039 mmol, 30%) as a light brown oil. 
OR [α]D23.5 42.8 (c 0.40, CHCl3)  
IR (thin film, cm-1) 3384, 2955, 2876, 1687, 1506, 1455, 1414, 1379, 1238, 1181, 1095, 1009, 
878, 794, 735, 570 
1H NMR (500 MHz, CDCl3) δ 6.91 (s, 1H), 6.49 (d, J = 1.7 Hz, 1H), 5.99 – 5.80 (m, 1H), 5.50 
(ddd, J = 15.7, 8.7, 5.0 Hz, 1H), 4.71 (ddd, J = 11.5, 8.5, 3.3 Hz, 1H), 4.23 (dd, J = 7.8, 3.6 Hz, 
1H), 4.13 – 4.07 (m, 1H), 3.60 – 3.39 (m, 2H), 2.89 (dd, J = 9.9, 3.3 Hz, 1H), 2.83 (dt, J = 9.3, 4.3 
Hz, 1H), 2.70 (s, 3H), 2.58 (ddd, J = 15.1, 5.0, 2.2 Hz, 1H), 2.43 (dd, J = 14.0, 7.8 Hz, 1H), 2.28 
(dt, J = 15.0, 3.5 Hz, 2H), 2.24 – 2.06 (m, 5H), 1.82 – 1.61 (m, 4H), 1.56 (tt, J = 13.7, 4.3 Hz, 1H), 
1.43 (dtt, J = 13.5, 8.4, 4.8 Hz, 1H), 1.35 – 1.16 (m, 6H), 1.17 – 1.06 (m, 8H), 1.03 – 0.88 (m, 



































13C NMR (126 MHz, CDCl3) δ 215.2, 170.0, 164.6, 152.8, 138.4, 135.5, 127.1, 119.7, 116.2, 75.8, 
75.3, 62.8, 60.6, 55.3, 54.2, 54.1, 44.7, 43.5, 42.0, 37.0, 33.1, 32.7, 29.8, 27.9, 24.5, 23.8, 22.7, 
22.6, 19.4, 15.6, 7.3, 7.2, 5.8, 5.5 














































































































































































































































































 To a 5% w/v solution of CSA in MeOH (1.7 mL) was added 2.29 (34 mg, 0.042 mmol). 
The resulting mixture was stirred at room temperature for 1 hour. The mixture was concentrated 
under reduced pressure, then resuspended in CH2Cl2 (3 mL) and washed with sat. NaHCO3 
solution (1 x 1.5 mL). The aqueous wash was extracted with CH2Cl2 (2 x 1 mL). The organic 
extracts were combined, dried over Na2SO4, and concentrated to give 2.30 (22 mg, 0.38 mmol, 
90% yield) as crude product, which was carried to the next step without further purification. 
OR [α]D20.1 -7.7 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3359, 2959, 2930, 2246, 1668, 1507, 1462, 1376, 1298, 1251, 1181, 1092, 
1027 
1H NMR (400 MHz, CDCl3) δ 6.94 (s, 1H), 6.57 (s, 1H), 5.83 – 5.51 (m, 2H), 4.44 (d, J = 10.4 
Hz, 1H), 4.19 (dt, J = 16.2, 8.0 Hz, 1H), 3.83 (d, J = 11.2 Hz, 1H), 3.76 – 3.58 (m, 2H), 3.49 (h, J 
= 8.3, 7.3 Hz, 3H), 3.33 – 3.14 (m, 1H), 2.91 – 2.58 (m, 4H), 2.50 – 2.19 (m, 4H), 2.19 – 1.94 (m, 
4H), 1.88 (s, 1H), 1.72 (dq, J = 15.0, 8.8, 6.5 Hz, 4H), 1.66 – 1.52 (m, 1H), 1.33 (qd, J = 12.4, 7.9 
Hz, 3H), 1.17 (d, J = 10.0 Hz, 5H), 1.07 (d, J = 6.8 Hz, 3H), 1.02 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 164.6, 159.4, 153.2, 141.4, 134.9, 127.9, 119.3, 115.4, 82.0, 75.9, 
72.8, 70.2, 58.3, 52.4, 51.2, 46.2, 45.8, 44.90, 40.8, 38.5, 33.0, 28.6, 27.4, 25.8, 24.3, 20.9, 20.7, 
20.2, 19.3, 15.9 































































































































































































































































































 To a room temperature solution of 2.30 (10.5 mg, 0.0181 mmol) in DMF (0.181 mL) was 
added NaN3 (1.4 mg, 0.022 mmol). The resulting mixture was stirred at 60 °C for 14 hours. The 
mixture was cooled to room temperature and diluted with EtOAc (3 mL). The mixture was 
washed was water (1 x 3 mL), and the aqueous wash was extracted with EtOAc (3 x 2 mL). The 
organic extracts were combined, dried over Na2SO4, and concentrated. The resulting residue was 
filtered through a by silica gel plug, eluting with 1:20 MeOH:CH2Cl2, 1% TEA to give 2.31 (9.9 
mg, 0.017 mmol, 93% yield) as a colorless oil. 
OR [α]D20.4 -13.3 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3371, 2930, 2683, 2493, 2094, 1666, 1504, 1464, 1376, 1295, 1252, 1178, 
1070, 1031, 982, 933, 873, 836, 775, 730, 670, 557 
1H NMR (MHz, CDCl3) δ 6.95 (s, 1H), 6.58 (s, 1H), 5.73 (ddd, J = 14.9, 9.1, 5.6 Hz, 1H), 5.62 
(dd, J = 15.7, 7.9 Hz, 1H), 4.45 (d, J = 10.1 Hz, 1H), 4.22 (dd, J = 11.9, 4.1 Hz, 1H), 3.86 (d, J = 
11.2 Hz, 1H), 3.67 (td, J = 9.5, 8.4, 3.3 Hz, 2H), 3.46 (td, J = 7.7, 3.7 Hz, 1H), 3.35 – 3.15 (m, 
3H), 2.70 (s, 3H), 2.63 – 2.51 (m, 1H), 2.46 – 2.26 (m, 4H), 2.24 – 2.09 (m, 2H), 2.07 (d, J = 1.3 
Hz, 2H), 2.04 – 1.93 (m, 1H), 1.93 – 1.87 (m, 1H), 1.76 (q, J = 12.2 Hz, 2H), 1.56 (ddd, J = 15.7, 







































13C NMR (MHz, CDCl3) δ 164.6, 153.1, 135.0, 127.9, 119.5, 115.6, 115.3, 82.2, 76.0, 72.7, 70.4, 
58.3, 52.4, 51.4, 51.2, 51.2, 46.0, 45.8, 40.8, 38.4, 29.5, 29.8, 28.9, 27.3, 25.8, 24.3, 21.0, 20.8, 
20.1, 19.3, 15.9 


















































































































































































































































































2.6.3 Preparation of 2.27 
 
To a cooled (0℃) suspension of 2.18 (34.4 g, 79.8 mmol) in THF (400 mL, 0.2 M) was 
added KHMDS (1.0 M in THF, 72.3 mL) over 40 min. The mixture was warmed to room 
temperature and stirred for 2 h. The mixture was cooled to -78℃ and solution of 2.17 (5.0 g, 47 
mmol) in THF (110 ml) was slowly added to the reaction mixture over 60 min. The reaction was 
allowed to warm to room temperature and stirred for 12 h. Upon completion, the reaction mixture 
was quenched by the addition of saturated aqueous NH4Cl (150 mL), poured into water (100 mL), 
and extracted with Et2O (3 × 100 mL). The combined organic layers were then washed with brine 
(100 mL), dried over MgSO4, and concentrated. The crude 1H NMR spectrum indicated 94:6 Z/E 
ratio. The residue was purified by silica gel column chromatography, eluting with 1:50→1:30 
EtOAc: hexanes to afford pure 2.19 (7.1 g, 86% yield) as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ 5.72 (dt, J = 10.6, 7.8 Hz, 1H), 5.56 – 5.49 (m, 2H), 4.05 – 3.98 
(m, 2H), 3.93 – 3.85 (m, 2H), 3.55 (t, J = 6.5 Hz, 2H), 2.36 (dt, J = 9.1, 7.1 Hz, 2H), 1.88 (dt, J = 
7.9, 6.6 Hz, 2H) 
13C NMR (125 MHz, CDCl3) δ 135.1, 127.6, 99.0, 64.9, 44.1, 32.1, 25.0 
IR (thin film, cm-1) 2955, 2883, 1665, 1425, 1345, 1310, 1209, 1123, 1084, 1024, 969, 725, 650 
cm-1 































































































To the metal cylinder of a Parr bomb (without a glass liner) was added 2.19 (2.20 g, 12.5 
mmol) in toluene (8.0 mL), Rh(acac)(CO)2 (32.12 mg, 0.1245 mmol, 1 mol%), and (S,S)-Ph-BPE 
(126.1 mg, 0.2490 mmol, 2 mol%). The Parr bomb was charged to 500 psi with H2/CO (1:1) and 
vented (repeated 5 times). The bomb was then pressurized to 200 psi and heated to 70°C. After 18 
h, the bomb was allowed to cool to room temperature and de-pressurized. Aliquot 1H NMR 
indicated full conversion of dioxolane and 50:1 proximal to distal ratio. The aldehyde could be 
used immediately in allylation step without any purification. 
Crotylation procedure: To a cooled (0°C) solution of trans-crotyl chloride (3.97 g, 13.7 mmol) in 
CH2Cl2 (45.0 mL) was added DBU (6.1 mL, 41 mmol) and trans-crotyltrichlorosilane (2.28 mL, 
14.9 mmol). The reaction was allowed to warm to room temperature for 1 h. The reaction mixture 
was cooled to -78 °C, and the solution of the above crude aldehyde (1.0 equiv) was added, rinsing 
with CH2Cl2 (5.0 mL). After completion of addition, the reaction was allowed to warm to 0 °C. 
After 6h, the reaction mixture was quenched with TBAF·3H2O (3.93 g, 12.5 mmol). After 1 h, the 
reaction mixture was concentrated to dryness and re-suspended in Et2O (60.0 mL) in order to fully 
precipitate the DBU•HCl salts. The residual mixture was filtered, concentrated, and purified by 
silica gel flash column chromatography (EtOAc/Hexanes = 1:5) afforded alcohol 2.20 (3.27 g, 
78% yield, 22:1 dr) as a colorless oil.  




















1H NMR (500 MHz, CDCl3) δ 5.88 – 5.80 (m, 1H), 5.14 – 5.06 (m, 2H), 4.97 (dd, J = 3.4, 1.2 Hz, 
1H), 4.04 – 3.96 (m, 2H), 3.92 – 3.83 (m, 2H), 3.70 (dt, J = 8.7, 1.6 Hz, 1H), 3.55 (td, J = 6.6, 1.2 
Hz, 2H), 2.60 (s, 1H), 2.33 (h, J = 7.4 Hz, 1H), 1.89 – 1.73 (m, 3H), 1.70 – 1.41 (m, 4H), 0.97 (dd, 
J = 6.8, 1.1 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 141.7, 115.0, 106.2, 73.6, 65.0, 64.6, 44.8, 42.7, 41.3, 33.0, 25.8, 
23.0, 17.0 
IR (thin film, cm-1) 2957, 2931, 2875, 1638, 1459, 1406, 1309, 1128, 1081, 1029, 969, 943, 727, 
651 cm-1 



























































































































To a cooled (-78°C) solution of 2.20 (0.929 mg, 3.53 mmol, 1.0 equiv) in CH2Cl2 (70 mL) 
was added 2,4,6-collidine (7.0 mL, 53 mmol) and freshly distilled TBSOTf (0.89 mL, 3.9 mmol). 
The reaction was allowed to warm to 0 °C. After 30 min, the freshly distilled TMSOTf (3.2 mL, 
18 mmol) was added before the reaction was cooled to about -10°C (ice/MeOH bath). After 15 
min (Note: this reaction is very time sensitive as more side products were observed after longer 
reaction time.) The reaction mixture was immediately quenched with water (20 mL). After 
vigorously stirring for 2h, the aqueous layer was separated and extracted with CH2Cl2 (3 × 15 mL). 
The combined organic layers were then washed with 1N HCl (2×15 mL) and water (20 mL), dried 
over MgSO4, filtered, and concentrated. Purification was accomplished by pH 7.0 buffered silica 
gel chromatography, eluting with 1:80 → 1:40  EtOAc/hexanes to afford aldehyde 2.21 (0.963mg, 
82% yield) as a colorless oil.  
OR  [α]D22 -26.9 (c 3.0, CH2Cl2) 
1H NMR (500 MHz, CDCl3) δ 9.76 (d, J = 1.8 Hz, 1H), 5.74 (ddd, J = 17.2, 10.4, 8.3 Hz, 1H), 
5.05 – 4.96 (m, 2H), 3.92 (dd, J = 5.5, 3.4 Hz, 1H), 3.51 (t, J = 6.6 Hz, 2H), 2.43 – 2.31 (m, 2H), 
1.81 – 1.67 (m, 3H), 1.52 – 1.33 (m, 3H), 1.03 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), 0.06 (d, J = 14.7 
Hz, 6H) 
13C NMR (100 MHz, CDCl3) δ 204.5, 139.6, 116.8, 75.5, 56.9, 44.8, 42.5, 32.8, 26.1, 25.4, 24.9, 
18.4, 18.0, -4.0, -4.2 


































































































































































To a cooled (0 ºC) solution of NaH (60% dispersion in mineral oil; 270 mg, 6.75 mmol) in 
THF (20.0 mL) was added the solution of 2.21 (839 mg, 4.50 mmol) in THF (10 mL plus a 2.0 
mL wash) via cannula. After 15 min, nBuLi (2.5 M in hexanes; 1.80 mL, 4.50 mmol) was added, 
and the solution gradually took a bright yellow color. The yellow solution was stirred at 0 ºC for 
30 min and then cooled to –78 ºC. A solution of aldehyde (500 mg, 1.50 mmol) in THF (10 mL 
plus a 2.0 mL wash) was added dropwise via cannula. The resulting solution was stirred at –78  ºC 
for 1h and then quenched with saturated NH4Cl (30 mL). The aqueous phase was extracted with 
EtOAc (3 x 20 mL), and the combined organic layers were dried over Na2SO4, filtered, and 
concentrated under reduce pressure to yield a clear oil. The residue was purified by silica gel 
chromatography, eluting with hexanes → 5:95 EtOAc hexanes to afford  2.23 as a colorless oil in 
a 3:1 mixture of diastereomers (458.6 mg (major), 151.7 mg (minor), 78% yield). The major and 
minor diastereomers could be separated by column chromatography, and the major is characterized 
below, which exists as an approximately 2:1 mixture of keto: enol forms in CDCl3 solution: 
OR [α]D19 -24.9 (c 0.7, CHCl3) 
IR (thin film, cm-1) 3546, 2957, 2930, 2857, 1737, 1700, 1638, 1472, 1462, 1406, 1392, 1367, 
1317, 1252, 1156, 1103, 1035, 1005, 914, 864, 836, 778 cm-1 
Note: 1H NMR spectra data for 2.23 not provided here due to 2:1 mixture of keto: enol forms 


























13C NMR (125 MHz, CDCl3) δ 208.7, 182.9, 173.2, 167.5, 142.0, 141.8, 114.3, 114.2, 89.9, 81.6, 
81.2, 77.6, 76.6, 74.9, 72.3, 53.2, 47.2, 45.0, 45.0, 44.9, 44.7, 41.1, 40.0 33.2, 32.4, 28.4, 28.4, 
28.14, 28.11, 26.8, 26.3, 26.3 26.3 26.2, 26.1, 26.0, 25.9, 24.9, 24.7 23.8 23.5, 22.8 22.2, 20.9, 
19.7, 18.4, 18.3, -3.2, -3.4, -4.1, -4.2 









































































































































































































































































Tetramethylammonium triacetoxyborohydride (1.39 g, 6.87 mmol) was added to 
CH3CN/AcOH (4 mL/4 mL), and the resulting solution was stirred for 30 min at room temperature. 
The reaction was cooled to -20 °C before 2.23 (0.446 g, 0.859 mmol ) in CH3CN/AcOH (2 mL/2 
mL) was added. After 30 h, the reaction was quenched by the addition of 30 mL of a saturated 
aqueous NaHCO3. The aqueous layer was then extracted with CH2Cl2  (3 × 15 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, and concentrated. The residue was 
purified by silica gel chromatography, eluting with 1:15 → 1:10 EtOAc:hexanes to give compound 
2.24 (321.8 mg, 72%) as a colorless oil. 
OR  [α]D19 -36.2 (c 0.8, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 6.17 (ddd, J = 17.5, 10.3, 8.6 Hz, 1H), 5.09 – 4.99 (m, 2H), 3.98 
(d, J = 4.6 Hz, 1H), 3.88 (ddd, J = 10.4, 4.6, 2.5 Hz, 1H), 3.71 (d, J = 5.5 Hz, 1H), 3.64 (dd, J = 
4.3, 2.0 Hz, 1H), 3.58 – 3.55 (m, 2H), 2.81 (d, J = 5.4 Hz, 1H), 2.46 (tt, J = 7.3, 5.3 Hz, 1H), 2.41 
(d, J = 2.5 Hz,1H), 2.38 (d, J = 2.5 Hz, 1H), 1.86 – 1.72 (m, 2H), 1.70 – 1.64 (m, 1H), 1.63 – 1.55 
(m, 3H), 1.46 (s, 9H), 1.25 (tdd, J = 12.0, 9.6, 3.3 Hz, 1H), 1.06 (d, J = 7.1 Hz, 3H), 0.92 (d, J = 
2.8 Hz, 12H), 0.86 (s, 3H), 0.07 (d, J = 13.6 Hz, 6H) 
13C NMR (125 MHz, CDCl3) δ 173.00, 142.14, 114.16, 81.26, 77.5, 77.4, 76.2, 74.3, 45.2, 45.1, 
41.1, 40.6, 38.5, 33.2, 28.3, 28.3, 26.5, 26.4, 25.5, 22.5, 22.0, 21.7, 18.5, -3.1, -4.0. 
IR (thin film, cm-1) 3476, 2958, 2930, 2857, 1722, 1472, 1391, 1368, 1301, 1254, 1153, 1037, 
911, 867, 836, 773 cm-1 






























































































































































































































To a cooled (-78  °C) solution of 2.24 (113 mg, 0.217 mmol) in CH2Cl2 (3.0 mL) was added 
2,6-lutidine (50.5 µL, 0.434 mmol) and TESOTf (51.5 µL, 0.227 mmol) dropwise in sequence. 
After 30 minutes, Dess-Martin periodinane (184 mg, 0.434 mmol) was added, and the reaction 
was warmed to room temperature. After 15 hours, the reaction was quenched with 
Na2S2O3/NaHCO3 (1:1, 4.0 mL). The aqueous layer was then extracted with CH2Cl2 (3 × 10 mL), 
dried over Na2SO4, and concentrated. The crude mixture was purified by silica gel column 
chromatography, eluting with 1:80 → 1:60 EtOAc:hexanes to afford 2.25 (121 mg, 88%) as a 
colorless oil.  
OR  [α]D19 -26.1 (c 1.1, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 5.94 – 5.83 (m, 1H), 5.10 – 5.02 (m, 2H), 4.23 (dd, J = 7.0, 2.9 Hz, 
1H), 3.78 (t, J = 3.6 Hz, 1H), 3.48 (td, J = 6.8, 2.2 Hz, 2H), 3.03 (dt, J = 7.9, 4.1 Hz, 1H), 2.49 
(dd, J = 17.3, 3.0 Hz, 1H), 2.30 – 2.21 (m, 1H), 2.18 (dd, J = 17.3, 7.0 Hz, 1H), 1.76 – 1.64 (m, 
3H), 1.55 (s, 1H), 1.52 – 1.46 (m, 1H), 1.44 (s, 9H), 1.38 – 1.24 (m, 2H), 1.20 (s, 3H), 1.09 (s, 
3H), 1.05 (d, J = 6.9 Hz, 3H), 0.96 (t, J = 8.0 Hz, 9H), 0.91 (s, 9H), 0.71 – 0.57 (m, 6H), 0.03 (d, 
J = 8.6 Hz, 6H) 
13C NMR (125 MHz, CDCl3) δ 216.2, 171.6, 140.5, 115.5, 80.7, 77.5, 75.2, 74.7, 53.4, 52.1, 45.4, 
45.1, 41.0, 33.4, 28.4, 26.9, 26.4, 25.9, 24.0, 20.9, 18.7, 18.4, 7.3, 5.3, -3.4, -3.8. 
IR (thin film, cm-1) 2955, 2932, 2877, 2857, 1730, 1695, 1472, 1367, 1297, 1252, 1154, 1094, 
1065, 913, 835, 774, 737cm-1 






































































































































































































































tert-Butyl ester 2.25 (109 mg, 0.172 mmol) was dissolved in CH2Cl2 (3.0 mL) and treated 
with 2,6-lutidine (0.120 mL, 1.03 mmol, 6.0 equiv). After cooling the reaction mixture to 0 °C, 
TESOTf (0.155 mL, 0.688 mmol, 4.0 equiv) was added dropwise. The reaction mixture was 
allowed to warm to room temperature while stirring over 2 h, quenched with NH4Cl, then diluted 
with EtOAc (20.0 mL), and washed with 1N HCl (2 × 5 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting 
with 20:80 → 30:70 EtOAc:hexanes to afford 2.26 (75.7 mg, 76% yield) as a clear oil. 
OR  [α]D19 -9.2 (c 1.2, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 5.87 (ddd, J = 17.3, 10.5, 7.9 Hz, 1H), 5.09 – 5.00 (m, 2H), 4.31 
(dd, J = 7.6, 2.8 Hz, 1H), 3.84 (dd, J = 4.4, 3.1 Hz, 1H), 3.48 (td, J = 6.7, 2.2 Hz, 2H), 3.00 (dt, J 
= 6.9, 4.6 Hz, 1H), 2.59 (dd, J = 16.7, 2.8 Hz, 1H), 2.33 (dd, J = 16.6, 7.6 Hz, 1H), 2.23 (pd, J = 
7.0, 3.0 Hz, 1H), 1.71 (dddd, J = 12.6, 10.1, 7.8, 5.3 Hz, 3H), 1.66 – 1.60 (m, 1H), 1.40 – 1.25 (m, 
3H), 1.21 (s, 3H), 1.12 (s, 3H), 1.05 (d, J = 7.0 Hz, 3H), 0.95 (t, J = 8.0 Hz, 9H), 0.91 (s, 9H), 0.63 
(qd, J = 7.9, 2.0 Hz, 6H), 0.05 (d, J = 5.8 Hz, 6H) 
13C NMR (125 MHz, CDCl3) δ 216.4, 178.0, 140.2, 115.6, 77.4, 75.3, 74.3, 53.2, 51.7, 45.0, 44.9, 
39.7, 33.1, 27.0, 26.3, 26.3, 25.8, 24.2, 19.6, 18.6, 18.6, 18.2, 7.1, 5.3, -3.5, -4.0 
IR (thin film, cm-1) 2954, 2932, 2878, 2857, 1703, 1472, 1462, 1418, 1302, 1252, 1095, 1003, 
915, 835, 774, 735 cm-1 
HRMS (ASAP+) calcd for C29H59ClO5Si2 [M+H]+: 577.3511; found 577.3501  
TESOTf (8 eq.)
2,6-lutidine



























































































































































































































To a cooled (0 °C) solution of 2.25 (33 mg, 0.052 mmol) in THF (1.0 mL) in a polyethylene 
tube was added HF·pyridine (0.52 mL). After addition, the reaction was warmed to ambient 
temperature and stirred for 20 hours. The reaction was cooled to 0 °C, and TMSOMe (1.0 mL) 
was added dropwise, warmed to ambient temperature and stirred for 30 minutes. The reaction was 
concentrated and dried under high vacuum, and the residue was purified by silica gel 
chromatography, eluting with 1:4 → 1:2 EtOAc:hexanes to afford  2.27 (18.2 mg, 86%) as a pale 
yellow oil. The NMR data are consistent with previous data (ACS Med. Chem. Lett., 2017, 8 (7), 
701–704) 
1H NMR (500 MHz, CDCl3) δ 5.86 (ddd, J = 17.2, 10.4, 7.7 Hz, 1H), 5.13 – 5.07 (m, 2H), 4.23 
(dd, J = 10.3, 2.4 Hz, 1H), 3.60 (dd, J = 8.3, 2.6 Hz, 1H), 3.58 – 3.44 (m, 2H), 3.37 (s, 1H), 3.27 – 
3.18 (m, 1H), 2.56 (s, 1H), 2.45 – 2.36 (m, 1H), 2.36 – 2.25 (m, 2H), 1.88 – 1.70 (m, 3H), 1.61 – 
1.49 (m, 1H), 1.46 (s, 9H), 1.37 (tdd, J = 11.2, 7.9, 6.1 Hz, 2H), 1.23 (s, 3H), 1.09 (s, 3H), 1.03 (d, 
J = 6.8 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 219.7, 172.5, 141.2, 115.5, 81.8, 73.7, 72.9, 52.0, 48.3, 44.8, 41.3, 
37.4, 33.0, 28.2, 25.5, 24.7, 22.2, 19.2, 16.9 
Spectra and OR are consistent with known compounds. 
  
HF•pyridine



















2.7 Biological data 
In Vitro Cell Growth Inhibition Assays 
Assay protocols 
PC3, human prostate cancer, and A549, human lung cancer, cell lines were obtained from 
the NCI anticancer drug screen. All cells were maintained in RPMI medium supplemented with 
10% fetal bovine serum. Growth inhibition was determined by the resazurin method, following 
exposure to serial dilutions of each compound for 4 days prior to assay and GI50 determinations as 
described.26 Each compound was tested with an initial 10-dose dilution series, followed by 
narrower, replicate 2-dose series, each of which was a separate experiment. The results presented 






 GI50 nM na GI50 nM na 
paclitaxel 3.5 2 22 2 
epothilone B 0.5 2 2.1 2 
ixabepilone 11 2 12 2 
2.31 >3000 2 >3000 2 
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CHAPTER 3: Synthesis and biological validation of linker-equipped iso-fludelone analogs 
3.1 Introduction 
3.1.1 Narrow therapeutic index of epothilone B and early SAR investigations 
 Early investigation into epothilone B, the most cytotoxic natural member of the epothilone 
class,1 as a cancer therapeutic revealed its low therapeutic index and resulting unsuitability for use 
as a drug in its natural form.2 The Danishefsky group at Memorial Sloan Kettering Cancer Institute, 
motivated by the promise of the epothilones as a taxane replacement able to overcome MDR in 
resistant cell lines, set out to explore structural modifications aimed at increasing the viability of 
an epothilone-derived drug. In pursuing these goals, they utilized  knowledge gained from their 
total synthetic efforts toward epothilones A and B.3 Their early efforts in the total synthesis of 
epothilone B and subsequent in vivo evaluation of the resulting candidates revealed that a likely 
cause of metabolic instability and resulting toxicity of epothilone B is the C12-13 epoxide linkage 
present in the epothilone B structure.4 In this work, (12,13)-desoxy (dEpo) epothilone A and B 
analogs were prepared and tested alongside epothilones A and B (Figure 3.1). 
 
Figure 3.1: EpoB and dEpoB as synthesized and evaluated by the Danishefsky group.4 
 
While dEpoB exhibited lower cytotoxicity than epothilone B (in the low nM IC50 range (dEpoB) 
compared to sub-nM range (EpoB) in various CCRF cell lines), it also displayed a broader 































clinical trials. A bacterial fermentation process for the production of dEpoB was eventually 
developed in collaboration with Kosan Biosciences by manipulation of genes controlling relevant 
biosynthetic clusters, which abrogated the need for total synthesis of this drug lead.5  
3.1.2 Discovery of 12,13-desoxy-9,10-dehydro epothilone structures as promising drug leads 
 A minor fermentation product identified during the dEpoB bacterial fermentation 
development was an epothilone containing unsaturation at both the C12-13 and C10-11 positions, 
a compound later named epothilone 490 (Figure 3.2).6 Initial investigation revealed that this 
doubly unsaturated product largely retained the low nanomolar potency of dEpoB in vitro, with 
IC50 values ranging from 8-30 nM in a variety of cancer cell lines, but it underperformed in murine 
models. While a conclusive reason was not determined, it was tentatively attributed to the high 
esterase activity of murine plasma, and the phenomenon was therefore speculated to be isolated to 
mouse models.2 Because of the general requirement for using murine models in drug development, 
this candidate was abandoned. However, the promising cytotoxicity profile led to a synthetic effort 
aimed at exploring structure activity relationships pertaining to unsaturation in this region of the 
epothilone scaffold. 
 
Figure 3.2: Epo 490, a C10-11 unsaturated epothilone analog with promising in vivo cytotoxicity. 
 
 Although Epo 490 was ultimately not pursued for development, the researchers in the 

















pertaining to subsequent drug candidates. This strategy involved the coupling of alcohol A to acid 
B to produce ester C. This coupling was followed by RCM and deprotection to give conjugated 
diene D, which proceeded with high E/Z selectivity, and deprotection to give Epo 490 (Scheme 
3.1).7 
 
Scheme 3.1: Fragment coupling, RCM, and final steps of the Danishefsky synthesis of Epo 490.7 
 Simultaneously, the researchers pursued development of a C12 trifluoromethyl analog. 
This was motivated by the known tendency of fluoride incorporation to alter the biological activity 
of drug molecules, as well as the hope that this modification would increase the metabolic stability 
of the drug. To this end, they synthesized trifluoromethyl-containing alcohol fragment E, coupled 
it to carboxylic acid F to generate ester G, and subjected G to the RCM conditions utilized on ester 
C (an Epo 490 synthetic intermediate, see above). They found that their previously-successful 
RCM conditions failed on the trifluoromethyl substrate (Scheme 3.2).2 To probe possible reasons 
for this failure, they synthesized ester J, which contains a single carbon “spacer” that increases 









































1) Zn, THF, AcOH, 86%
2) HF•pyridine, THF


















conditions efficiently closed the substrate into the 17-membered ring (Scheme 3.3). This strategy 
was also effective for synthesis of the parent methyl 17-membered ring product, and deprotection 
of both products furnished 17-membered analogs K and L.8,9 
 
Scheme 3.2: Fragment coupling and attempted RCM of Danishefsky first generation synthesis of a C12-
trifluorometyl dEpoB analog, trifluoromethyl group shown in red. 
 

































































I: R = Me
J: R = CF3
K: R = Me




Scheme 3.4: Initial Danishefsky synthesis of fludelone and C9-10 unsaturated dEpoB with significant 
formation of seven-membered RCM byproduct. 
 Biological testing of both the 16-membered and 17-membered ring analog showed that the 
17-membered analog retained much of the cytotoxicity in the methyl case, with IC50 values ranging 
from 40-126 nM in CCRF cell lines,9 leading to the hypothesis that double unsaturation could be 
exploited to produce a more potent analog.8 These observations led to a final effort to synthesize 
a trifluoromethyl-containing 16-membered doubly-unsaturated ring, with the initially-desired 
C10-11 unsaturation necessarily shifted to the C9-10 position to allow for success of the RCM.10 
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3.4). Ester coupling of alcohol N and acid O followed by RCM of the resulting ester Q led to 
recovery of desired ring-closed product S, although with a seven-membered ring product as the 
major species formed. Deprotection afforded the desired CF3-containing epothilone analog, which 
was named fludelone. The same strategy was utilized to obtain C12-Me, C9-10 unsaturated dEpoB 
T, which was named dehydelone. 
3.1.3 Biological evaluation 
 Testing of both C9-10 unsaturated analogs on xenograft tumor models was performed. 
While methyl analog T (dehydelone) showed increased potency compared to dEpoB, it was unable 
to completely eliminate tumors in mouse xenograft models, likely due to its dose-limiting toxicity. 
Fludelone, in contrast, had partially attenuated cytotoxicity and a broad therapeutic index, allowing 
for complete clearance of the tumors.2  
3.1.4 Optimization of dehydelone and fludelone synthesis 
 The promising biological data obtained from fludelone necessitated a synthesis able to 
produce significant quantities of the molecule. The unfavorable RCM was an obvious bottleneck 
that led to a revisiting of the synthetic strategy. Because the main source of diminished yield was 
a competing RCM involving the olefinic side chain, a strategy was attempted involving installation 
of the side chain by Wittig olefination after closing of the macrolactone by RCM with C12-methyl 
functionality (Scheme 3.5). Potential issues with the presence of the ketone, including 
epimerization of the neighboring asymmetric alcohol and ketolization, were not observed, and the 
desired RCM proceeded in high yield with the desired macrolactone as the major product. 
Olefination was achieved in high yield and E/Z selectivity. This strategy was successfully extended 
to the C12-trifluoromethyl analog.10 Notably, this general retrosynthetic strategy was also used in 
the Leighton group’s synthesis of a linker-equipped EpoB analog.11 
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Scheme 3.5: Optimized fludelone synthesis with aromatic side chain attachment occurring after RCM. 
 
3.1.5 Discovery of iso-fludelone 
 Following the discovery of fludelone, further efforts to optimize the structure as a cancer 
drug lead were attempted. Toward this end, the thiazole side chain present on fludelone was 
replaced with an isoxazole chain in an attempt to increase potency, resulting in the molecule now 
known as iso-fludelone. These efforts were successful, with an increase in potency and 
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Figure 3.3: Iso-fludelone, with IC50 values (nM) of 0.045 (A549 cells), 0.154 (HCT-116 cells), and 1.55 
(MX-1 cells).12 
3.2 Synthesis of linker-equipped iso-fludelone analog 
3.2.1 Linker-equipped iso-fludelone retrosynthetic analysis 
 The high metabolic stability and potency of iso-fludelone, in our view, make it an ideal 
candidate for an epothilone ADC payload. We also speculate that the electron-withdrawing nature 
of both the isoxazole and trifluoromethyl functionalities should suppress the pathway involved in 
unimolecular lactone cleavage through the allylic carbocation intermediate (Figure 3.4). 
 












































Figure 3.5: Disconnection strategy for synthesis of linker-equipped iso-fludelone synthesis. 
In addition, the robust chemistry for synthesis of the trifluoromethyl-containing fragment 
established by Danishefsky and coworkers as well as our synthesis of the epothilone 
polypropionate fragment developed during our ixabepilone efforts detailed in Chapter 2 made a 
linker-equipped iso-fludelone a convenient target for us. In parallel with the Danishefsky strategy, 
we envisioned our target arising from the ester coupling of retrosynthetic fragments 3.1 and 3.2, 
followed by RCM, Wittig olefination for side chain incorporation, and subsequent deprotection to 
afford our desired product (Figure 3.5) 
3.2.2 Coupling of iso-fludelone retrosynthetic fragments 
 Alcohol 3.4, which we obtained through the methods utilized by Danishefsky and 
coworkers,10 was coupled to polypropionate fragment 3.3 (synthesis covered in Chapter 2) using 
standard EDCI coupling protocol to produce ester 3.5 in good yield. This substrate was subjected 
to RCM conditions to afford ring-closed product 3.6 in respectable yield as the major product. 













































isoxazole 3.8. Isoxazole 3.8 was treated with HF•pyridine to afford 3.9, iso-fludelone as the final 
product (Scheme 3.6). 
 
Scheme 3.6: Fragment coupling, RCM, and final steps of a linker-equipped iso-fludelone synthesis. 
3.2.3 Azide and acetamide iso-fludelone analog synthesis 
 With our chloride-functionalized iso-fludelone analog in hand, we pursued the synthesis of 
analogs for biological testing. Azide 3.11 was obtained through treatment of chloride 3.10 with 
























































































intermediate was treated with NHS ester 3.13 to afford acetamide 3.14 (Scheme 3.7). Analogs 3.11 
and 3.14 were tested for cytotoxicity. 
 
Scheme 3.7: Derivatization of iso-fludelone to analogs for biological testing. 
3.3 Biological analysis of iso-fludelone analogs 
3.3.1 In vitro cellular cytotoxicity against PC3 cells 
 Initial biological results, obtained by Dr. Dan Sackett, for analogs 3.11 and 3.14 were 
promising, with both analogs demonstrating cytotoxicity profiles comparable to EpoB in the 
human prostate cancer PC3 cell line (Table 3.1). This result is both highly satisfying and 
predictable. By utilizing established synthetic strategies to generate our major retrosynthetic 
fragments, a fragment coupling strategy with precedent in our group, and a previously-optimized 
drug scaffold, we reduced the risk of unforeseen synthetic issues and potential lack of biological 
activity to create a highly potent linker-functionalized epothilone analog that we hope will 










































































Table 3.1: Cytotoxicity of iso-fludelone analogs in PC3 human prostate cancer cell line. 
 
3.4 Summary and outlook 
 Motivated by our desire to expand the list of potential payloads for ADCs and by our early 
failure to achieve the synthesis of a biologically active linker-equipped ixabepilone analog, we 
pursued the synthesis of a linker-equipped analog of iso-fludelone, an epothilone analog with high 
metabolic stability, broad therapeutic index, and what we hoped would be a decreased tendency 
toward lactone cleavage. Our disconnection strategy mirrored that of the Danishefsky group’s 
fludelone synthesis, with major disconnections at the lactone bond and C9-10 olefin and 
attachment of the aromatic side chain by Wittig olefination post fragment coupling. We took 
advantage of our latest generation polypropionate synthesis and known chemistry from the 
Danishefsky group to generate the relevant retrosynthetic fragments. 
 The synthesis proceeded smoothly with no major issues arising. Following attainment of a 
linker-equipped iso-fludelone analog, we substituted the linker chloride functionality with an azide 
functionality and evaluated this analog in cytotoxicity assays. We also converted the azide analog 
to an acetamide in a two-step process to generate a second analog for testing that mimics a potential 
connection to an antibody. We were gratified to find that both compounds demonstrated 












































 We believe that our linker-equipped iso-fludelone analog has great promise as an ADC 
payload. Chapter 5 details some of our work toward incorporating it into a small molecule-drug 
conjugate, but incorporation into an ADC remains unexplored. Future work, perhaps in 
collaboration with a biotechnology partner, should focus on evaluation of our linker-equipped iso-
fludelone against a panel of cancer cell lines, acid stability assays, and linkage of our analog to 



















3.5 Experimental procedures and characterization 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were purified 
by passage through an activated alumina column. Thin-layer chromatography (TLC) was carried 
out on glass backed silica gel TLC plates (250 µm for analytical and 1000 or 2000 µm for 
preparative) from Silicycle; visualization by UV light, cerium ammonium molybdate (CAM), 
phosphomolybdic acid (PMA), p-anisaldehyde stain, or potassium permanganate (KMnO4) stain. 
HPLC analysis was carried out on an Agilent 1200 Series using a Chiralpak OD-H (250 x 4.5 mm 
ID) column. Diasteriomeric ratios for all compounds were determined by 1H NMR analysis of the 
unpurified reaction mixtures. 1H NMR spectra were recorded on a Bruker AVIII 400 (400 MHz) 
and AVIII 500 (500 MHz) spectrometer and are reported in ppm, relative to residual protonated 
solvent peak (CDCl3, 7.26 ppm) unless otherwise indicated. Data are reported as follows: 
(bs=broad singlet, s=singlet, d=doublet, t=triplet, q=quarter, m=multiplet, dd=doublet of doublets, 
ddd=doublet of doublet of doublets, ddt=doublet of doublet of triplet, td=triplet of doublets; 
coupling constant(s) in Hz; integration). Proton decoupled 13C spectra were recorded on a Bruker 
AVIII 400 (100 MHz) and AVIII 500 (125 MHz) spectrometer and are reported in ppm from 
CDCl3 internal standard (77.16 ppm) unless otherwise indicated. High-resolution mass spectra 
were obtained from the Columbia University Mass Spectrometry Facility on a Waters XEVO 
G2XS QToF mass spectrometer equipped with a UPC2 SFC inlet, electrospray ionization (ESI) 
probe, atmospheric pressure chemical ionization (APCI) probe, and atmospheric solids analysis 
probe (ASAP). Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR 
spectrometer. Optical rotations were recorded on a Jasco DIP-1000 digital polarimeter. Buffered 
silica gel (pH 7.00) was prepared as follows: A 1000 mL round bottom flask charged with silica 
 116 
gel (250 g) and 25.0 mL of pH 7.00 buffer solution (potassium dihydrogen phosphate/sodium 
hydroxide, Fluka Analytical) was stirred on a rotary evaporator under atmospheric pressure 
overnight. 
SAFETY STATEMENT. No unexpected or unusually high safety hazards were encountered. 
3.5.1 Preparation of 3.11 
 
 To a 0 °C solution of 3.4 (82 mg, 0.37 mmol) in CH2Cl2 (3.35 mL) was added EDCI (0.369 
mmol) and DMAP (0.369 mmol). The resulting solution was stirred at 0 °C for 15 minutes, 
followed by dropwise addition of 3.3 (213 mg, 0.369 mmol, 1 eq.) in CH2Cl2 (1 mL). After 5 
minutes, the reaction was allowed to warm to room temperature over 3 h. Analysis by TLC showed 
full consumption of acid 3.3, and the reaction mixture was concentrated. The resulting residue was 
filtered through a silica gel plug, eluting with 20:80 EtOAC:hexanes to afford ester 3.5 (205 mg, 
71% yield) as a colorless oil. Recovered alcohol 3.4 (22 mg, 0.099 mmol) was subjected to the 
same reaction conditions, with a modification of 1.5 equivalents acid 3.3 and 1.5 equivalents 
DMAP. Purification by the above method afforded ester 3.5 (89 mg, quantitative yield) as a 
colorless oil.   
OR [α]D23 -12.3 (c 1.0, CHCl3) 
IR (thin film) 3079, 2955, 2876, 1733, 1691, 1640, 1458, 1415, 1379, 1359, 1316, 1294, 1238, 




























1H NMR (400 MHz, CDCl3) δ 6.19 (td, J = 7.4, 2.0 Hz, 1H), 5.97 – 5.62 (m, 2H), 5.26 – 4.89 (m, 
4H), 4.30 (dd, J = 6.8, 3.3 Hz, 1H), 3.85 (dd, J = 5.0, 3.5 Hz, 1H), 3.50 (t, J = 6.7 Hz, 2H), 3.10 – 
2.92 (m, 3H), 2.71 (dd, J = 17.2, 3.3 Hz, 1H), 2.60 (tt, J = 5.5, 2.4 Hz, 2H), 2.39 (dd, J = 17.2, 6.8 
Hz, 1H), 2.23 – 2.11 (m, 4H), 1.79 – 1.61 (m, 3H), 1.48 (ddq, J = 13.8, 10.4, 4.5 Hz, 1H), 1.32 
(qd, J = 8.5, 6.1 Hz, 2H), 1.24 (s, 3H), 1.17 (d, J = 2.7 Hz, 1H), 1.13 – 1.01 (m, 5H), 1.01 – 0.87 
(m, 18H), 0.61 (q, J = 7.9 Hz, 12H) 
13C NMR (126 MHz, CDCl3) δ 216.3, 204.7, 171.9, 140.3, 133.4, 130.6 (d, J = 28.8 Hz), 129.2 
(d, J = 6.3 Hz), 124.0 (d, J = 273.4 Hz), 116.8, 115.5, 75.8, 74.4, 72.3, 53.1, 51.7, 45.0, 44.4, 39.7, 
33.2, 30.0, 28.5, 26.8, 26.5, 25.3, 24.1, 20.0, 18.6, 7.2, 7.1, 5.6, 5.2 










































































































































































































































































To a solution of ester 3.5 (294 mg, 0.376 mmol, 1 eq.) in toluene (260 mL) heated at reflux 
was added a solution of Grubbs second generation catalyst (48 mg, 15 mol%) in toluene (5 mL) in 
one portion. The resulting solution was stirred at reflux temperature for 30 minutes with constant 
N2 sparging, then cooled to 0 °C. The solution was filtered through a silica gel plug, eluting with 
30:70 EtOAc:hexanes to afford crude product. The crude product was partially purified by running 
through a second silica gel plug, eluting with 10:90 EtOAc:hexanes to afford crude product 3.8 
(139 mg) as a light brown oil, which was taken through the next step without further purification. 
 To a 0 °C solution of Wittig salt 3.7 (180 mg, 0.563 mmol) in THF (5.4 mL) was added 
dropwise a solution of KHMDS (112 mg, 0.563 mmol) in toluene (1.13 mL). The resulting mixture 
was stirred at 0 °C for 30 minutes, then cooled to -78 °C. To the cooled mixture was added 
dropwise crude metathesis product (71 mg, 0.094 mmol) in THF (5 mL). The mixture was stirred 
at -78 °C for 1.5 h, then warmed to -40 °C and stirred for an additional 1 h, at which point TLC 
indicated full conversion. To the reaction mixture was added 10 mL of saturated aqueous NaHCO3, 



















































EtOAc. The organics were combined, dried, and concentrated. The resulting residue was purified 
by silica gel flash chromatography, eluting with 5:95 ® 10:90 EtOAc:hexanes to afford isoxazole 
3.8 (78 mg, 49% yield, two steps) as a colorless oil. 
OR [α]D23 13.0 (c 1.0, CHCl3)  
IR (thin film, cm-1) 2955.85, 2876.56, 1743.38, 1688.95, 1603.30, 1456.89, 1415.47, 1380.08, 
1320.92, 1246.32, 1169.03, 1113.70, 1005.98 
1H NMR (400 MHz, CDCl3) δ 6.46 – 6.34 (m, 1H), 6.20 (ddd, J = 10.3, 4.8, 2.3 Hz, 1H), 5.99 (d, 
J = 1.0 Hz, 1H), 5.71 (dd, J = 15.7, 8.0 Hz, 1H), 5.60 (dd, J = 9.3, 3.1 Hz, 1H), 5.41 – 5.25 (m, 
1H), 4.43 (dd, J = 7.7, 3.0 Hz, 1H), 4.10 (d, J = 9.5 Hz, 1H), 3.60 – 3.39 (m, 2H), 3.10 – 2.97 (m, 
2H), 2.87 – 2.76 (m, 2H), 2.52 – 2.41 (m, 5H), 2.35 (dd, J = 14.3, 3.1 Hz, 1H), 2.23 – 2.05 (m, 
4H), 1.87 (tt, J = 13.4, 4.2 Hz, 1H), 1.70 (dddd, J = 23.6, 19.9, 10.6, 6.9 Hz, 2H), 1.56 (s, 1H), 
1.43 (s, 1H), 1.17 – 0.82 (m, 28H), 0.74 – 0.50 (m, 12H) 
13C NMR (126 MHz, CDCl3) δ 215.4, 170.1, 169.2, 159.7, 142.1, 133.4, 131.0 (d, J = 28.0 Hz), 
130.3 (d, J = 6.3 Hz), 126.9, 124.2 (d, J = 273.8 Hz), 115.8, 102.3, 76.8, 75.5, 73.7, 54.0, 53.3, 
44.8, 42.1, 41.4, 33.1, 32.6, 29.6, 28.0, 25.2, 22.9, 21.6, 19.4, 15.3, 12.3, 7.3, 7.1, 5.8, 5.4 
























































































































































































































































































 To a cooled (0 °C) solution of isoxazole 3.8 (25 mg, 0.030 mmol) was added dropwise 
HF•pyridine (0.3 mL). The solution was warmed to room temperature and stirred for 3 h. The 
solution was cooled to 0 °C and quenched with methoxytrimethylsilane (1.92 mL). The quenched 
solution was stirred at room temperature for 3 h and then concentrated. The resulting residue was 
purified by silica gel flash chromatography, eluting with 40:60 EtOAc:hexanes to give diol 3.9 (10 
mg, 55%) as a colorless foam. 
OR [α]D23 -37.7 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3458.17, 2961.13, 2928.83, 2872.00, 1736.97, 1684.90, 1601.68, 1448.26, 
1381.07, 1317.14, 1247.42, 1168.67, 1112.88, 1055.20, 1003.66, 910.47, 648.90 
1H NMR (400 MHz, CDCl3) δ 6.43 (t, J = 1.3 Hz, 1H), 6.25 – 6.10 (m, 1H), 6.03 (d, J = 1.0 Hz, 
1H), 5.79 – 5.48 (m, 2H), 5.39 (dd, J = 7.3, 3.9 Hz, 1H), 4.26 (q, J = 6.0 Hz, 1H), 3.73 (q, J = 5.1 
Hz, 1H), 3.52 (td, J = 6.6, 3.2 Hz, 2H), 3.16 (td, J = 6.8, 3.9 Hz, 1H), 3.04 – 2.87 (m, 2H), 2.70 
(dt, J = 15.2, 8.9 Hz, 1H), 2.63 – 2.48 (m, 2H), 2.48 – 2.39 (m, 5H), 2.26 (p, J = 5.8 Hz, 1H), 2.06 
– 2.02 (m, 3H), 2.00 – 1.82 (m, 2H), 1.81 – 1.70 (m, 2H), 1.68 (s, 1H), 1.53 (ddt, J = 13.7, 10.0, 
4.6 Hz, 1H), 1.45 – 1.29 (m, 4H), 1.14 – 1.06 (m, 3H), 1.05 (s, 3H) 
13C NMR (101 MHz, CDCl3) δ 216.6, 170.1, 169.3, 141.7, 132.9, 130.9 (d, J = 28.5 Hz), 129.9, 
128.0, 121.7 (d, J = 223.7 Hz), 117.6, 114.7, 102.4, 76.5, 74.1, 72.2, 53.4, 50.5, 44.7, 39.4, 39.2, 
32.9, 31.1, 28.7, 27.1, 24.4, 22.4, 19.0, 18.1, 16.3, 12.3 
HF•pyridine
THF


























































































































































































































































































































 To a vial containing diol 3.10 (10 mg) was added NaN3 (2 eq.) and DMF (0.3 mL). The 
resulting mixture was heated for 12 h at 60 °C. The mixture was concentrated, and the resulting 
reside was purified by silica gel flash chromatography, eluting with 40:60 EtOAc:hexanes to afford 
azide 3.11 (8.6 mg, 85% yield) as a colorless foam. 
OR [α]D23 -40.8 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3473.70, 2959.80, 2928.81, 2871.38, 2096.27, 1738.69, 1685.29, 1601.93, 
1450.15, 1380.93, 1317.87, 1248.45, 1168.96, 1113.17, 1051.26, 1003.75,  
1H NMR (400 MHz, CDCl3) δ 6.43 (t, J = 1.3 Hz, 1H), 6.16 (td, J = 8.2, 7.4, 4.1 Hz, 1H), 6.02 (d, 
J = 1.1 Hz, 1H), 5.76 – 5.50 (m, 2H), 5.40 (dd, J = 7.3, 3.9 Hz, 1H), 4.26 (d, J = 6.1 Hz, 1H), 3.73 
(s, 1H), 3.26 (td, J = 6.7, 4.0 Hz, 2H), 3.16 (td, J = 6.7, 4.0 Hz, 1H), 3.06 – 2.86 (m, 2H), 2.79 – 
2.63 (m, 1H), 2.55 (d, J = 6.3 Hz, 2H), 2.49 – 2.38 (m, 5H), 2.26 (p, J = 6.1 Hz, 1H), 2.05 (s, 3H), 
2.00 – 1.83 (m, 2H), 1.68 – 1.49 (m, 5H), 1.31 (s, 4H), 1.10 (d, J = 7.0 Hz, 3H), 1.05 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 216.5, 170.1, 169.3, 141.7, 132.9, 130.8 (d, J = 28.3 Hz), 130.0 
(d, J = 6.0 Hz), 128.0, 124.1 (d, J = 273.4 Hz), 114.7, 102.4, 76.5, 74.1, 72.2, 53.4, 51.2, 50.5, 
39.4, 39.2, 31.1, 29.9, 29.3, 28.7, 27.5, 24.3, 22.4, 19.1, 18.1, 16.3, 12.4 










































































































































































































































































































3.5.2 Preparation of 3.14 
 
 To a solution of azide 3.11 (10 mg, 0.016 mmol) in THF (0.164 mL) and H2O (16.4 µL) 
was added PPh3 (1 eq.). The resulting solution was heated to 38 °C and stirred for 12 h. The 
solution was concentrated and partially purified by silica gel flash chromatography, eluting with 
1:20 ® 1:10 MeOH:CH2Cl2 to give crude 3.12. Without further purification, the resulting crude 
residue was dissolved in DMF (0.25 ml), and succinate ester 3.13 (4 mg, 0.0246 mmol) was added 
to the solution. The mixture was stirred at room temperature for 48 h. The mixture was 
concentrated and purified by silica gel flash chromatography, eluting with 1:20 MeOH:CH2Cl2 → 
100% ethyl acetate to afford acetamide 3.14 (7 mg, 68% yield) as a colorless oil. 
OR [α]D23 -31.1 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3358.60, 2927.37, 2856.44, 1736.33, 1654.98, 1603.59, 1555.74, 1447.96, 
1376.65, 1318.41, 1247.77, 1168.79, 1112.93, 1052.68, 1004.76, 943.55, 755.34 
1H NMR (500 MHz, CDCl3) δ 6.45 (t, J = 1.3 Hz, 1H), 6.17 (t, J = 7.3 Hz, 1H), 6.05 (s, 1H), 5.79 
– 5.64 (m, 2H), 5.59 – 5.37 (m, 2H), 4.30 (t, J = 6.3 Hz, 1H), 3.76 (dd, J = 7.4, 3.8 Hz, 1H), 3.45 
– 3.31 (m, 1H), 3.24 – 3.05 (m, 2H), 3.04 – 2.85 (m, 3H), 2.69 (dt, J = 15.7, 8.0 Hz, 1H), 2.56 (d, 
J = 15.8 Hz, 1H), 2.50 (s, 2H), 2.43 (s, 3H), 2.19 (d, J = 9.6 Hz, 1H), 2.13 (s, 1H), 2.06 (d, J = 1.3 
Hz, 3H), 1.97 (d, J = 2.5 Hz, 1H), 1.95 (s, 3H), 1.52 (dt, J = 13.5, 6.2 Hz, 2H), 1.43 (d, J = 5.7 Hz, 
























































13C NMR (126 MHz, CDCl3) δ 216.7, 170.1, 169.4, 141.8, 135.4 – 132.0 (m), 130.9 (d, J = 27.9 
Hz), 129.9 (d, J = 6.1 Hz), 127.9, 123.3 (d, J = 498.2 Hz), 114.6, 102.4, 99.9, 76.4, 74.2, 71.5, 
53.4, 50.7, 39.6 (d, J = 3.7 Hz), 38.6, 31.3, 29.8, 28.9, 27.5, 23.8, 23.5, 21.5, 19.7, 18.7, 17.6, 16.5, 
12.4 














































































































































































































































































































3.6 Biological data 
In Vitro Cell Growth Inhibition Assays 
Assay protocols 
PC3, human prostate cancer, and A549, human lung cancer, cell lines were obtained from 
the NCI anticancer drug screen. All cells were maintained in RPMI medium supplemented with 
10% fetal bovine serum. Growth inhibition was determined by the resazurin method, following 
exposure to serial dilutions of each compound for 4 days prior to assay and GI50 determinations as 
described.13 Each compound was tested with an initial 10-dose dilution series, followed by 
narrower, replicate 2-dose series, each of which was a separate experiment. The results presented 




 GI50 nM na 
epothilone B 3.1 2 
paclitaxel 0.6 2 
3.11 1.1 2 
3.14 0.8 2 
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CHAPTER 4: Synthesis and biological evaluation of novel fluorinated epothilone analogs 
4.1 Introduction 
4.1.1 Major efforts in structural modification of the epothilone scaffold 
 Following the successful synthesis and biological validation of our linker-equipped iso-
fludelone analogs, we became interested in exploring truly novel structural modifications aimed 
at increasing the acid stability of the epothilones. To explore possible options, we looked to the 
extensive literature exploring the structure-activity relationships in various segments of the 
epothilone scaffold, and we ultimately became interested in the C12-15 and side chain regions of 
the molecule. Certain structural changes in these segments have been shown to be well-tolerated, 
which is discussed below (Figure 4.1). The regions are also proximal to the labile bond in the 
undesired macrolactone cleavage pathway, creating the opportunity for analog syntheses aimed at 
inductive destabilization of the relevant cleavage pathway. Numerous structural modifications 
have been attempted in an effort to elucidate epothilone SAR and have been reviewed,1,2 and a 
comprehensive discussion is beyond the scope of this work. However, two broad strategies for 
structural modifications in these areas have had standout success, and they will be the focus of this 
introduction. 
 
















side chain region labile bond
16
 134 
 The first strategy involves the C12-13 epoxide, which has been shown to be unimportant 
for the activity of epothilones. Such activity has been demonstrated by (12,13)-desoxy epothilones, 
which show only a modest decrease in activity compared to their epoxy counterparts (as covered 
in Chapter 3).3 In addition, Nicolaou and coworkers investigated (12,13)-cyclopropyl and (12,13)-
cyclobutyl epothilone analogs, examples of which also showed modest activity, further 
demonstrating that the epoxide oxygen has at most limited importance to binding interactions 
(Figure 4.2).4 A number of Nicolaou’s analogs also contained scrambled C12 stereochemistry, and 
several of these also demonstrated cytotoxicity with IC50 values in the low to mid nM range 
(although stereochemistry at C13 seems to be critical if the epoxide is present).4,5 
 
Figure 4.2: Examples of (12,13)-cyclopropyl and -cyclobutyl epothilone analogs that exhibit significant 
biological activity.4,5 
 A second significant strategy for structural modification is substitution of the thiazole side 
chain. This technique was employed to good effect by the Danishefsky group in their development 
of iso-fludelone, as detailed extensively in Chapter 3.6 In addition, Nicolaou and coworkers 
explored the substitution of unsubstituted and methyl-substituted pyridines in place of the side 
chain thiazole. By altering the position of the nitrogen in the heterocycle, it was observed that 
placement of the nitrogen atom adjacent to the site of attachment is essential for activity, and 





























low and sub-nanomolar range (Figure 4.3).7 Later, Nicolaou and coworkers explored a variety of 
diverse aryl group substitutions, resulting in the discovery of an epothilone with an exotic side 
chain an order of magnitude more cytotoxic than epothilone B (Figure 4.4).4,8–10 
 
Figure 4.3: Pyridine epothilone analogs with IC50 values in the low (single digit) or sub-nM range in 
1A9, PTX10, A8 and B10 cell lines.7 
 
Figure 4.4: Side chain-substituted epothklone an order of magnitude more cytotoxic than epothilone B, 
with substituted aryl group shown in red. 
 Although extensive SAR studies of the regions in question have been demonstrated, one 
area that has received limited attention is the C16 methyl group of the side chain (see Figure 4.1). 
Tubulin polymerization assays of cis- and trans-C16 ethyl-substituted (12,13)-desoxy EpoA were 
completed by Nicolaou et al. and failed to demonstrate definitive activity in tubulin polymerization 
assays,11 but this substitution was not demonstrated in the epothilone B system, providing a 

























































identified as a minor metabolite from S. cellulosum, but biological activity studies were not 
reported (Figure 4.5c).12 
In addition to C16 alkyl substitutions, an epothilone B analog with the C16 methyl group 
substituted for a fluoride has been explored in a pharmaceutical context and is present in the patent 
literature.13 This fluoro analog showed promising cytotoxicity and will be discussed in upcoming 
sections. The limited past exploration of substitutions at the C16 site combined with its proximity 
to the labile bond of interest indicated to us a potentially promising site of modification to generate 
novel epothilone analogs. We decided to explore the introduction of inductively electron-
withdrawing substituents at this position, as this strategy would theoretically destabilize the 
transition state required for allylic carbocation formation and macrolactone opening. 
 
Figure 4.5: Known analogs with C16 substitution; a) cis-12,13-desoxy C16 ethyl-substituted epothilone 
A; b) trans-12,13-desoxy C16 ethyl-substituted epothilone A; c) C16 ethyl-substituted epothilone B, 
identified as minor metabolite from S. cellulosum. 
4.1.2 Linker-equipped trifluoromethyl analog design and fragment coupling strategy 
 Our initial ideas focused on substitution of one to three of the C16 methyl hydrogens with 
fluoride moieties. We hoped that the highly electron-withdrawing nature of the fluoride substituent 
in close proximity to the labile bond would achieve the desired stabilization of the lactone (Figure 











































quickly decided to target a trifluoromethyl analog. A number of trifluoromethyl-containing starting 
materials are commercially available and relatively inexpensive, obviating the need to utilize 
fluoride-introducing methodologies, which made the trifluoromethyl analog a more 
straightforward initial target compared to mono- or di-fluoro targets. In addition, the presence of 
three fluoride substituents would maximize the desired electron-withdrawing capability. The 
trifluoromethyl group is widely understood to be sterically larger than the ethyl group,14 occupying 
a steric volume between those of ethyl and isopropyl, and the possible steric basis for a lack of 
activity of previously-identified C16-ethyl EpoA was a potential point of concern. However, the 
stereoelectronic basis for this lack of activity is unclear, and the relative absence of exploration of 
C16 substitutions in the EpoB system convinced us to move forward. 
 






























Figure 4.7: C16 trifluoromethyl-substituted analog fragment coupling strategy. 
 As a result, we decided to target a C16-trifluoromethyl analog of epothilone B. We aimed 
to implement our highly convergent coupling strategy as attempted in our ixabepilone work 
(described in Chapter 2), combining two fully elaborated fragments through esterification followed 
by RCM (Figure 4.7). Although we observed significant seven-membered side product formation 
in our ixabepilone work during the RCM step, we hoped that the added steric bulk and electronic 
deactivation of the side chain olefin would slow the undesired seven-membered ring-forming 
pathway relative to the desired pathway (Figure 4.8). Early on, we also hoped we could develop a 
synthesis utilizing late-stage incorporation of the aryl side chain, which would allow for facile 




















































Figure 4.8:  Possible RCM pathways, with hypothesized bias toward desired product. 
4.1.3 Linker-equipped fluoro analog design and fragment coupling strategy 
 While we pursued a synthesis of the trifluoromethyl analog, we also became interested in 
a simple fluoro-substituted analog, with the C16 methyl group omitted and replaced with a single 
fluoride (Figure 4.9). Discussion of this type of analog present in the patent literature, in particular 
promising in vitro studies reported in a German patent,13 convinced us that this analog might be a 
more promising one to pursue. We also hoped that the electron-withdrawing nature of the single 












































Figure 4.9: C16 fluoro-substituted analog as present in patent literature. 
 
Figure 4.10: C16 fluoro analog fragment coupling strategy. 
 Reported methods for the synthesis of this molecule are long, tedious, and not convergent. 
We sought to improve upon reported methods by again utilizing two fully elaborated fragments, 
with esterification followed by ring-closing metathesis (Figure 4.10). Similar to the trifluoromethyl 
analog, we hoped that the electron-withdrawing nature of the fluoride substituent would deactivate 
its associated olefin from undesired reaction in the RCM step, avoiding formation of an undesired 
seven-membered ring byproduct. Unlike the trifluoromethyl analog, the fluoride substituent is 
































































electronic contributions to transition state energies and generating uncertainty as to the reaction 
outcomes. 
4.2 Synthesis of alcohol fragment of trifluoromethyl analog 
4.2.1 Potential strategies for trifluoromethyl installation and their shortcomings 
 An early and central challenge in the synthesis of the trifluoromethyl analog was selecting 
a trifluoromethyl-containing starting material with usable functionality and establishing the E/Z 
geometry at the side chain tri-substituted olefin. We became interested in ketone G (Figure 4.11b) 
as a possible substrate for olefination, as one can imagine the aldehyde necessary for allylation 
arising from the reduction of the ester. However, the unique configuration of substituents, with the 
trifluoromethyl group cis to the aryl group and gem to a carbinol (masked or otherwise) or ester is 
rare in the literature, and a scalable method for olefination of this type of substrate with the desired 
E/Z selectivity is to our knowledge unprecedented. 
 
Figure 4.11: Traditional methods for construction of the trisubstituted olefin. 
Wittig olefination and olefin metathesis, popular methods for synthesizing olefins, would 
be unlikely to give product enriched in the desired E/Z isomer, and we were unable to find claims 
in the literature to contradict this assumption. Despite these concerns, we attempted a Wittig 


























no olefinic product, further convincing us that Wittig olefination was not a promising strategy to 
pursue. 
4.2.2 Discovery of monolithiation strategy for construction of desired olefin geometry 
 As we struggled with our olefination strategy, we encountered a report demonstrating the 
selective formation of trisubstituted vinyl bromides from MEM-protected dibromo substrate I 
using a substrate-directed monolithiation (Scheme 4.1).15 This report gave us hope that if we could 
obtain a vinyl bromide substrate with appropriate geometry, we could attach the thiazole group via  
cross-coupling methodology. We hoped that we could carry the vinyl bromide through to a late 
stage in the synthesis, allowing for the facile synthesis of a series of aryl group-substituted analogs. 
This cross-coupling strategy is well-precedented in Nicolaou’s exploration of side chain-modified 
epothilones, with aryl group attachment occurring post fragment coupling. 
In the literature, the monolithiation demonstrated a high degree of stereoselectivity, with 
lithiation occurring syn to the trifluoromethyl group in coordinating solvents such as THF, and 
with the subsequent use of the resulting E vinyl bromides as cross coupling partners. Although the 
E geometry was not useful for our purposes, the report also contained an exception to the 
selectivity in which the lithiation occurring in a non-coordinating solvent such as hexanes gave the 
Z vinyl bromide in modest 3:1 selectivity relative to the E isomer. With this knowledge in hand, 
we set out to implement this strategy in our synthesis. 
 





















4.2.3 Implementation of monolithiation strategy to set tri-substituted olefin geometry 
 We began with MEM-protected dibromide I, synthesized using methods established in the 
initial report. We were pleased to find that we could reproduce the results in the report with 
isomeric ratios approaching the reported values as indicated by proton and fluorine NMR 
spectroscopy. Further application of our synthetic strategy then required removal of the MEM 
ether to reveal the unprotected alcohol. This step proved to be challenging, with well-established 
mild deprotection protocols failing to initiate reaction and harsh protocols resulting in product 
degradation (Scheme 4.2). We suspect that the strong electron-withdrawing nature of the 
trifluoromethyl group is responsible for this unusual stability of the MEM ether; the inductive 
effect of the trifluoromethyl group would decrease the Lewis basicity of the oxygen three bonds 
away, slowing the protonation step necessary for deprotection. This led us to consider other more 
easily-cleavable protecting groups. 
 
Scheme 4.2: Failed attempts at removal of the MEM ether, with failure likely due to the electron-
withdrawing nature of the trifluoromethyl group. 
 In pursuing more easily cleavable protecting group strategies, we first tried a triethylsilyl 
ether, as silyl ethers can be easily removed under neutral conditions. However, much of the TES-
protected substrate did not survive the monolithiation step and produced a mixture of products. 
We then tried a PMB ether, feeling it would be more stable to the monolithiation conditions and 
readily cleaved through single electron oxidation (DDQ). Although this change resulted in a lack 
of substrate solubility in the monolithiation conditions, we found that a mixture of hexanes and 







1) TiCl4, CH2Cl2, 0 °C
2) CeCl3•7H2O, MeCN, reflux
3) PPTS, t-BuOH, reflux
4) 33% HBr in AcOH, r.t.
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the monolithiation of substrate 4.5, we were pleased to observe E/Z selectivity results comparable 
to monolithiation of the MEM-protected substrate. Stereoselectivity varied widely from excellent 
to fair depending on the reaction, indicating a need for further optimization, but always produced 
a mixture enriched in the desired Z isomer 4.6 (Scheme 4.3). Notably, these isomers were difficult 
to separate by column chromatography. 
 
Scheme 4.3: Successful implementation of the monolithiation strategy on a PMB protected substrate. 
 Moving forward with our synthetic plan, the next step would involve removal of the PMB 
ether for further functionalization of the alcohol. When we attempted the removal, however, we 
observed extremely low yields after isolation. We suspect the product is volatile, which could 
partially explain this observation. To circumvent this issue, we decided to attach the aryl group at 
this stage. This strategy had the distinct disadvantage of ending our hopes to generate a series of 
variable side chain analogs at a late stage in the synthesis, but we felt it would likely prevent 
volatility of the resulting intermediate. We first attempted a Stille coupling on vinyl bromide 4.6 
using a known thiazole-containing tri-n-butylstannane (Scheme 4.4).16 Although we recovered 
some desired product, the recovered mixture was inseparable by available methods, and the 
toxicity of tin reagents and our resulting lack of enthusiasm to produce 4.10 in large enough 





















Scheme 4.4: Non-ideal Stille coupling for installation of aryl group. 
 The Suzuki coupling, as a much safer alternative to the Stille, was an obvious choice for 
us. We were initially dubious of this reaction, as literature precedent shows that thiazole boronic 
acids with the relevant substitution pattern are ineffective Suzuki coupling partners.17 We 
circumvented this issue by instead borylating our vinyl bromide 4.6 using standard conditions to 
produce pinacol boronic ester 4.8. We then coupled 4.8 with a commercially available 
bromothiazole using standard Suzuki conditions to produce olefin 4.10 in excellent yield. We also 
attempted this reaction on a mixture of E/Z vinyl bromides (4.6/4.7) and found that the resulting 
product mixture after Suzuki coupling was easily separable. We adopted this strategy during scale 
up to avoid the difficult separation of 4.6 and 4.7 (Scheme 4.5). 
 
Scheme 4.5: Successful borylation and aryl installation on the trisubstituted olefin substrate utilizing a 
mixture of E/Z vinyl bromides and vinyl boronic esters for scale up. 
4.2.4 Proof of olefin geometry  
 Although we were quite certain of the geometry of our olefin product based on correlation 
with 19F NMR data from the initial report, we needed to establish it to move forward with 





































4.6 (Z) /4.7 (E) 4.8 (Z) /4.9 (E) 4.10
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we believed to be the desired Z isomer. The product that we suspected to have Z geometry showed 
signal amplification of the methylene protons α to the trifluoromethyl group when the vinylic 
proton was irradiated, suggesting accurate assignment (Figure 4.12). This data gave us the 
confirmation we needed to move forward with the synthesis. 
 
Figure 4.12: 1D NOESY spectrum of hypothesized desired isomer 4.10, with relevant NOE signal in blue. 
 
4.2.5 Completion of trifluoromethyl-containing fragment synthesis 
 We then continued with the synthesis. Deprotection of 4.10 proceeded smoothly by 
reaction with DDQ to afford alcohol 4.11 in moderate yield. Oxidation of 4.11 by DMP afforded 
aldehyde 4.12, which was unstable and required immediate allylation to avoid degradation. 


























96% ee. Alcohol 4.13 was protected with TBSOTf to afford protected product 4.14, which was 
oxidatively cleaved to give aldehyde 4.15. Aldehyde 4.15 was treated with ylide 4.16, resulting in  
Scheme 4.6: Transformation of PMB ether 4.10 to alcohol fragment 4.1. 
olefination to afford ester 4.17. Ester 4.17 was reduced with DIBAL-H to afford homoallylic 
alcohol 4.18. Following the route as utilized in our ixabepilone work, we treated 4.18 with pTsCl 
in an attempt to obtain the corresponding tosylate. These conditions, however, resulted in 
degradation of the product. Consultation with the literature gave us the idea to chlorinate 4.18 
using Appel conditions,18 which proceeded smoothly to give chloride 4.19. Treatment of 4.19 with 

















































































































4.3 Fragment coupling and biological evaluation of trifluoromethyl analog 
4.3.1 Coupling of alcohol and polypropionate fragment 
 We then proceeded to couple the fragments. With fragment 4.1 in hand and using 
polypropionate fragment 4.2 as prepared in our previous work, we coupled the fragments via EDCI 
ester coupling to yield ester 4.21. Olefin metathesis using Grubbs 2nd generation metathesis 
catalyst proceeded smoothly to afford ring-closed product 4.22. Notably, as we hypothesized, no  
 
Scheme 4.7: Fragment coupling and final steps to azide analog 4.24. 
seven-membered ring product was observed, which can likely be explained by a combination of 
steric blocking and electronic deactivation of the side chain olefin. Deprotection with HF•pyridine 
gave diol 4.23 as our target analog. We substituted the chloride of diol 4.23 with an azide 



























































































4.3.2 Attainment and biological testing of initial candidate 
  We proceeded to evaluate 4.24 for biological activity in vivo, with experiments performed 
by Dr. Dan Sackett. We were disappointed to find that azide analog 4.24 displayed no activity at 
the relevant nanomolar concentration range. Although the biological results were not what we had 
hoped, azide 4.24 was only the first of several possible analogs that could be tested. We 
hypothesize that biological activity might be attained by removing the unsaturation at the C9-10 
olefin and adding an epoxide bridge between C12 and C13 (Scheme 4.8). Pursuing these steps may 
serve as the basis for future work on this analog type. 
 
Scheme 4.8: Proposed modifications to investigate for biological activity. 
4.4 Synthesis of alcohol fragment of fluoro analog 
4.4.1 Synthesis of fluoride-containing fragment 4.35 
 In an early effort to accomplish the synthesis of the fluoro analog, we began by searching 
for synthetic precedent. We discovered that while there is some documentation of this type of 
fluoride-containing analog, it is limited to patent literature, and the documented synthesis involves 
a complicated retrosynthetic strategy involving several fragments.13 We were hopeful that we 
could accomplish this synthesis using our more straightforward two-fragment coupling strategy. 
Our main concern with this strategy was possible participation of the side chain olefin during our 





















































olefin resulting from the electron-withdrawing fluoride substituent would slow this path relative 
to the desired macrolactone pathway. 
 The reported synthetic strategy to install the trisubstituted olefin utilized a largely non-
selective Wittig olefination using starting formyl thiazole 4.28 and the ylide of fluorinated 
phosphonate 4.27. We attempted several alternate strategies to install the desired functionality with  
 
Scheme 4.9: Construction of fluoride-containine intermediate 4.35. 
a higher level of stereoselectivity, including bromofluorination and hydrofluorination of 
olefins,19,20 but none of these strategies was ultimately successfully. We therefore turned to the 
known method to construct the olefin.13 Although reaction yields are low, the position of this step 
at the beginning of the synthesis and the relative affordability of the starting materials made it 
possible to obtain suitable quantities of product to continue the synthesis.  
 After committing to this strategy, we moved forward with the synthesis. Ester product 4.29 

































































































then reduced by treatment with DIBAL-H, affording a mixture of aldehyde 4.31 and alcohol 4.30. 
The products were separated, and remaining alcohol 4.30 was oxidized to aldehyde 4.31 by 
treatment with DMP. Aldehyde 4.31 was allylated using a Brown allylation to afford chiral alcohol 
4.32. This reaction gave a 92% ee, slightly lower than other Brown allylations discussed in this 
dissertation, which all gave 95-96% ee. A possible explanation for this observation is differences 
in the temperature requirements for the reaction. Aldehyde 4.31 exists as a solid at room 
temperature, in contrast to the other Brown allylation substrates that exist as oils, and it was 
observed to have lower solubility in the diethyl ether reaction solvent. This lower solubility 
required an increase in temperature to push the reaction to completion, likely deteriorating ee by 
further allowing a non-asymmetric pathway. Indeed, after stirring at -78 °C for two hours, warming 
to 0 °C was required to achieve close to full reaction conversion. Alcohol 4.32 was protected using 
TBSOTf, and the resulting product 4.33 was oxidatively cleaved to afford aldehyde 4.34. Aldehyde 
4.34 underwent Wittig olefination by treatment with ylide 4.16 to yield ester product 4.35 (Scheme 
4.9). Future work will focus on the completion of this fragment using methods developed for the 
trifluoromethyl analog synthesis. 
4.5 Fragment coupling and biological evaluation of fluoro analog 
4.5.1 Proposed coupling of alcohol and polypropionate fragment 
 Future fragment coupling work will focus on the completion of the target molecule using 
the strategy developed for the trifluoromethyl analog synthesis. Of particular interest will be the 
behavior of the vinyl fluoride group during RCM and epoxidation reactions, which may be affected 




4.6 Summary and outlook 
 Inspired by the SAR studies of Danishefsky and Nicolaou and in an attempt to create a 
novel epothilone analog with enhanced acid stability, we pursued the synthesis of two linker-
equipped fluoride-containing analogs. The first analog contained a trifluoromethyl group at the 
C16 position and was intended to serve as a starting point for future mono- or di-fluoro 
substitutions at this same position. After initial difficulties in establishing the correct olefin 
geometry in the side chain, we utilized a substrate-directed monolithiation to produce a vinyl 
bromide with appropriate geometry, which was then borylated and cross-coupled with the 
necessary bromothiazole. The remainder of the synthesis proceeded without issue to produce the 
first epothilone analog with trifluoromethyl substitution at the C16 position, and we observed the 
beneficial effects of the C16 trifluoromethyl group on the RCM, which suppressed the undesired 
seven-membered ring-forming pathway. We obtained initial cytotoxicity data for a C9-10 
unsaturated trifluoro analog, which exhibited no discernable activity. Future work should focus on 
hydrogenation of the C9-10 olefin and epoxidation of the C12-13 olefin, with respective 
cytotoxicity assays. Mono- and difluoro substitution at the C16 methyl group should also be 
pursued. 
 The second analog target contained fluoro substitution at C16, replacing the methyl group 
with a single fluoride moiety. A non-linker equipped version of this analog showed promising 
activity in the patent literature. We established the side chain olefin geometry using known 
methods, and proceeded through the synthesis of the side chain-containing fragment using the 
same strategy as utilized in the trifluoromethyl analog. This fragment remains unfinished, and 
future work should focus on completing the fragment and coupling it to the polypropionate 
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fragment, followed by RCM and final steps. Assuming success of the synthesis, cytotoxicity assays 
should be performed.  
 Regardless of biological activity, we would in future like to pursue acid stability studies of 
our synthesized molecules. Data obtained from these studies would hopefully give insight into our 
hypotheses concerning the effects of electron-withdrawing substituents at the C16 position, 



















4.7 Experimental procedures and characterization 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were purified 
by passage through an activated alumina column. Thin-layer chromatography (TLC) was carried 
out on glass backed silica gel TLC plates (250 µm for analytical and 1000 or 2000 µm for 
preparative) from Silicycle; visualization by UV light, cerium ammonium molybdate (CAM), 
phosphomolybdic acid (PMA), p-anisaldehyde stain, or potassium permanganate (KMnO4) stain. 
HPLC analysis was carried out on an Agilent 1200 Series using a Chiralpak OD-H (250 x 4.5 mm 
ID) column. Diasteriomeric ratios for all compounds were determined by 1H NMR analysis of the 
unpurified reaction mixtures. 1H NMR spectra were recorded on a Bruker AVIII 400 (400 MHz) 
and AVIII 500 (500 MHz) spectrometer and are reported in ppm, relative to residual protonated 
solvent peak (CDCl3, 7.26 ppm) unless otherwise indicated. Data are reported as follows: 
(bs=broad singlet, s=singlet, d=doublet, t=triplet, q=quarter, m=multiplet, dd=doublet of doublets, 
ddd=doublet of doublet of doublets, ddt=doublet of doublet of triplet, td=triplet of doublets; 
coupling constant(s) in Hz; integration). Proton decoupled 13C spectra were recorded on a Bruker 
AVIII 400 (100 MHz) and AVIII 500 (125 MHz) spectrometer and are reported in ppm from 
CDCl3 internal standard (77.16 ppm) unless otherwise indicated. High-resolution mass spectra 
were obtained from the Columbia University Mass Spectrometry Facility on a Waters XEVO 
G2XS QToF mass spectrometer equipped with a UPC2 SFC inlet, electrospray ionization (ESI) 
probe, atmospheric pressure chemical ionization (APCI) probe, and atmospheric solids analysis 
probe (ASAP). Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR 
spectrometer. Optical rotations were recorded on a Jasco DIP-1000 digital polarimeter. Buffered 
silica gel (pH 7.00) was prepared as follows: A 1000 mL round bottom flask charged with silica 
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gel (250 g) and 25.0 mL of pH 7.00 buffer solution (potassium dihydrogen phosphate/sodium 
hydroxide, Fluka Analytical) was stirred on a rotary evaporator under atmospheric pressure 
overnight. 
SAFETY STATEMENT. No unexpected or unusually high safety hazards were encountered. 
4.7.1 Preparation of 4.1 
 
 
To a room temperature solution of 4.4 (2 g, 7 mmol) in CH2Cl2 (23.5 mL) and 
cyclohexane (11.75 mL) was added 4-methoxybenzyl-2,2,2,-trichloroacetimidate (1.76 mL, 8.45 
mmol) and pyridinium p-toluenesulfonate (23.5 mg, 0.705 mmol). The resulting mixture was 
stirred at room temperature for 12 hours. The mixture was diluted with CH2Cl2 (20 mL), washed 
with saturated NaHCO3 (1 x 30 mL) and H2O (1 x 30 mL), and the organic layer was dried over 
over Na2SO4 and concentrated. The resulting was residue was purified by silica gel 
chromatography, eluting with 0:100 ®5:95 EtOAc:hexanes to give pure 4.5 as a yellow oil (2.36 
g, 5.93 mmol, 84% yield). 
IR (thin film, cm-1) 3002, 2936, 2910, 2860, 2838, 2063, 1884, 1611, 1586, 1513, 1463, 1387, 
1358, 1298, 1248, 1175, 1136, 1107, 1071, 1034, 942, 923, 818, 759, 713, 640, 603, 572, 519, 
478 
1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.6 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 4.49 (s, 1H), 
















13C NMR (126 MHz, CDCl3) δ 159.6, 133.9, 133.7, 133.4, 133.2, 129.7, 129.4, 125.7, 123.5, 
121.3, 119.1, 114.0, 104.9, 104.9, 72.4, 68., 68.92, 55.4 



























































































































































 To a cooled (-78 °C) solution of 4.5 (2.36 g, 5.93 mmol) in hexanes (31.6 mL) and 
toluene (40 mL) was added dropwise a 2.5 M solution of nBuLi in hexanes (2.37 mL, 5.93 
mmol). The resulting suspension was stirred at -78 °C for 30 minutes and quenched by the slow 
addition of MeOH (1.28 mL, 31.6 mmol) at -78 °C. The mixture was allowed to warm to room 
temperature, diluted with Et2O (30 mL), and washed with H2O (3 x 20 mL), and the organic 
layer was dried over Na2SO4 and concentrated. The residue was filtered through a plug of silica 
gel, eluting with 40:60 EtOAc:hexanes to give a 17:10 mixture of Z:E isomers 4.6 and 4.7 as a 
yellow oil (1.88 g, 5.89 mmol, 89% yield). The mixture was carried through the next step 
without further purification. A small amount of each isomer was isolated by preparative TLC, 
eluting with 10:90 EtOAC:hexanes for characterization purposes. 
Z isomer: 
IR (thin film, cm-1) 3067, 3002, 2911, 2863, 2839, 2061, 1884, 1635, 1612, 1586, 1513, 1463, 
1362, 1341, 1302, 1248, 1210, 1170, 1134, 1054, 1035, 946, 926, 821, 737, 706, 637, 569, 518, 
466, 422 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.7 Hz, 2H), 6.95 – 6.85 (m, 3H), 4.49 (s, 2H), 4.09 
(d, J = 1.6 Hz, 2H), 3.82 (s, 3H) 
13C NMR (101 MHz, CDCl3) δ 159.7, 132.8 (d, J = 30.23 Hz), 129.6, 129.2, 122.5 (d, J = 
275.53 Hz), 114.1, 114.0 (q, J = 4.30 Hz), 72.5, 68.2 (d, J = 2.96 Hz), 55.4 






















IR (thin film, cm-1) 3082, 3002, 2914, 2861, 2839, 3059, 1635, 1612, 1586, 1513, 1464, 1391, 
1362, 1333, 1302, 1247, 1771, 1130, 1091, 1066, 1035, 993, 946, 926, 845, 822, 763, 748, 711, 
673, 628, 570 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (m, 3H), 6.89 (d, J = 8.7 Hz, 2H), 4.49 (s, 2H), 4.30 
(s, 2H), 3.81 (s, 3H) 
13C NMR (101 MHz, CDCl3) δ 159.6, 132.7 (d, J = 29.66 Hz), 129.7, 129.6, 122.8 (d, J = 
274.86 Hz), 119.9 (q, J = 7.29 Hz), 72.5, 64.6, 55.4 









































































































































































































































 To a degassed room temperature mixture of 4.6 and 4.7 (1.89 g, 5.81 mmol), B2pin2 (1.62 
g, 6.39 mmol), and KOAc (1.14 g, 11.6 mmol) in dioxane (14.5 mL) was added 
Pd(dppf)Cl2•CH2Cl2 (238 mg, 0.291 g). The mixture was stirred at 100 °C under N2 atmosphere 
for 12 hours, at which point TLC (20:80 EtOAc:hexanes) indicated complete conversion. The 
mixture was diluted with CH2Cl2 (20 mL) and filtered through a plug of silica gel, eluting with 
20:80 EtOAc:hexanes to yield a mixture of 4.8 and 4.9 as a colorless oil (1.88 g, 5.05 mmol, 
88% yield). The Z:E mixture was carried to the next step without further purification. A small 
amount of each starting material isomer was subjected separately to the same protocol for 
characterization purposes. 
Z isomer: 
IR (thin film, cm-1) 2980, 2927, 2858, 1672, 1613, 1586, 1513, 1463, 1374, 1321, 1248, 1199, 
1166, 1124, 1036, 968, 904, 849, 822, 740, 709, 668, 636, 596, 576, 542, 518, 406 
1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 6.16 (d, J = 0.8 
Hz, 1H), 4.48 (s, 1H), 4.11 (d, J = 1.7 Hz, 1H), 3.81 (s, 2H), 1.29 (s, 8H) 
13C NMR (126 MHz, CDCl3) δ 159.5, 140.6 (d, J = 29.16), 129.8, 129.5, 123.3 (d, J = 274.85), 
114.0, 84.4, 72.2, 67.6 (d, J = 2.20), 55.4, 29.9, 24.8 
E isomer: 
IR (thin film, cm-1) 2979, 2926, 2854, 1737, 1660, 1613, 1586, 1513, 1464, 1373, 1316, 1246, 











4.6 (Z) /4.7 (E) 4.8 (Z) /4.9 (E)
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1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.34 – 6.10 (m, 
1H), 4.48 (s, 2H), 4.32 (d, J = 0.7 Hz, 2H), 3.80 (s, 2H), 1.27 (s, 12H) 
13C NMR (126 MHz, CDCl3) δ 159.4, 143.6 (d, J = 29.0 Hz), 130.0, 129.6, 123.1 (d, J = 275.2 













































































































































































































































































 To a degassed room temperature mixture of 4.8 and 4.9 (984 mg, 2.64 mmol), 4-bromo-
2-methylthiazole (564 mg, 3.17 mmol), and K3PO4 (3.36 g, 15.8 mmol) in dioxane (26.4 mL) 
and H2O (5.28 mL) was added Pd(PPh3)4 (214 mg, 0.185 mmol). The mixture was stirred at 80 
°C under N2 atmosphere for 12 hours. The mixture was cooled to room temperature, and dioxane 
was removed using a rotary evaporator. EtOAc (20 mL) was added, and the organic layer was 
washed with sat. NaHCO3 solution (1 x 15 mL). The aqueous layer was extracted with EtOAc (1 
x 15 mL). The organic layers were combined, dried over Na2SO4, and concentrated. The residue 
was purified by silica gel chromatography, eluting with 0:100 ® 10:90 EtOAc:hexanes to yield 
Z isomer 4.10 as a yellow oil (491 mg, 1.43 mmol, 54% yield) and E isomer as a yellow oil (381 
mg, 1.11 mmol, 42% yield). 
Z isomer: 
IR (thin film, cm-1) 3000, 2929, 2859, 2058, 1884, 1656, 1612, 1586, 1512, 1463, 1384, 1356, 
1301, 1285, 1246, 1172, 1121, 1058, 1034, 960, 892, 821, 758, 698, 666, 638, 612, 573, 544, 
517, 472, 420 
1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.28 (d, J = 8.6 Hz, 2H), 7.09 (s, 1H), 6.89 (d, J = 
















4.8 (Z) /4.9 (E) 4.10
 167 
13C NMR (126 MHz, CDCl3) δ 165.0, 159.5, 148.1, 130.6 (d, J = 3.9 Hz), 129.74 129.6, 127.0 
(d, J = 29.8 Hz), 123.3 (d, J = 275.1 Hz), 119.9 (d, J = 5.2 Hz), 114.0, 72.2, 69.1 (d, J = 3.3 Hz), 
55.4, 19.2 
HRMS (ASAP+) calculated for C16H17NO2SF3 [M+H]+: 344.0932; found 344.0934 
E isomer: 
IR (thin film, cm-1) 3106, 3001, 2931, 2838, 2059, 1883, 1662, 1612, 1586, 1512, 1464, 1442, 
1373, 1328, 1288, 1245, 1171, 1115, 1065, 1034, 946, 914, 821, 755, 711, 673, 645, 620, 570, 
516, 444 
1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.23 (d, J = 1.7 Hz, 1H), 
6.86 (d, J = 8.6 Hz, 2H), 4.57 (s, 2H), 4.53 (s, 2H), 3.80 (s, 3H), 2.69 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 166.1, 159.4, 149.3, 130.1, 129.8, 129.6 (q, J = 6.1 Hz), 127.6 – 
126.8 (m), 124.5 (d, J = 273.4 Hz), 122.5, 113.9, 72.3, 62.9, 55.4, 19.4 






























































































































































































































































































































































 To a room temperature solution of 4.10 (577 mg, 1.68 mmol) in CH2Cl2 (16.8 mL) and 
H2O (0.933 mL) was added DDQ (400 mg, 1.76 mmol). The mixture was stirred at room 
temperature for 5 hours. The mixture was diluted with CH2Cl2 (15 mL), filtered through a pad of 
Celite, and concentrated. The resulting residue was purified by silica gel chromatography eluting 
with 30:70 ® 40:60 EtOAc:hexanes to give 4.11 as a colorless oil (269 mg, 1.21 mmol, 72% 
yield). 
IR (thin film, cm-1) 3255, 2924, 2853, 1569, 1512, 1438, 1398, 1354, 1284, 1218, 1172, 1119, 
1028, 978, 892, 800, 760, 701, 674, 631, 610, 576, 543, 471 
1H NMR (500 MHz, CDCl3) δ 7.34 (s, 1H), 7.13 (s, 1H), 4.37 (s, 2H), 3.86 (s, 1H), 2.71 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 165.7, 148.0, 131.0 (d, J = 28.9 Hz), 128.0 (d, J = 3.7 Hz), 123.5 
(d, J = 275.1 Hz), 120.3 – 118.5 (m), 61.4 (d, J = 3.9 Hz), 18.9 




















































































































































 To a room temperature solution of 4.11 (25 mg, 0.11 mmol) in CH2Cl2 (0.750 mL) was 
added Dess Martin periodinane (52 mg, 0.12 mmol). The mixture was stirred at room 
temperature for 2 hours. The mixture was diluted with CH2Cl2 (2 mL) and washed with sat. 
NaHCO3 solution (1 x 2 mL). The aqueous layer was extracted with CH2Cl2 (1 x 2 mL). The 
organic layers were combined, dried over Na2SO4, and concentrated. The resulting residue was 
filtered through a silica gel plug, eluting with 30:70 EtOAc:hexanes to give 4.12 as a yellow oil 
(22.9 mg, 1.04 mmol, 92% yield). The product decomposes quickly and was carried immediately 
through the next reaction. 
IR (thin film, cm-1) 3387, 3107, 2923, 3852, 2730, 2373, 1700, 1627, 1599, 1481, 1433, 1377, 
1280, 1226, 1126, 1056, 1011, 964, 890, 820, 768, 748, 718, 676, 636, 583, 570, 528, 497 
1H NMR (400 MHz, CDCl3) δ 9.69 (q, J = 1.6 Hz, 1H), 7.86 (s, 1H), 7.82 (s, 1H), 2.76 (s, 3H) 
13C NMR (101 MHz, CDCl3) δ 186.9 (d, J = 3.4 Hz), 166.3, 147.1, 143.3 (d, J = 3.0 Hz), 128.7 
(d, J = 5.2 Hz), 126.7 (d, J = 30.3 Hz), 122.5 (d, J = 274.9 Hz), 19.3 





























































































































































 To a -40 °C solution of (–)-Ipc2BCl (142 mg, 0.444 mmol) in Et2O (3.16 mL) was added 
dropwise allyl magnesium bromide (1 M solution in Et2O, 0.395 mL, 3.95 mmol). The resulting 
mixture was allowed to warm to room temperature over 1 hour. The mixture was cooled to -78 
°C, and 4.12 (73 mg, 0.33 mmol) in Et2O (0.632 mL) was added dropwise over 10 minutes. The 
mixture was stirred at -78 °C for 2 hours. The mixture was warmed to 0 °C and quenched by the 
addition of 50 µL MeOH, and 0.296 mL 30% H2O2 in H2O, 54 mg NaOAc, and 2 mL H2O were 
sequentially added. The mixture was warmed to room temperature and stirred vigorously for 20 
minutes. The layers were separated, and the aqueous layer was extracted with CH2Cl2 (2 x 3 
mL). The organic layers were combined, dried over Na2SO4, and concentrated. The resulting 
residue was purified by silica gel chromatography, eluting with 20:80 ® 30:70 EtOAc:hexanes 
to give 4.13 as a colorless oil (70 mg, 0.276 mmol, 84% yield, 95% ee).  
OR [α]D23.7 -108.2 (c 0.29, CHCl3)  
IR (thin film, cm-1) 3243, 2921, 2851, 1642, 1513, 1434, 1276, 1278, 1215, 1172, 1146, 1120, 
1048, 979, 918, 763, 677, 584 
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 7.20 (s, 1H), 5.93 – 5.81 (m, 1H), 5.25 – 5.13 (m, 
2H), 4.62 – 4.44 (m, 1H), 2.71 (s, 3H), 2.61 (dt, J = 14.2, 5.1 Hz, 1H), 2.48 (s, 1H), 2.35 (dt, J = 
14.8, 7.7 Hz, 1H) 
13C NMR (126 MHz, CDCl3) δ 165.3, 148.2, 133.8, 133.3 (q, J = 28.3, 27.8 Hz), 127.9 (q, J = 
3.8 Hz), 123.6 (d, J = 275.5 Hz), 119.3 (q, J = 5.1 Hz), 119.1, 69.0 (d, J = 3.2 Hz), 41.4, 19.0 








































































































































































































 To a -78 °C solution of 4.13 (185 mg, 0.703 mmol) and 2,6-lutidine (0.122 mL, 1.06 
mmol) in CH2Cl2 (4.7 mL) was added dropwise TBSOTf (0.194 mL, 0.843 mmol). The resulting 
solution was stirred at -78 °C for 5 minutes and then allowed to warm to room temperature over 
1 hour. The mixture was diluted with CH2Cl2 (5 mL) and washed with saturated NH4Cl solution 
(1 x 3 mL). The aqueous layer was extracted with CH2Cl2 (2 x 3 mL), the organic layers were 
combined, dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel 
chromatography, eluting with 0:100 ® 5:95 EtOAc:hex to give 4.14 as a colorless oil (258 mg, 
0.682 mmol, 97%). 
OR [α]D22.1 -35.1 (c 0.35, CHCl3)  
IR (thin film, cm-1) 3078, 2954, 2930, 2889, 2857, 1657, 1643, 1510, 1470, 1435, 1391, 1359, 
1277, 1256, 1214, 1169, 1143, 1119, 1052, 989, 915, 832, 811, 777, 752, 675, 607, 587, 555, 
494, 413 
1H NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 7.12 (s, 1H), 5.91 – 5.72 (m, 1H), 5.13 – 5.00 (m, 
2H), 4.50 (ddd, J = 6.9, 3.7, 0.9 Hz, 1H), 2.71 (s, 3H), 2.48 (ddd, J = 13.7, 6.8, 4.6 Hz, 1H), 2.31 
(dt, J = 14.1, 7.1 Hz, 1H), 0.92 (s, 9H), 0.07 (d, J = 19.6 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 164.9, 148.7, 134.1, 133.0 (q, J = 28.2 Hz), 128.7 (d, J = 3.9 
Hz), 123.7 (d, J = 275.2 Hz), 119.3 (d, J = 5.1 Hz), 118.1, 70.8 (d, J = 3.2 Hz), 42.9, 25.9, 19.2, 
18.3, -4.6, -4.9 

































































































































































































































 To a room temperature solution of 4.14 (234 mg, 0.675 mmol) and 2,6-lutidine (0.10 mL, 
1.3 mmol) in dioxane (5.19 mL) and H2O (1.73 mL) was added OsO4 (2.5 wt% solution in 
tBuOH, 0.128 mL, 0.0101 mmol). The resulting mixture was stirred at room temperature for 15 
minutes, followed by addition of NaIO4 (332 mg, 2.30 mmol). The resulting mixture was stirred 
at room temperature for 2 hours. To the mixture was added H2O (3 mL) and NaS2O3 (74 mg, 
0.47 mmol), and the mixture was extracted with CH2Cl2 (2 x 10 mL). The organic layers were 
combined, dried over Na2SO4, and concentrated. The resulting residue was filtered through a 
plug of pH 7 buffered silica gel, eluting with 10:90 EtOAc:hexanes to give 4.15 as a colorless oil 
(234 mg, 0.614 mmol, 91%). 
OR [α]D23.9 -32.6 (c 0.30, CHCl3)  
IR (thin film, cm-1) 2954, 2930, 2889, 2857, 2720, 1727, 1657, 1509, 1470, 1441, 1391, 1359, 
1279, 1257, 1220, 1168, 1121, 1075, 1040, 1003, 973, 940, 888, 837, 779, 677, 606, 573, 489, 
426 
1H NMR (500 MHz, CDCl3) δ 9.80 (dd, J = 2.5, 1.7 Hz, 1H), 7.34 (s, 1H), 7.22 (s, 1H), 5.00 
(ddd, J = 7.6, 3.5, 1.2 Hz, 1H), 2.81 – 2.63 (m, 5H), 0.90 (s, 9H), 0.10 (d, J = 22.0 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 199.9, 165.2, 148.1, 132.0 (q, J = 28.7 Hz), 129.4 (d, J = 3.9 
Hz), 123.5 (d, J = 275.3 Hz), 120.0 (d, J = 4.9 Hz), 66.8 (d, J = 3.2 Hz), 51.5, 25.8, 19.2, 18.2, -
4.5, -5.2 





















































































































































































































 To a room temperature solution of 4.15 (231 mg, 0.609 mmol) in benzene (12.18 mL) 
was added 4.16 (342 mg, 0.914 mmol). The mixture was stirred at 80 °C for 4 hours and cooled 
to room temperature. The mixture was concentrated, and the resulting residue was filtered 
through a plug of silica gel, eluting with 10:90 EtOAc:hexanes to give 4.17 as a colorless oil 
(260 mg, 0.548 mmol, 90% yield). 
OR [α]D23.8 -25.7 (c 0.35, CHCl3)  
IR (thin film, cm-1) 3080, 2952, 2930, 2857, 1716, 1650, 1509, 1470, 1436, 1392, 1360, 1282, 
1256, 1210, 1168, 1120, 1046, 1002, 955, 914, 836, 809, 778, 676, 607, 574, 489 
1H NMR (500 MHz, CDCl3) δ 7.34 (s, 1H), 7.20 (t, J = 1.0 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 
5.79 (ddt, J = 17.2, 10.1, 6.1 Hz, 1H), 5.06 – 4.93 (m, 2H), 4.54 (dd, J = 8.2, 3.2 Hz, 1H), 3.74 
(s, 3H), 3.08 (dt, J = 6.3, 1.8 Hz, 2H), 2.72 (s, 3H), 2.59 (ddd, J = 15.1, 7.3, 3.4 Hz, 1H), 2.45 
(dt, J = 15.4, 7.9 Hz, 1H), 0.91 (s, 10H), 0.07 (d, J = 16.9 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 167.8, 165.0, 148.4, 139.5, 135.2, 132.9 (q, J = 28.2 Hz), 131.8, 
129.0 (d, J = 3.9 Hz), 123.6 (d, J = 275.2 Hz), 119.7 (d, J = 5.0 Hz), 115.4, 70.2 (d, J = 3.2 Hz), 
51.9, 37.8, 31.0, 25.9, 19.2, 18.3, -4.6, -5.1 







































































































































































































































































 To a -78 °C solution of 4.17 (257 mg, 0.540 mmol) in THF (3 mL) was added dropwise 
DIBAL-H (1 M solution in CH2Cl2, 1.62 mL, 1.62 mmol). The mixture was allowed to warm to 
room temperature over 3 hours. The mixture was quenched at 0 °C with MeOH (37 µL, 0.91 
mmol), and saturated Rochelle’s salt solution (0.38 mL) and Et2O (3.5 mL) were added 
sequentially. The mixture was warmed to room temperature and stirred vigorously for 2.5 hours. 
To the mixture was added H2O (5 mL), and the layers were separated. The aqueous layer was 
extracted with Et2O (3 x 5 mL), and the organic layers were combined, dried over Na2SO4, and 
concentrated. The resulting residue was purified by silica gel chromatography, eluting with 20:80 
® 30:70 EtOAc:hexanes to give 4.18 as a colorless oil (236 mg, 0.497 mmol, 92% yield). 
OR [α]D21.1 40.8 (c 0.3, CHCl3)  
IR (thin film, cm-1) 3359, 3079, 2953, 2929, 2856, 1671, 1635, 1510, 1470, 1439, 1405, 1359, 
1278, 1256, 1218, 1169, 1145, 1120, 1051, 1003, 945, 914, 835, 811, 778, 676, 608, 575, 419 
1H NMR (500 MHz, CDCl3) δ 7.28 (s, 1H), 7.10 (d, J = 1.0 Hz, 1H), 5.75 (ddt, J = 16.6, 10.0, 
6.5 Hz, 1H), 5.60 (t, J = 7.4 Hz, 1H), 5.14 – 4.92 (m, 2H), 4.58 – 4.50 (m, 1H), 4.06 (s, 2H), 2.82 
(dt, J = 6.6, 1.9 Hz, 2H), 2.71 (s, 3H), 2.47 (dt, J = 14.6, 5.4 Hz, 1H), 2.35 (dt, J = 14.6, 7.2 Hz, 
1H), 1.94 (s, 1H), 0.91 (s, 9H), 0.07 (d, J = 19.5 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 165.3, 148.4, 139.8, 135.7, 133.0 (q, J = 28.2 Hz), 129.3 (d, J = 
4.1 Hz), 123.7 (d, J = 275.3 Hz), 122.9, 118.8 (d, J = 5.0 Hz), 115.7, 70.5 (d, J = 3.1 Hz), 67.2, 
36.3, 32.5, 25.9, 19.1, 18.3, -4.7, -4.9 



































































































































































































































































 To a room temperature solution of 4.18 (104 mg, 0.232 mmol) in CCl4 was added PPh3 
(122 mg, 0.465 mmol). The resulting solution was stirred at 80 °C under Ar atmosphere for 15 h. 
The mixture was concentrated, and the resulting residue was purified by pH 7 buffered silica gel 
chromatography, eluting with 0:100 ® 5:95 EtOAc:hexanes to give 4.19 as a clear oil (98 mg, 
0.211 mmol, 91% yield). 
OR [α]D20.7 -23.8 (c 0.34, CHCl3)  
IR (thin, cm-1) 3079, 2953, 2929, 2895, 2857, 1657, 1638, 1509, 1470, 1438, 1392, 13590, 1330, 
1257, 1215, 1167, 1144, 1120, 1050, 1002, 956, 918, 835, 011, 778, 749, 691, 608, 574, 542, 
494, 414 
1H NMR (500 MHz, CDCl3) δ 7.33 (s, 1H), 7.16 (s, 1H), 5.81 – 5.64 (m, 2H), 5.15 – 4.93 (m, 
2H), 4.48 (dd, J = 7.7, 3.6 Hz, 1H), 4.04 (s, 2H), 2.94 (qd, J = 15.3, 6.6 Hz, 2H), 2.72 (s, 3H), 
2.48 (ddd, J = 14.9, 7.1, 3.6 Hz, 1H), 2.34 (dt, J = 15.0, 7.6 Hz, 1H), 0.91 (s, 9H), 0.07 (d, J = 
19.5 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 165.0, 148.5, 135.9, 134.8, 133.1 (q, J = 28.4 Hz), 128.8 (d, J = 
4.0 Hz), 127.7, 123.7 (d, J = 275.4 Hz), 119.5 (q, J = 5.1 Hz), 116.5, 70.6 (d, J = 3.2 Hz), 49.7, 
37.1, 32.5, 25.9, 19.2, 18.3, -4.6, -4.9 






























































































































































































































































 To a 0 °C solution of 4.19 (61 mg, 0.20 mmol) in THF (2 mL) was added dropwise 
Super-H (1 M solution in THF, 0.408 mL, 0.408 mmol). The mixture was stirred at 0 °C for 1 
hour, then quenched with NaOH (3N, 10 µL). To the mixture was added Et2O (5 mL), and the 
mixture was washed with brine (2 x 3 mL). The organic layers were combined, dried over 
Na2SO4, and concentrated. The resulting residue was purified by preparative TLC, eluting with 
5:95 EtOAc:hexanes, to give 4.20 as a colorless oil (61 mg, 0.14 mmol, 70% yield). 
OR [α]D21.3 -19.8 (c 0.34, CHCl3)  
IR (thin film, cm-1) 3079, 2955, 2929, 2857, 1656, 1637, 1509, 1470, 1142, 1391, 1359, 1328, 
1277, 1256, 1214, 1166, 1144, 1119, 1052, 1024, 1004, 991, 968, 944, 913, 834, 810, 777, 675, 
607, 573, 498 
1H NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 7.15 (t, J = 1.0 Hz, 1H), 5.73 (ddt, J = 16.7, 10.1, 
6.6 Hz, 1H), 5.28 (t, J = 7.4 Hz, 1H), 5.08 – 4.94 (m, 2H), 4.42 (dd, J = 8.1, 3.6 Hz, 1H), 2.82 
(dd, J = 14.6, 6.4 Hz, 1H), 2.71 m, 4H), 2.48 – 2.35 (m, 1H), 2.25 (dt, J = 15.0, 7.7 Hz, 1H), 1.69 
(q, J = 1.2 Hz, 3H), 0.91 (s, 9H), 0.05 (d, J = 14.7 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 164.9, 148.7, 136.0, 135.7, 133.7 (q, J = 28.0 Hz), 128.4 (d, J = 
4.0 Hz), 123.8 (d, J = 275.4 Hz), 121.8, 119.2 (d, J = 5.3 Hz), 115.4, 71.4 (d, J = 3.1 Hz), 37.3, 
36.7, 25.9, 23.6, 19.2, 18.3, -4.6, -4.9 










































































































































































































































 To a 0 °C solution of 4.20 (58 mg, 0.13 mmol) in THF (1.34 mL) was added dropwise 
TBAF (1 M solution in THF, 0.215 mL, 0.215 mmol). The resulting solution was stirred at room 
temperature for 45 minutes, then allowed to warm to room temperature over 2 hours. The 
reaction was diluted with Et2O (6 mL) and H2O (4 mL), and the layers were shaken and 
separated. The aqueous layer was extracted with Et2O (3 x 4 mL), and organic layers were 
combined, dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel 
chromatography, eluting with 10:90 ® 20:80 ® 30:70 EtOAc:hexanes, to give 4.1 as a colorless 
oil (40 mg, 0.126 mmol, 94%). 
OR [α]D22.5 -88.5 (c 0.74, CHCl3)  
IR (thin film, cm-1) 3238, 3079, 2966, 2924, 2854, 1657, 1636, 1513, 1440, 1376, 1279, 1213, 
1170, 1147, 1117, 1045, 992, 977, 911, 842, 762, 678, 620, 501 
1H NMR (500 MHz, CDCl3) δ 7.35 (s, 1H), 7.21 (s, 1H), 5.76 (ddt, J = 16.7, 10.0, 6.6 Hz, 1H), 
5.32 (ddd, J = 9.8, 5.6, 2.3 Hz, 1H), 5.12 – 4.93 (m, 2H), 4.51 – 4.41 (m, 1H), 2.87 – 2.76 (m, 
2H), 2.71 (s, 3H), 2.57 – 2.48 (m, 2H), 2.32 (dt, J = 15.4, 8.1 Hz, 1H), 1.75 (d, J = 1.3 Hz, 3H) 
13C NMR (126 MHz, CDCl)3 δ 165.3, 148.4, 137.7, 135.8, 133.5 (q, J = 28.1 Hz), 127.8 (d, J = 
3.8 Hz), 123.7 (d, J = 275.5 Hz), 120.8, 119.2 (d, J = 5.2 Hz), 115.7, 69.7 (d, J = 3.0 Hz), 36.6, 
35.7, 23.8, 19.0 























































































































































































































4.7.2 Preparation of 4.24 
 
 
 To a 0 °C solution of 4.1 (26 mg, 0.082 mmol) in CH2Cl2 (0.82 mL) was added DMAP 
(15 mg, 0.12 mmol) and EDCI (24 mg, 0.12 mmol). The resulting was mixture for stirred at 0 °C 
for 15 minutes. To the mixture was added dropwise at 0 °C a solution of 4.2 (76 mg, 0.13 mmol) 
in CH2Cl2 (0.50 mL), and the resulting mixture was stirred at 0 °C for 5 minutes, warmed to 
room temperature, and stirred at room temperature for 4 hours. The mixture was concentrated, 
and the resulting residue was purified by pH 7 buffered silica gel chromatography, eluting with 
2:98 ® 5:95 EtOAc:hexanes to give 4.21 as a colorless oil (71 mg, 0.081l mmol, 97% yield). 
OR [α]D20 -15.0 (c 1.00, CHCl3) 
IR (thin film, cm-1) 3077, 2955, 2912, 2876, 1743, 1693, 1638, 1459, 1414, 1377, 1291, 1224, 
1159, 1124, 1004, 974, 913, 843, 738, 675, 405 
1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.04 (s, 1H), 5.85 (ddd, J = 17.0, 10.7, 8.0 Hz, 1H), 
5.72 (ddt, J = 16.6, 10.1, 6.5 Hz, 1H), 5.52 – 5.42 (m, 1H), 5.27 – 5.12 (m, 1H), 5.09 – 4.93 (m, 
4H), 4.26 (dd, J = 7.3, 2.9 Hz, 1H), 3.81 (dd, J = 4.8, 3.5 Hz, 1H), 3.48 (t, J = 6.7 Hz, 2H), 3.02 
(dt, J = 7.0, 4.4 Hz, 1H), 2.77 (t, J = 5.7 Hz, 2H), 2.71 (s, 3H), 2.62 (dd, J = 17.3, 2.9 Hz, 1H), 
2.53 (q, J = 6.6 Hz, 2H), 2.33 (dd, J = 17.3, 7.4 Hz, 1H), 2.22 – 2.12 (m, 1H), 1.80 – 1.63 (m, 
5H), 1.52 – 1.42 (m, 1H), 1.37 – 1.19 (m, 5H), 1.15 (d, J = 5.9 Hz, 1H), 1.07 (s, 3H), 1.04 – 1.00 


































13C NMR (126 MHz, CDCl3) δ 215.9, 171.1, 164.8, 147.8, 140.2, 137.1, 135.4, 131. – 130.0 
(m), 129.1 (d, J = 29.9 Hz), 123.1 (d, J = 275.4 Hz), 120.3 (q, J = 5.3 Hz), 119.3, 115.6, 115.2, 
75.6, 74.7, 72.4 (d, J = 2.9 Hz), 52.9, 51.8, 44.8, 44.3, 39.6, 36.5, 33.2, 33.0, 26.5, 25.3, 23.8, 
23.5, 20.6, 19.0, 18.5, 7.1 (d, J = 1.8 Hz), 5.4, 5.1 



























































































































































































































































































































































 To a degassed 110 °C solution of 4.21 (37 mg, 0.0422 mmol) in toluene (42 mL) was 
added at once Grubb’s second-generation catalyst (7.2 mg, 0.00844 mmol) in toluene (3 mL). 
The resulting solution was stirred at 110 °C for 30 minutes with N2 sparging. The mixture was 
sequentially cooled to room temperature then 0 °C and filtered through a plug of pH 7 buffered 
silica gel, eluting with 10:90 EtOAc:hexanes and concentrated. The resulting residue was 
purified by preparative TLC, eluting with 10:90 EtOAc:hexanes to give 4.22 as a colorless oil 
(16.3 mg, 0.0190 mmol, 49%). 
OR [α]D20 -39.4 (c 1.00, CHCl3) 
IR (thin film, cm-1) 2955, 2913, 2876, 1746, 1690, 1653, 1458, 1414, 1379, 1355, 1283, 1235, 
1222, 1171, 1148, 1122, 1007, 972, 886, 854, 785, 727, 675, 544, 499, 407 
1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 7.09 (s, 1H), 5.65 (dd, J = 15.9, 8.1 Hz, 1H), 5.53 
(d, J = 9.7 Hz, 1H), 5.33 (dt, J = 15.7, 6.2 Hz, 1H), 5.19 (dd, J = 9.9, 5.9 Hz, 1H), 4.33 – 4.26 
(m, 1H), 4.11 (d, J = 9.7 Hz, 1H), 3.47 (qt, J = 10.7, 6.7 Hz, 2H), 3.17 (dd, J = 14.6, 6.6 Hz, 1H), 
2.96 (dt, J = 9.2, 4.0 Hz,fdffzz 1H), 2.84 – 2.64 (m, 5H), 2.52 (dd, J = 14.8, 2.2 Hz, 1H), 2.42 
(dd, J = 14.6, 5.7 Hz, 1H), 2.33 (d, J = 15.5 Hz, 1H), 2.20 (p, J = 7.4 Hz, 1H), 1.89 – 1.78 (m, 
1H), 1.78 – 1.62 (m, 6H), 1.54 (tt, J = 13.7, 4.3 Hz, 1H), 1.49 – 1.36 (m, 1H), 1.13 (d, J = 15.2 


































13C NMR (126 MHz, CDCl3) δ 214.61, 170.40, 164.98, 147.76, 139.41, 132.38, 130.04, 129.59, 
123.22 (d, J = 275.3 Hz), 120.23 (d, J = 5.5 Hz), 119.71, 76.35, 74.97, 72.72, 53.98, 53.80, 
44.77, 41.03, 40.81, 35.25, 34.27, 33.21, 28.02, 24.27, 23.62, 23.44, 22.30, 21.94, 19.15, 7.34, 
7.09, 5.82, 5.48 










































































































































































































































































































 To a 0 °C solution of 4.22 (20 mg, 0.0236 mmol) in THF (0.47 mL) in a polypropylene 
vial was added dropwise HF•pyridine (0.24 mL). The resulting mixture was stirred warmed to 
room temperature and stirred for 3 hours. The mixture was cooled to 0 °C, and MeOMe3Si (1.54 
mL) was added dropwise. The resulting mixture was warmed to room temperature and stirred for 
3 hours. The mixture was concentrated by rotary evaporation and high vacuum to achieve 
removal of pyridine. The resulting residue was purified by pH 7 buffered silica gel 
chromatography, eluting with 40:60 EtOAc:hexanes to give 4.23 as a white solid (11.0 mg, 
0.0177 mmol, 75% yield). 
OR [α]D23 -74.9 (c 1.00, CHCl3) 
IR (thin film, cm-1) 3444, 2959, 2925, 2856, 1740, 1686, 1447, 1359, 1283, 1225, 1172, 1149, 
1124, 1076, 1022, 976, 941, 912, 804, 733, 650, 612, 498 
1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.08 (s, 1H), 5.71 – 5.39 (m, 3H), 5.13 (dd, J = 9.3, 
5.5 Hz, 1H), 4.45 – 4.31 (m, 1H), 3.76 (d, J = 5.2 Hz, 1H), 3.59 – 3.45 (m, 2H), 3.40 (d, J = 5.3 
Hz, 1H), 3.24 (ddd, J = 7.7, 6.1, 3.7 Hz, 1H), 2.96 (dd, J = 14.7, 7.6 Hz, 1H), 2.71 (s, 3H), 2.69 – 
2.53 (m, 2H), 2.53 – 2.38 (m, 3H), 2.37 – 2.28 (m, 1H), 1.98 – 1.85 (m, 1H), 1.82 – 1.67 (m, 
5H), 1.62 (d, J = 11.9 Hz, 1H), 1.49 (dtt, J = 18.0, 9.4, 4.2 Hz, 1H), 1.44 – 1.36 (m, 1H), 1.34 (s, 



































13C NMR (126 MHz, CDCl3) δ 216.48, 170.38, 165.67, 147.21, 138.60, 131.39, 130.14, 129.68 
(d, J = 30.1 Hz), 129.27, 123.02 (d, J = 275.2 Hz), 120.18 (d, J = 5.5 Hz), 119.78, 74.73, 72.15, 
71.64, 53.43, 50.82, 44.76, 39.34, 39.24, 35.19, 33.37, 32.90, 27.35, 24.39, 23.94, 22.54, 19.23, 
19.01, 18.89 





























































































































































































































































































 To a solution of 4.23 (10 mg, 0.0161 mmol) in DMF (0.2 mL) was added NaN3 (3 mg, 
0.0484 mmol). The mixture was stirred at 60 °C for 12 hours. The mixture was concentrated 
under high vacuum, and the resulting residue was purified by pH 7 buffered silica gel 
chromatography, eluting with 40:60 EtOAc:hexanes to give 4.24 as a white solid (9.3 mg, 0.0148 
mmol, 93% yield). 
OR [α]D21.5 -49.2 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3454, 2928, 2871, 2096, 1741, 1686, 1449, 1358, 1283, 1226, 1173, 1149, 
1126, 1044, 977, 940, 766, 678, 500 
1H NMR (400 MHz, CDCl33) δ 7.44 (s, 1H), 7.08 (s, 1H), 5.69 – 5.42 (m, 3H), 5.13 (dd, J = 9.5, 
5.5 Hz, 1H), 4.37 (d, J = 9.2 Hz, 1H), 3.75 (s, 1H), 3.41 (s, 1H), 3.24 (qd, J = 7.5, 7.1, 5.4 Hz, 
3H), 3.01 – 2.92 (m, 1H), 2.71 (s, 3H), 2.69 – 2.54 (m, 2H), 2.53 – 2.40 (m, 3H), 2.34 (dt, J = 
11.5, 6.6 Hz, 1H), 2.03 – 1.84 (m, 1H), 1.75 (t, J = 1.5 Hz, 3H), 1.67 – 1.44 (m, 4H), 1.33 (s, 
4H), 1.25 – 1.18 (m, 1H), 1.10 (d, J = 6.9 Hz, 3H), 1.04 (s, 3H) 
13C NMR (100 MHz, CDCl3) δ 216.44, 170.36, 165.72, 147.16, 138.53, 131.30, 130.17, 129.75 
(d, J = 30.1 Hz), 129.11 (d, J = 3.7 Hz), 123.01 (d, J = 275.2 Hz), 120.15 (d, J = 5.7 Hz), 119.77, 
74.66, 72.01, 71.61 (d, J = 3.2 Hz), 53.46, 51.24, 50.81, 39.34, 39.24, 35.18, 33.36, 29.27, 27.65, 
24.23, 23.92, 22.52, 19.15, 18.96, 18.82. 










































































































































































































































































































































4.7.3 Preparation of 4.35 
 
 To a suspension of NaH (60% w/w dispersion in mineral oil, 0.776 mg, 19.41 mmol, 2 
eq.) in DME (9 mL) at 0 ° C was added dropwise a solution of phosphonate 4.27 (4.70 g, 19.41 
mmol, 2 eq.) in DME (9 mL), and the resulting mixture was stirred at 0 °C for 1 hour. A solution 
of formyl thiazole 4.29 (1.23 g, 9.70 mmol, 1 eq.) in DME (9 mL) was added dropwise, and the 
resulting mixture warmed to room temperature over 1 hour. The mixture was poured into sat. 
NH4Cl solution (30 mL) and washed. The aqueous wash was extracted with EtOAc (3 x 15 mL). 
The organic layers were combined, washed with brine (1 x 15 mL), dried over Na2SO4, and 
concentrated. The resulting residue was purified by silica gel chromatography, eluting with 10:90 
→ 20:80 → 30:70 EtOAc:hexanes to give ester 4.29 as a colorless oil (0.728 g, 3.38 mmol, 35% 
yield). 
IR (thin film, cm-1) 3128, 2981, 2929, 1727, 1664, 1502, 1478, 1444, 1393, 1370, 1336, 1306, 
1265, 1229, 1176, 1150, 1094, 1021, 964, 894, 862, 808, 675, 677, 630, 565 
1H NMR (400 MHz, CDCl33) δ 7.67 (s, 1H), 7.20 (d, J = 34.8 Hz, 1H), 4.33 (q, J = 7.2 Hz, 2H), 
2.73 (s, 3H), 1.36 (t, J = 7.1 Hz, 3H) 
13C NMR (126 MHz, CDCl3) δ 165.44, 161.00 (d, J = 34.4 Hz), 148.75, 147.13 – 145.22 (m), 
122.38 (d, J = 14.8 Hz), 111.83 (d, J = 6.3 Hz), 61.99, 19.09, 14.22 

































































































































 To a -78 °C solution of 4.29 (0.728 g, 3.38 mmol, 1 eq.) in toluene (10 mL) was added 
dropwise DIBAL-H (1 M in CH2Cl2, 7.1 mL, 7.1 mmol, 2.1 eq.). The resulting mixture was 
stirred at -78 °C for 3 hours, then quenched with MeOH (0.17 mL), Et2O (20 mL), and 
Rochelle’s salt sat. solution (1.7 mL), warmed to room temperature, and stirred vigorously for 
2.5 hours. The mixture was washed with water (1 x 15 mL), and the aqueous layer was extracted 
with Et2O (3 x 10 mL). The organic layers were combined, dried over Na2SO4, and concentrated. 
The resulting residue was purified by silica gel chromatography, eluting with 20:80 → 30:70 → 
40:60 EtOAc:hexanes to give alcohol 4.30 as a colorless oil (158 mg, 0.912 mmol, 27% yield) 
and aldehyde 4.31 as a white solid (118 mg, 0.825 mmol, 24% yield). 
alcohol 4.30 
IR (thin film, cm-1) 3231, 3132, 2920, 2850, 1697, 1508, 1438, 1376, 1337, 1277, 1250, 1215, 
1190, 1146, 1078, 1031, 978, 885, 869, 846, 744, 678, 644, 670, 538, 499, 471 
1H NMR (400 MHz, CDCl33) δ 7.37 (d, J = 1.4 Hz, 1H), 6.27 – 6.07 (m, 1H), 4.28 (d, J = 12.4 
Hz, 2H), 3.06 (s, 1H), 2.70 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 165.21, 160.89 (d, J = 269.1 Hz), 147.40 (d, J = 2.0 Hz), 116.76 
(d, J = 13.3 Hz), 101.19 (d, J = 7.5 Hz), 60.35 (d, J = 33.1 Hz), 18.74 
HRMS (ASAP+) calculated for C7H9NOSF [M+H]+: 174.0389; found 174.0390 
aldehyde 4.31 
IR (thin film, cm-1) 3354, 3147, 3134, 3062, 3031, 2984, 2931, 2872, 2738, 2633, 2435, 2371, 
2302, 2228, 2170, 2028, 1946, 1906, 1760, 1686, 1648, 1535, 1478, 1440, 1399, 1380, 1350, 























1H NMR (400 MHz, CDCl3) δ 9.34 (d, J = 18.0 Hz, 1H), 7.84 (s, 1H), 6.92 (d, J = 33.7 Hz, 1H), 
2.75 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 183.36 (d, J = 23.9 Hz), 166.14, 155.13 (d, J = 271.1 Hz), 
146.09 (d, J = 4.1 Hz), 124.64 (d, J = 14.3 Hz), 120.42 (d, J = 6.1 Hz), 19.16 




























































































































































































































































 To a room temperature solution of 4.30 (158 mg, 0.912 mmol, 1 eq.) in CH2Cl2 (6 mL) 
was added DMP (424 mg, 1.00 mmol, 1.1 eq.) at once. The resulting mixture was stirred at room 
temperature for 2 hours. The mixture was diluted with CH2Cl2 (6 mL), and the resulting mixture 
was washed with sat. NaHCO3 solution (1 x 6 mL). The aqueous wash was extracted with 
CH2Cl2 (1 x 4 mL). The organic layers were combined, dried over Na2SO4, and concentrated. 
The resulting residue was purified by silica gel plug, eluting with 30:70 EtOAc:hexanes to give 
4.31 as a white solid (108 mg, 0.631 mmol, 69% yield). 





























 To a -40 °C solution of (-)-DIP-Cl (443 mg, 1.38 mmol, 1.35 eq.) in diethyl ether (8.4 
mL) was added dropwise a 1 M solution of allylmagnesium bromide in diethyl ether (1.22 mL, 
1.22 mmol, 1.2 eq.), and the resulting mixture was warmed to room temperature over 1 hour. The 
mixture was cooled to -78 °C, and to it was added dropwise a solution of 4.31 (226 mg, 1.02 
mmol, 1 eq.) in Et2O (5 mL) over 15 minutes. The resulting mixture was stirred at -78 °C for 1 
hour, then warmed to room temperature over two hours. The reaction was quenched by addition 
of MeOH (0.14 mL), H2O2 (30% solution in water, 0.924 mL), NaOAc (168 mg), and H2O (5 
mL), and the resulting mixture was stirred vigorously at room temperature for 20 minutes. The 
layers were separated, and the aqueous layer was extracted with CH2Cl2 (2 x 5 mL). The organic 
layers were combined, dried over Na2SO4, and concentrated. The resulting residue was purified 
by silica gel chromatography, eluting with 20:80 → 30:70 EtOAc:hexanes to give 4.32 as a 
colorless oil (190 mg, 0.891 mmol, 87 % yield). 
 
OR [α]D24.1 -10.1 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3228, 3133, 3077, 2978, 2921, 2851, 1693, 1641, 1508, 1476, 1433, 1376, 
1316, 1277, 1243, 1189, 1147, 1111, 1077, 1052, 988, 918, 885, 845, 744, 680, 648, 568, 536, 
490 
1H NMR (400 MHz, CDCl33) δ 7.34 (d, J = 0.8 Hz, 1H), 6.16 (d, J = 39.1 Hz, 1H), 5.94 – 5.72 
(m, 1H), 5.28 – 5.08 (m, 2H), 4.31 (dt, J = 12.4, 6.3 Hz, 1H), 2.76 (s, 1H), 2.69 (s, 3H), 2.63 – 


















13C NMR (126 MHz, CDCl3) δ 165.06, 161.81 (d, J = 271.0 Hz), 147.47 (d, J = 2.0 Hz), 133.31, 
118.95, 116.87 (d, J = 13.5 Hz), 101.20 (d, J = 7.6 Hz), 69.55 (d, J = 30.0 Hz), 38.72, 18.93 









































































































































 To a -78 °C solution of 4.32 (190 mg, 0.891 mmol, 1 eq.) and 2,6-lutidine (0.246 mL, 
1.07 mmol, 1.2 eq.) in CH2Cl2 (6 mL) was added dropwise TBSOTf (0.155 mL, 1.34 mmol, 1.5 
eq.). The resulting mixture was stirred at -78 °C for 5 minutes, then warmed to room temperature 
and stirred for 1 hour. The mixture was diluted with CH2Cl2 (6 mL) and washed with sat. NH4Cl 
solution (1 x 8 mL). The aqueous wash was extracted with CH2Cl2 (2 x 5 mL), and the organic 
layers were combined, dried over Na2SO4, and concentrated. The resulting residue was purified 
by flash chromatography, eluting with 0:100 → 5:95 EtOAc:hexanes to give 4.33 as a colorless 
oil (292 mg, 0.891 mmol, quantitative yield). 
OR [α]D21.9 -36.7 (c 0.43, CHCl3)  
IR (thin film, cm-1) 3133, 3078, 2953, 2929, 2887, 2856, 2362, 1835, 1695, 1642, 1507, 1470, 
1434, 1364, 1318, 1279, 1254, 1182, 1146, 1109, 1090, 1004, 991, 964, 939, 914, 836, 812, 777, 
742, 679, 567, 533, 509, 472 
1H NMR (400 MHz, CDCl33) δ 7.33 (s, 1H), 6.07 (d, J = 39.1 Hz, 1H), 5.81 (ddt, J = 17.2, 10.1, 
7.1 Hz, 1H), 5.22 – 4.96 (m, 2H), 4.27 (dt, J = 12.4, 6.0 Hz, 1H), 2.70 (s, 3H), 2.57 – 2.37 (m, 
2H), 0.91 (s, 9H), 0.09 (d, J = 7.4 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 164.52, 161.84 (d, J = 271.5 Hz), 147.96 (d, J = 2.1 Hz), 133.72, 
117.95, 116.58 (d, J = 13.8 Hz), 101.34 (d, J = 7.4 Hz), 71.09 (d, J = 30.7 Hz), 39.97, 25.91, 
19.13, 18.32, -4.72 (d, J = 32.7 Hz) 
HRMS (ASAP+) calculated for C16H27NOFSiS [M+H]+: 328.1567; found 328.1566  
TBSOTf
2,6-lutidine






































































































































































 To a room temperature solution of 4.33 (323 mg, 0.986 mmol) and 2,6-lutidine (0.148 
mL, 1.28 mmol) in dioxane (7.5 mL) and H2O (2.5 mL) was added OsO4 (2.5 wt% solution in 
tBuOH, 0.187 mL, 0.015 mmol). The resulting mixture was stirred at room temperature for 15 
minutes, followed by addition of NaIO4 (486 mg, 2,27 mmol). The resulting mixture was stirred 
at room temperature for 2 hours. To the mixture was added H2O (4 mL) and NaS2O3 (90 mg, 
0.465 mmol), and the mixture was extracted with CH2Cl2 (2 x 15 mL). The organic layers were 
combined, dried over Na2SO4, and concentrated. The resulting residue was filtered through a 
plug of pH 7 buffered silica gel, washing with 10:90 EtOAc:hexanes to give 4.34 as a colorless 
oil (269 mg, 0.817 mmol, 83%). 
OR [α]D24.0 -43.6 (c 0.43, CHCl3)  
IR (thin film, cm-1) 3856, 3678, 3653, 3132, 2953, 2929, 2887, 2856, 2723, 2370, 2344, 1726, 
1695, 1506, 1470, 1440, 1389, 1363, 1318, 1279, 1254, 1214, 1182, 1145, 1108, 1096, 1030, 
1001, 976, 940, 836, 779, 744, 681, 571, 536, 500, 463, 419 
1H NMR (400 MHz, CDCl33) δ 9.83 (t, J = 2.2 Hz, 1H), 7.36 (s, 1H), 6.16 (d, J = 38.8 Hz, 1H), 
4.78 (ddd, J = 13.2, 7.0, 4.3 Hz, 1H), 2.92 – 2.81 (m, 1H), 2.76 – 2.65 (m, 4H), 0.90 (s, 9H), 0.12 
(d, J = 4.6 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 200.00, 164.82, 160.45 (d, J = 270.6 Hz), 147.38 (d, J = 2.3 Hz), 
117.30 (d, J = 13.5 Hz), 101.94 (d, J = 7.3 Hz), 66.92 (d, J = 31.8 Hz), 48.66, 25.79, 18.65 (d, J 
= 119.3 Hz), -4.82 (d, J = 62.6 Hz) 

































































































































































 To a room temperature solution of 4.34 (269 mg, 0.817 mmol) in benzene (16.34 mL) 
was added 4.16 (459 mg, 1.23 mmol). The mixture was stirred at 80 °C for 4 hours and cooled to 
room temperature. The mixture was concentrated, and the resulting residue was filtered through 
a plug of silica gel, washing with 10:90 EtOAc:hexanes to give 4.35 as a colorless oil (281 mg, 
0.660 mmol, 81% yield). 
OR [α]D19.8 -23.9 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3080, 2952, 2929, 2888, 2856, 1715, 1639, 1506, 1470, 1435, 1373, 1317, 
1281, 1254, 1208, 1183, 1145, 1104, 1054, 1004, 954, 913, 836, 811, 778, 680, 628, 572, 547, 
500 
1H NMR (400 MHz, CDCl33) δ 7.34 (s, 1H), 6.90 (t, J = 7.3 Hz, 1H), 6.10 (d, J = 39.0 Hz, 1H), 
5.79 (ddt, J = 17.2, 10.1, 6.1 Hz, 1H), 5.07 – 4.92 (m, 2H), 4.34 (dt, J = 12.2, 6.1 Hz, 1H), 3.72 
(s, 3H), 3.08 (dt, J = 6.1, 1.8 Hz, 2H), 2.70 (s, 3H), 2.66 – 2.56 (m, 2H), 0.91 (s, 9H), 0.09 (d, J = 
4.6 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 167.70, 164.63, 161.30 (d, J = 271.3 Hz), 147.67 (d, J = 2.0 Hz), 
138.67, 135.17, 131.90, 116.93 (d, J = 13.7 Hz), 115.38, 101.56 (d, J = 7.3 Hz), 70.30 (d, J = 
31.1 Hz), 51.90, 34.69, 31.08, 25.83, 18.67 (d, J = 108.7 Hz), -4.80 (d, J = 42.9 Hz) 



























































































































































































































4.8 HPLC data 
HPLC analysis was carried out on an Agilent 1200. Series using a Chiralpak OD-H (250 x 4.5 mm 
ID) column. All racemic compounds were prepared by using the general procedure for the 
respective asymmetric reaction was a 1:1 mixture of (+)-Ipc2BCl and (-)-Ipc2BCl. The deviation 








































4.9 Biological data 
In Vitro Cell Growth Inhibition Assays 
Assay protocols 
PC3, human prostate cancer, and A549, human lung cancer, cell lines were obtained from 
the NCI anticancer drug screen. All cells were maintained in RPMI medium supplemented with 
10% fetal bovine serum. Growth inhibition was determined by the resazurin method, following 
exposure to serial dilutions of each compound for 4 days prior to assay and GI50 determinations as 
described.21 Each compound was tested with an initial 10-dose dilution series, followed by 
narrower, replicate 2-dose series, each of which was a separate experiment. The results presented 




 GI50 nM na 
4.24 >5000 2 
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CHAPTER 5: Synthesis and design of octreotide-drug conjugates 
5.1 Introduction 
5.1.1 Small molecule-drug conjugates as an alternative to ADCs 
 While ADCs are a highly promising and active area of research in cancer therapy, small 
molecule-drug conjugates (SMDCs) represent an emerging area of targeted delivery that has 
received less attention. In such modalities, the targeting antibody is replaced with a small molecule 
that serves a similar function, binding to receptors expressed on a tumor target and inducing 
internalization of the SMDC-receptor complex (Figure 5.1). Advantages of small molecules over 
antibodies include relative ease of synthesis and homogeneity of the synthesized products, in 
contrast to the less robust antibodies and synthetic processes that often result in polydisperse 
conjugate mixtures in the ADC modality.1 
 
Figure 5.1: a) components of an ADC; b) components of a SMDC. 
 Examples of tumor-expressed receptors targeted by small-molecule conjugates include 
carbonic anhydrase IX,2–4 the folate receptor,5,6 prostate-specific membrane antigen,7 and 
somatostatin receptors,8 and somatostatin receptors (SSTRs) have been the focus of our 
conjugation work. SSTRs are overexpressed on a variety of tumor types and thus are potential 
therapeutic target candidates.9 A series of synthetic peptide analogs of somatostatin, including 
lanreotide and octreotide (Figure 5.2), have been developed, providing the opportunity for SMDCs 
targeted to SSTR-expressing tumors.9 We pursued the synthesis of a series of epothilone-based 










Figure 5.2: a) octreotide; b) lanreotide. 
5.1.2 Octreotide: properties and applications as a targeting moiety 
  Somatostatin is a hormone involved in many pathways, including endocrine system 
regulation, neurotransmission, and cell proliferation. It has two active forms derived from cleavage 
of a preproprotein, one consisting of 14 amino acids and the other consisting of 28 amino acids. 
Octreotide is a synthetic octapeptide analog of somatostatin that retains high activity against 
SSTR2 and SSTR5 and exhibits more favorable pharmacokinetic properties compared to 
somatostatin.10 Binding of octreotide to its receptors results in internalization of the receptor-ligand 
complex. 
 Octreotide has been used to introduce a variety of cytotoxic payloads into tumor cells, 
including doxorubicin,11 periplocymarin,12 periplogenin,13 and paclitaxel (discussed below). It also 
has applications in tumor imaging, wherein it is conjugated to a chelated radionuclide and 
introduced into the test subject, resulting in accumulation of signal in tumors that express 
SSTR2/SSTR5.14 Of particular interest to our work are several examples of the targeted delivery 
of paclitaxel, the first example demonstrated by Huang et al. in 2000.15 In this study, paclitaxel 
was extended at its 2’ position via reaction with succinic anhydride, and the resulting acid 




























































tested in SSTR-expressing MCF-7 cells and SSTR-non-expressing CHO cells. The conjugates 
compared favorably to free paclitaxel in the MCF-7 cells but showed reduced activity in the CHO 
cells, implicating SSTR-mediated internalization. The researchers also synthesized and treated 
cells with fluorescein-octreotide conjugates and visualized internalization of the conjugates and 
subsequent distribution throughout the cytoplasm. 
 
Figure 5.3: a) octreotide-mono(paclitaxel) conjugate as investigated by Huang et al.; b) octreotide-
bis(paclitaxel) conjugate investigated by Huang et al., Sun et al., and Shen et al. 
 In later studies by Sun et al.16 and Shen et al.,17 mono- and bis-paclitaxel-octreotide 
conjugates were investigated in the context of non-small cell lung cancer (NSCLC) (Figure 5.3b). 
In in vitro studies, the mono-paclitaxel conjugate performed similarly to free paclitaxel in both 
A549 and Calu-6 cell lines, while the bis-paclitaxel conjugate was more effective in A549 than in 
Calu-6 cells relative to paclitaxel. This observation was attributed to differences in SSTR isotype 
expression between the two cell lines. In tumor xenograft models, A549-expressing tumors were 
treated with the conjugates. The mono-paclitaxel conjugate had similar efficacy in preventing 










































































work demonstrates that octreotide can be alkylated at both of its reactive amine sites and maintain 
its receptor-targeting properties. 
5.1.3 Considerations for taxane binding site accessibility 
 As mentioned in Chapter 1, the epothilones share a microtubule binding site with the 
taxanes. This binding site is located on the interior surface of the microtubule, so successful 
binding requires access of the cytotoxic agent to the microtubule lumenal space (Figure 5.4).18 
This requirement raises questions about the nature of drug conjugate trafficking as it pertains to 
conjugate degradation in the cellular environment. In previous paclitaxel conjugate studies that 
demonstrate internalization and resulting cytotoxic activity, it is unclear whether octreotide 
remains intact and connected to the drug, or if the conjugate is trafficked to an organelle for 
degradation before liberation of a partially-freed payload. As such, there is uncertainty concerning 
the ability of an octreotide conjugate, a relatively large molecule compared to both paclitaxel and 
the epothilones alone, to enter the microtubule lumen and allow for drug binding. The trafficking 
of the internalized SSTR-ligand complex has implications for both conjugate and drug stability, 
some of which we attempted to address through conjugate design. 
5.1.4 Linker considerations for epothilone conjugation and design of conjugates 
 In designing our series of conjugates, we initially relied on established linker technology. 
To this end, we designed two conjugates, each containing a linker used in an approved ADC. The 
first conjugate utilized the simple non-cleavable thiol and amine reactive linker 5.1 as implemented 
in approved ADC Kadcyla (Figure 5.4a), and the second utilized the valine-citrulline cathepsin B-





Figure 5.4: a) non-cleavable linker utilized in Kadcyla; b) cleavable linker utilized in Adcetris; c) non-
cleavable PEG linker of >6 nm in length. 
 
Figure 5.5: Schematic of microtubule cross section showing relevant dimensions. 
 Additionally, we hypothesized that a potential issue with the non-cleavable Kadcyla linker 
conjugate might be accessibility of the conjugate to the epothilone binding site. As the binding site 













































~5 nm taxane/epothilone binding site
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through the microtubule pores to exert their effects. In an attempt to remedy a potential blockade 
of the conjugate from accessing the binding site, we also designed a conjugate with 24-unit PEG 
linker 5.2 of sufficient length (~9 nm) to span the ~5 nm outer radius of the microtubule (Figure 
5.4b). This linker length would in theory allow for the octreotide to remain on the microtubule 
exterior with simultaneous entry of the payload into the lumen through pores on the microtubule 
surface. (See Figure 5.5 for microtubule dimensions.) We began by synthesizing a series of 
epothilone B-octreotide conjugates utilizing these strategies. Following the successful completion 
of our iso-fludelone analog, we synthesized a second-generation series of iso-fludelone-octreotide 
conjugates. 
5.1.5 Multivalency in drug conjugation and design of DM1 dimer conjugates 
 In addition to our series of monovalent conjugates, we became interested in exploring a 
drug conjugate with a bivalent microtubule-binding drug moiety. Multivalency in drug design is a 
well-known strategy that has enjoyed considerable attention, but examples of multivalency 
(outside of multiple drug moieties attached to a single targeting construct) in the context of cancer 
therapy are few and mostly limited to the pyrrolobenzodiazepene DNA crosslinkers.5 In designing 
our bivalent conjugate, we had two options regarding drug release: 1) release of two discrete 
cytotoxic molecules that could act independently, or 2) release of two molecules tethered together 
that would necessarily act in close proximity to each other. Because of the potential for interesting 
synergistic effects of proximal dual binding, we settled on the latter option. This design strategy 
required a tether that could span at minimum the distance between two adjacent binding sites. In 
considering the cytotoxic payload, we chose DM1 (Figure 5.6a) for its precedent as a successful 
octreotide conjugate payload and its binding site on the exterior of the microtubule,19 shortening 
the minimum requirement for linker length to ~60 Å (approximated as 1/13th of microtubule 
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circumference [repeating binding sites along 13 microtubule subunits]), as compared to the ~160 
Å distance between interior binding sites (approximated as the distance between two exterior 
binding sites plus two times the microtubule outer radius). Our design and synthetic strategy for a 
bivalent DM1 conjugate involved elaboration from a trisubstituted, bifunctional “linchpin”: the 
duplicated functional groups of the linchpin would act as sites of attachment for DM1-linker 
constructs, and the single functionality would be attached to an octreotide-linker construct (Figure 
5.6b). 
 
Figure 5.6: a) DM1; b) schematic of octreotide-tethered DM1 dimer design. 
5.1.6 Visualization of relevant species and design of amine-reactive di-yne tags 
 We also became interested in visualization of some of our targeted delivery constructs. We 
were inspired by recent work from the Min group at Columbia utilizing di-ynes as imaging tags.20 
This technique utilizes Raman imaging to visualize tagged molecules in the cell. Because the IR 
absorption frequency for di-ynes is in the IR-silent region of the cell, molecules of interest can be 
imaged with high selectivity and resolution. The Min group also found that capping of the di-yne 
with phenyl substituents increased sensitivity up to 20-fold. To this end, we set out to synthesize 
amine-reactive doubly phenyl-capped di-yne tag 5.4 for reaction with a variety of interesting 




























Figure 5.7: Proposed amine-reactive doubly phenyl-capped di-yne tag. 
5.2 Synthesis and biological evaluation of epothilone B-octreotide conjugates 
5.2.1 Synthesis of epothilone B-octreotide conjugate with cyclohexyl linker 
 Synthesis of the first epothilone B conjugate began with protection of the lysine residue of 
commercially-available octreotide acetate with Boc anhydride to produce Boc carbamate 5.5 using 
known methods.21 (See Figure 5.8 for octreotide structure abbreviation used through the remainder 
of this chapter.) The resulting 5.5 was acylated with commercially-available NHS ester 5.1 to give 
maleimide 5.10. Separately, linker functionalized amino EpoB 5.6, which was acylated with 
prepared NHS ester 5.7 to give disulfide 5.8, was reduced with Cleland’s reagent (dithiothreitol) 
to give thiol 5.9 (Scheme 5.1). Thiol 5.9 was reacted with maleimide 5.1 to give Boc-protected 
conjugate 5.11. Finally, 5.11 was treated with TFA to produce completed conjugate 5.12 (Scheme 
5.2). 
 


































Scheme 5.1: Transformation of amine analog 5.6 into thiol analog 5.9. 
 
Scheme 5.2: Synthesis of non-cleavable octreotide-EpoB conjugate. 
5.2.2 Synthesis of epothilone B-octreotide conjugate with PEG linker 
 Synthesis of the PEG linker conjugate proceeded in much the same manner. Prepared Boc-























































































































5.2 to afford maleimide 5.13. Maleimide 5.13 was treated with prepared thiol 5.9 to produce 
protected conjugated 5.14, which was treated with TFA to produce final conjugate 5.15 (Scheme 
5.3). 
 
Scheme 5.3: Synthesis of non-cleavable PEG linker-containing octreotide-EpoB conjugate. 
5.2.3 Synthesis of epothilone B-octreotide conjugate with cleavable linker 
 In synthesizing a cleavable conjugate, we had to rethink our strategy. The cleavable linker 
is designed to release drug at its amine-reactive end (Figure 5.9). In the initial two conjugates, we 
used the amine-reactive linker functional groups to attach octreotide, which in this case would 
simply result in the release of octreotide with drug still bound to the linker, defeating the purpose 
of the cleavable technology. We initially attempted to functionalize octreotide with NHS ester 5.17 
(Scheme 5.4, reaction not shown), which, if successful, would render it maleimide-reactive and 
allow us to rearrange reaction steps. However, this reaction unfortunately produced a complex 

































































Figure 5.9: Self-immolation of cleavable linker following cathepsin B cleavage. 
 
Scheme 5.4: Synthesis of cleavable octreotide-EpoB conjugate. 
 Our final strategy involved acylation of EpoB amine 5.6 with commercially-available 
linker 5.3 to produce maleimide 5.16. We then treated maleimide 5.16 with a small excess of thiol 
5.17, directly followed by treatment with Fmoc-protected octreotide 5.18 (prepared by known 

































































































































































1) DIPEA, DMF, r.t., 1.25 h























avoid potential issues with acid-sensitivity of the peptide linker. This reaction resulted in a mixture 
of products that was dominant in desired product, which we were able to purify. The Fmoc-
protected conjugate 5.19 was deprotected with piperidine to give conjugate 5.20 (Scheme 5.4). A 
competing side reaction was observed involving substitution of octreotide with piperidine 
presumably via a retro-Michael addition at the maleimide, but this issue could be minimized with 
short reaction time. 
5.2.4 Biological evaluation octreotide-EpoB conjugates 
 These conjugates were screened in cell lines for activity by our collaborator at Columbia 
University Medical Center, Dr. Antonio Fojo. None of the conjugates showed significant activity 
in the initial results at the relevant low nanomolar concentration ranges. Potential reasons for this 
are numerous and include cellular trafficking issues and failure of the drug to reach its binding 
site, but we suspect a contributing factor may be the known instability of the epothilone B 
macrolactone, as discussed in previous chapters. 
5.3 Synthesis and biological evaluation of iso-fludelone-octreotide conjugates 
5.3.1 Synthesis of iso-fludelone-octreotide conjugate with cyclohexyl linker 
 Following our successful synthesis of a linker-equipped iso-fludelone, as detailed in 
Chapter 3, we designed an analogous series of conjugates, replacing epothilone B with iso-
fludelone. Synthesis of an iso-fludelone conjugate with a cyclohexyl linker proceeded in a manner 
similar to synthesis of its epothilone B counterpart to produce 5.25 (Schemes 5.5 and 5.6). 
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Scheme 5.5: Transformation of amine analog 5.21 into thiol analog 5.23. 
 





































































































5.3.2 Synthesis of iso-fludelone-octreotide conjugate with PEG linker 
 Synthesis of an iso-fludelone conjugate with a PEG linker proceeded in a manner similar 
to synthesis of its epothilone B counterpart to produce conjugate 5.27 (Scheme 5.7). 
 
Scheme 5.7: Synthesis of PEG linker-containing octreotide-iso-fludelone conjugate. 
5.3.3 Synthesis of iso-fludelone-octreotide conjugate with cleavable linker 
Synthesis of an iso-fludelone conjugate with a cleavable peptide linker proceeded in a 


















































Scheme 5.8: Synthesis of cleavable octreotide-iso-fludelone conjugate. 
5.3.4 Biological evaluation of octreotide-iso-fludelone conjugates 
 These conjugates were tested in cell lines by our collaborator at CUMC, Dr. Antonio Fojo. 
Again, none of the conjugates showed significant activity in the initial results at the relevant low 
nanomolar concentration ranges. Possible activity was observed at ~1 µM concentration, which 
was not observed in the epothilone B conjugate series.  However, additional experiments to verify 
these results are necessary to come to a definitive conclusion. If these conjugates are indeed more 
biologically active than the epothilone B conjugate series, it would be consistent with our 

































































































































1) DIPEA, DMF, r.t., 20 min.


























5.4 Design, synthesis, and biological evaluation of bivalent octreotide-DM1 conjugates 
5.4.1 Design and synthesis of modular “linchpin” for DM1 and octreotide attachment 
 In designing the linchpin for our bivalent DM1-octreotide conjugate, we discovered 
substituted benzyl alcohol 5.31 as a commercially available product (Scheme 5.9). This molecule 
carries the desired trisubstituted bifunctional motif necessary for synthesis of our conjugate. We 
envisioned simple substitution of the alcohol functionality to a thiol for easy attachment to a 
maleimide-containing octreotide-linker construct, and we saw potential for elaboration of the 
halide substituents to include amine functionalities through cross-coupling reactions, with the 
eventual goal of acylating the amines with PEG chains terminating in reactive functionalities for 
payload attachment.  
 
Scheme 5.9: Synthesis of thiol 5.36 from alcohol 5.31. 
To this end, we successfully coupled two equivalents of Boc-protected pinacolboronic ester 










































of the alcohol. We then performed a Mitsunobu substitution on 5.33, using thioacetic acid as the 
nucleophile to generate thioester 5.34. Treatment with LiOH successfully reduced the thioester but 
resulted in unwanted dimerization of the product via disulfide bond formation to afford disulfide 
5.35. The disulfide was easily cleaved using Cleland’s reagent, resulting in molecular linchpin 
5.36 with the desired functionality (Scheme 5.9). 
5.4.2 Synthesis of DM1 dimer-octreotide conjugate 
 After achieving synthesis of the linchpin, we continued with our DM1 dimer synthesis. 
With molecular linchpin 5.36 in hand, we treated it with Fmoc-octreotide-linker construct 5.37 to 
produce conjugate 5.38. Conjugate 5.38 was Boc deprotected to produce diamine 5.39, which was 
treated with commercially available bifunctional PEG linker 5.40 to yield conjugate 5.41. 
Conjugate 5.41 was treated with two equivalents of DM1 to produce bivalent DM1 conjugate 5.42, 
which underwent final Fmoc deprotection to yield bivalent conjugate 5.43 (Scheme 5.10). 
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Scheme 5.10: Construction of octreotide-tethered DM1 dimer conjugate. 
5.4.3 Biological evaluation of octreotide-DM1 dimer conjugate 
 The bivalent DM1 conjugate showed essentially no activity against the relevant cell lines. 
Again, potential issues are numerous but include failure of construct internalization and 
aggregation in the cellular environment. Unlike the epothilone conjugates, there are no known 





























































































































































5.5 Design and synthesis of amine-reactive di-yne tags 
5.5.1 Synthesis of amine-reactive di-yne tag 
 As a simple proof of concept in pursuit of imaging goals, we designed a simple di-yne tag 
with double phenyl capping and amine reactivity. We envisioned the di-yne motif arising from a 
Hay–Glaser coupling of alkynes of two phenylacetylenes. Phenylactetylene itself was an obvious 
choice for the nonreactive end of the tag. In choosing the reactive end, we targeted phenylacetic 
acid ester 5.44 (Scheme 5.11). 
 
Scheme 5.11: Synthesis of amine-reactive di-yne tag 5.4 from known ester 5.44. 
Ester 5.44 was obtained using known methods23 and was successfully coupled to phenylacetylene 
to afford ester 5.45 via a protocol that utilized high excess of the simpler phenylacetylene to 
minimize homocoupling of the ester. Ester 5.45 was saponified by treatment with NaOH and 
precipitated from the reaction mixture by acidification to afford carboxylic acid 5.46, which 
underwent EDCI-mediated coupling with NHS to yield NHS ester 5.4 as the desired compound 























Scheme 5.12: Tagging of octreotide with amine-reactive di-yne. 
5.5.2 Tagging of octreotide with di-yne reagent 
 NHS ester 5.47 was reacted with mono-Fmoc-protected octreotide to afford tagged 
octreotide 5.48, which was successfully deprotected with piperidine to give tagged octreotide 5.49 
as a potential probe for visualization of octreotide cellular trafficking pathways (Scheme 5.12).  
5.6 Summary and outlook 
 Inspired by recent work exploring the conjugation of cytotoxic payloads to the synthetic 
SST analog octreotide, we initially pursued the synthesis of a series of epothilone B-octreotide 
conjugates using our methyl-extension linker technology. We were successful in synthesizing a 
non-cleavable conjugate using the Kadcyla linker, a non-cleavable conjugate using a PEG linker 
of sufficient length to span the microtubule outer radius, and a cleavable conjugate using the 
Adcetris cathepsin B cleavable linker. None of these conjugates proved to be effective within the 
relevant low nM concentration range. 
 Following our successful synthesis of a linker-equipped iso-fludelone analog, we pursued 
the synthesis of the same series of conjugates with the new payload. We were ultimately successful 
in this endeavor, and initial results showed low but not insignificant activity at 1 µM that requires 
further confirmation. We also synthesized a non-cleavable octreotide-DM1 dimer conjugate 





















binding sites on the microtubule exterior. Unfortunately, this conjugate failed to demonstrate 
activity. 
 Possible explanations for the general failure of our conjugates to demonstrate significant 
activity are numerous. One possible reason is the aforementioned sensitivity of the macrolactone 
ring. Depending on the trafficking of the internalized conjugate in the cellular space, the cytotoxic 
payload may encounter conditions that cause it to degrade, eliminating cytotoxicity. Another 
possibility is the potential challenge of accessing the binding site in the microtubule lumen. This 
seems to be undermined by the discussed success of similar paclitaxel-octreotide conjugates that 
must access the same space, but there may be additional unknown factors at play.  
 A possible area to pursue in the future is detailed exploration the trafficking of internalized 
SSTRs to better understand the chemical environments an octreotide-drug conjugate may 
encounter. Insights into the cellular trafficking of octreotide conjugates may inform efforts to 












5.7 Experimental procedures and characterization 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were purified 
by passage through an activated alumina column. Thin-layer chromatography (TLC) was carried 
out on glass backed silica gel TLC plates (250 µm for analytical and 1000 or 2000 µm for 
preparative) from Silicycle; visualization by UV light, cerium ammonium molybdate (CAM), 
phosphomolybdic acid (PMA), p-anisaldehyde stain, or potassium permanganate (KMnO4) stain. 
HPLC analysis was carried out on an Agilent 1200 Series using a Chiralpak OD-H (250 x 4.5 mm 
ID) column. Diasteriomeric ratios for all compounds were determined by 1H NMR analysis of the 
unpurified reaction mixtures. 1H NMR spectra were recorded on a Bruker AVIII 400 (400 MHz) 
and AVIII 500 (500 MHz) spectrometer and are reported in ppm, relative to residual protonated 
solvent peak (CDCl3, 7.26 ppm) unless otherwise indicated. Data are reported as follows: 
(bs=broad singlet, s=singlet, d=doublet, t=triplet, q=quarter, m=multiplet, dd=doublet of doublets, 
ddd=doublet of doublet of doublets, ddt=doublet of doublet of triplet, td=triplet of doublets; 
coupling constant(s) in Hz; integration). Proton decoupled 13C spectra were recorded on a Bruker 
AVIII 400 (100 MHz) and AVIII 500 (125 MHz) spectrometer and are reported in ppm from 
CDCl3 internal standard (77.16 ppm) unless otherwise indicated. High-resolution mass spectra 
were obtained from the Columbia University Mass Spectrometry Facility on a Waters XEVO 
G2XS QToF mass spectrometer equipped with a UPC2 SFC inlet, electrospray ionization (ESI) 
probe, atmospheric pressure chemical ionization (APCI) probe, and atmospheric solids analysis 
probe (ASAP). Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR 
spectrometer. Optical rotations were recorded on a Jasco DIP-1000 digital polarimeter. Buffered 
silica gel (pH 7.00) was prepared as follows: A 1000 mL round bottom flask charged with silica 
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gel (250 g) and 25.0 mL of pH 7.00 buffer solution (potassium dihydrogen phosphate/sodium 
hydroxide, Fluka Analytical) was stirred on a rotary evaporator under atmospheric pressure 
overnight. 
SAFETY STATEMENT. No unexpected or unusually high safety hazards were encountered. 
5.7.1 Preparation of 5.9 
 
 To a vial containing amine 5.6 (8.0 mg, 14.2 µmol, 1 eq.) was added a solution of NHS 
ester 5.7 (3.5 mg, 14.2 µmol , 1 eq.) in CH2Cl2 (0.4 mL) at room temperature, followed by addition 
of TEA (2 µL, 14.2 µmol, 1 eq.). The resulting mixture was stirred at room temperature for 18 
hours. The reaction mixture was concentrated, and the resulting residue was purified by silica gel 
chromatography, eluting with 1:20 → 1:10 MeOH:CH2Cl2 to afford disulfide 5.8 (7.8 mg, 11.30 
µmol, 80% yield) as a white solid. 
OR [α]D23.3 -36.0 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3355, 2928, 2869, 1733, 1652, 1547, 1463, 1439, 1379, 1343, 1253, 1186, 
1145, 1052, 975, 883, 754, 665, 571 
1H NMR (500 MHz, CDCl3) δ 6.97 (s, 1H), 6.56 (s, 1H), 5.69 (t, J = 5.9 Hz, 1H), 5.44 (dd, J = 
6.8, 3.4 Hz, 1H), 4.22 (dd, J = 10.1, 2.9 Hz, 1H), 3.66 (t, J = 5.0 Hz, 1H), 3.40 (dt, J = 8.3, 4.4 
Hz, 1H), 3.34 – 3.26 (m, 1H), 3.20 (dq, J = 13.0, 6.3 Hz, 1H), 2.95 (t, J = 7.0 Hz, 2H), 2.80 (t, J 










































1.2 Hz, 3H), 2.07 – 1.95 (m, 2H), 1.87 (tdd, J = 12.5, 8.4, 4.8 Hz, 1H), 1.72 – 1.62 (m, 1H), 1.62 
– 1.53 (m, 2H), 1.53 – 1.45 (m, 4H), 1.45 – 1.37 (m, 4H), 1.34 (s, 3H), 1.26 (s, 4H), 1.23 – 1.16 
(m, 1H), 1.03 (s, 3H), 0.99 (d, J = 6.8 Hz, 3H) 
13C NMR (126 MHz, CDCl3) δ 219.79, 171.15, 170.74, 165.19, 152.07, 137.05, 119.56, 116.38, 
76.69, 73.49, 61.44, 61.17, 53.07, 50.49, 39.10, 38.97, 36.09, 34.97, 32.90, 32.04, 31.85, 31.06, 
29.96, 29.87, 27.92, 24.28, 23.01, 22.40, 21.64, 21.16, 20.55, 19.28, 17.72, 16.08 




































































































































































































































































































 To a solution of disulfide 5.8 (7.8 mg, 11.2 mmol, 1 eq.) in EtOAc (0.25 mL) and MeOH 
(0.25 mL) was added a solution of Cleland’s reagent (2.6 mg, 16.8 mmol, 1.5 eq.) in K3PO4 pH 
7.5 buffer (83 µL) at room temperature. The resulting solution was stirred at room temperature for 
3 hours, at which point complete conversion was observed. The reaction mixture was diluted with 
EtOAc (2 mL) and washed with sat. NH4Cl solution (2 mL). The layers were separated, and the 
aqueous layer was extracted with EtOAc (3 x 2 mL). The organic layers, were combined, dried 
over Na2SO4, and concentrated. The resulting residue was purified by preparative TLC, eluting 
with 1:20 MeOH:CH2Cl2, and the product-containing silica was washed with the same solvent 
mixture. The wash was concentrated to afford thiol 5.9 (7.0 mg, 10.7 mg, 96% yield) as a white 
solid. 
OR [α]D20.7 -40.7 (c 0.78, CHCl3)  
IR (thin film, cm-1) 3360, 2928, 1731, 1649, 1550, 1440, 1380, 1337, 1261, 1185, 1146, 1046, 
978, 881, 738, 669, 570 
1H NMR (500 MHz, CDCl3) δ 6.97 (s, 1H), 6.57 (s, 1H), 5.65 (t, J = 5.8 Hz, 1H), 5.45 (t, J = 5.0 
Hz, 1H), 4.23 (dd, J = 10.1, 3.0 Hz, 1H), 3.77 – 3.61 (m, 3H), 3.41 (dd, J = 7.8, 4.2 Hz, 1H), 
3.32 (dt, J = 13.6, 6.8 Hz, 1H), 3.22 (dq, J = 13.0, 6.3 Hz, 1H), 3.04 – 2.90 (m, 3H), 2.85 – 2.77 
(m, 3H), 2.70 (s, 3H), 2.55 (dd, J = 14.4, 10.1 Hz, 1H), 2.50 – 2.42 (m, 2H), 2.10 (s, 3H), 2.02 









































1.47 (m, 4H), 1.46 – 1.37 (m, 3H), 1.35 (s, 3H), 1.27 (s, 4H), 1.03 (s, 3H), 0.99 (d, J = 6.8 Hz, 
3H) 
13C NMR (126 MHz, CDCl3) δ 219.81, 171.06, 170.77, 165.28, 152.04, 137.07, 119.55, 116.38, 
76.68, 73.49, 61.44, 61.14, 53.09, 50.55, 40.65, 39.09, 38.95, 35.03, 31.99, 31.79, 30.00, 27.95, 
24.31, 22.43, 21.68, 21.25, 20.61, 20.52, 19.27, 17.72, 16.14, 14.34, 14.26 























































































































































































































































































5.7.2. Preparation of 5.12 
 
 To a vial containing amine 5.5 (4.0 mg, 3.39 mmol, 1 eq.) was added NHS ester 5.1 (2.3 
mg, 6.78 mmol, 2 eq.), and the mixture was dissolved in DMF (0.25 mL) and stirred at r.t. for 12 
hours. DMF was removed under high vacuum, and the resulting reside was purified by preparative 
TLC eluting with 1:10 MeOH:CH2Cl2. The product-containing silica was washed with the same 
solvent combination (20 mL), and the wash was concentrated to afford maleimide 5.10 (4.1 mg, 
3.06 mmol, 90% yield) as a film and carried to the next step without characterization. 
 
 To a solution of maleimide 5.10 (4.1 mg, 3.06 µmol, 1 eq.) in DMF (0.125 mL) was added 
a solution of thiol 5.9 (2 mg, 3.06 µmol, 1 eq.) in DMF (0.125 mL) at room temperature. To the 
resulting solution was added DIPEA (0.5 µL, 3.06 µmol, 1 eq.), and the solution was stirred at 
room temperature for 40 min. The reaction mixture was concentrated under reduced pressure, and 
the resulting residue was purified by preparative HPLC, eluting with 1:20 MeOH:CH2Cl2 and 
washing with the same solvent mixture. The wash was concentrated to afford octreotide-epothilone 
B conjugate 5.11 (2.7 mg, 1.36 µmol, 44% yield) as a film. 














































 To a solution of octreotide-epothilone B conjugate 5.11 (2.7 mg, 1.36 µmol, 1 eq.) in 
CH2Cl2 (0.5 mL) was added TFA (0.06 mL) at room temperature. The resulting solution was stirred 
at room temperature for 30 minutes and then concentrated to afford octreotide-epothilone B 
conjugate 5.12 (quantitative yield) as crude product. 
5.7.3 Preparation of 5.15 
HRMS (MALDI+) calculated for C94H131N13O20S4Na [M+Na]+: 1912.8414; found 1912.9263 
 
 To a vial containing a solution of amine 5.5 (5.8 mg, 4.91 µmol, 1 eq.) and NHS ester 5.2 
(6.8 mg, 4.91 µmol, 1 eq.) in DMF (0.3 mL) was added. DIPEA (1.7 µL, 9.83 µmol, 2 eq.). The 
resulting solution was stirred at room temperature for 17 hours, at which point the reaction mixture 
was concentrated under reduced pressure. The resulting residue was dissolved in CH2Cl2 (2 mL) 
and washed with 3% citric acid solution (1 x 2 mL). The layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (1 x 2 mL). The organic layers were combined, dried over 
Na2SO4, and concentrated to afford maleimide 5.13 (10.8 mg, 5.50 µmol, 92 % yield) as a film. 
























































 To a vial containing maleimide 5.13 (10.8 mg, 4.50 µmol, 1 eq.) was added a solution of 
thiol 5.9 (2.9 mg, 4.50 µmol, 1 eq.) in DMF (0.35 mL). To the resulting solution was added DIPEA 
(0.8 µL, 4.50 µmol, 1 eq.) at room temperature. The resulting solution was stirred at room 
temperature for 1.5 hours, at which point the reaction mixture was concentrated under reduced 
pressure. The resulting residue was purified by preparative TLC, eluting with 1:20 MeOH:CH2Cl2 
and washing with the same solvent mixture. The wash was concentrated to afford octreotide-iso-
fludelone conjugate 5.14 (5.6 mg, 1.9 µmol, 41% yield) as a film. 
HRMS (MALDI+) calculated for C145H232N14O47S4Na [M+Na+]: 3072.4975; found 3072.4971 
 
 To a solution of 5.14 (2.9 mg, 0.982 µmol, 1 eq.) in CH2Cl2 (0.25 mL) was added TFA (25 
µL). The resulting solution was stirred at room temperature for 20 minutes, at which point it was 
concentrated under reduced pressure to afford 5.15 (quantitative yield) as crude product. 






























































5.7.4 Preparation of 5.20 
 
 To a room temperature solution 5.6 (3.8 mg, 6.73 µmol) and cleavable linker 5.3 (5.0 mg, 
6.73 µmol) in DMF (0.25 mL) was added DIPEA (3.5 µL 20.2 µmol). The resulting mixture was 
stirred at room temperature for 24 hours. The mixture was concentrated under reduced pressure, 
and the resulting residue was purified by preparative TLC, eluting with 1:10 MeOH:CH2Cl2 to 
afford 5.16 as a white solid (5.5 mg, 4.73 µmol, 70%). 




















































































 To a solution of 5.16 (3.8 mg, 3.27 µmol) and NHS ester 5.17 (0.66 mg, 3.27 µmol) in 
DMF (0.25 mL) was added DIPEA (1.1 µL, 6.70 µmol). The resulting mixture was stirred at 
room temperature for 1.25 hours, then concentrated under reduced pressure. To the resulting 
residue was added a solution of Fmoc octreotide 5.18 (4.2 mg, 3.27 µmol) in DMF (0.3 mL), and 
the resulting mixture was stirred at room temperature for 12 hours. The mixture was 
concentrated under reduced pressure, and the resulting residue was purified by preparative TLC, 
eluting with 1:10 MeOH:CH2Cl2 to give 5.19 as a white solid (1.3 mg, 0.52 µmol, 18%). 












































































1) DIPEA, DMF, r.t., 1.25 h












 To a room temperature solution of 5.19 (1.3 mg, 0.52 µmol) in DMF (0.2 mL) was added 
piperidine (40 µL). The resulting mixture was stirred for 2 hours, then concentrated under 
reduced pressure to give crude product. The resulting residue was purified by preparative TLC, 
eluting with 1:5 MeOH:CH2Cl2 to give 5.20 as a film (0.8 mg, 67%). 



























































































5.7.5 Preparation of 5.23 
 
 To a vial containing amine 5.21 (7.0 mg, 11.6 µmol, 1 eq.) was added a solution of NHS 
ester 5.7 (2.89 mg, 11.6 µmol , 1 eq.) in CH2Cl2 (0.43 mL) at room temperature, followed by 
addition of TEA (1.6 µL, 11.6 µmol, 1 eq.). The resulting mixture was stirred at room temperature 
for 12 hours. The reaction mixture was concentrated, and the resulting residue was purified by 
silica gel chromatography, eluting with 1:20 → 1:10 MeOH:CH2Cl2 to afford disulfide 5.22 (5.2 
mg, 7.23 µmol, 62% yield) as a white solid. 
OR [α]D24 -25.9 (c 1.0, CHCl3)  
IR (thin film, cm-1) 3379, 2925, 2869, 1812, 1786, 1740, 1656, 1602, 1543, 1448, 1431, 1376, 
1319, 1248, 1205, 1168, 1112, 1066, 1001, 976, 950, 904, 809, 648 
1H NMR (400 MHz, CDCl3) δ 6.45 (t, J = 1.3 Hz, 1H), 6.17 (t, J = 7.4 Hz, 1H), 6.05 (d, J = 1.0 
Hz, 1H), 5.81 (s, 1H), 5.68 (dd, J = 15.7, 7.2 Hz, 1H), 5.58 – 5.46 (m, 1H), 5.43 (dd, J = 7.3, 3.7 
Hz, 1H), 4.29 (d, J = 6.2 Hz, 1H), 3.76 (s, 1H), 3.47 – 3.33 (m, 1H), 3.17 (dq, J = 11.9, 5.8 Hz, 
1H), 3.08 (ddd, J = 7.8, 6.5, 1.7 Hz, 2H), 3.05 – 2.91 (m, 4H), 2.90 – 2.75 (m, 2H), 2.69 (dt, J = 
15.9, 8.1 Hz, 1H), 2.57 (t, J = 7.1 Hz, 3H), 2.52 – 2.47 (m, 2H), 2.43 (s, 3H), 2.39 (s, 2H), 2.25 – 
2.12 (m, 1H), 2.06 (d, J = 1.3 Hz, 3H), 2.01 – 1.87 (m, 1H), 1.63 (s, 2H), 1.59 – 1.38 (m, 3H), 







































13C NMR (100 MHz, CDCl3) δ 216.70, 171.42, 170.12, 169.20 (d, J = 31.7 Hz), 159.86, 141.80, 
132.85, 130.96 (d, J = 27.9 Hz), 129.83, 127.88, 114.63, 102.39, 76.41, 74.07, 71.59, 53.34, 
50.80, 39.64 (d, J = 4.6 Hz), 38.58, 36.10, 32.90, 31.50, 31.32 (d, J = 5.9 Hz), 29.77, 28.93, 
27.39, 25.74, 23.52, 23.02, 21.70, 19.65, 18.75, 16.47, 12.36 






























































































































































































































































































































 To a solution of disulfide 5.22 (5.2 mg, 7.23 mmol, 1 eq.) in EtOAc (0.16 mL) and MeOH 
(0.16 mL) was added a solution of Cleland’s reagent (2 mg, 10.85 mmol, 1.5 eq.) in K3PO4 pH 7.5 
buffer (53 µL) at room temperature. The resulting solution was stirred at room temperature for 3 
hours, at which point complete conversion was observed. The reaction mixture was diluted with 
EtOAc (2 mL) and washed with sat. NH4Cl solution (2 mL). The layers were separated, and the 
aqueous layer was extracted with EtOAc (3 x 2 mL). The organic layers, were combined, dried 
over Na2SO4, and concentrated. The resulting residue was purified by preparative TLC, eluting 
with 1:20 MeOH:CH2Cl2, and the product-containing silica was washed with the same solvent 
mixture. The was concentrated to afford thiol 5.23 (4.1 mg, 6.09 µmol, 84% yield) as a film. 
OR [α]D18 -14.5 (c 1.0, CHCl3) 
IR (thin film, cm-1) 3371, 2924, 2854, 1736, 1652, 1602, 1547, 1146, 1379, 1319, 1249, 1169, 
1113, 1049, 979, 946, 798 
1H NMR (500 MHz, CDCl3) δ 6.50 – 6.41 (m, 1H), 6.17 (t, J = 7.4 Hz, 1H), 6.05 (d, J = 1.0 Hz, 
1H), 5.77 (s, 1H), 5.68 (dd, J = 15.7, 7.2 Hz, 1H), 5.56 – 5.48 (m, 1H), 5.43 (dd, J = 7.3, 3.7 Hz, 
1H), 4.30 (t, J = 6.3 Hz, 1H), 3.77 (s, 1H), 3.71 – 3.64 (m, 1H), 3.46 – 3.33 (m, 1H), 3.19 (dq, J 
= 11.8, 5.7 Hz, 1H), 3.09 (q, J = 5.9 Hz, 1H), 3.04 – 2.90 (m, 2H), 2.87 – 2.63 (m, 5H), 2.56 (d, J 






































18.1, 16.1, 5.1 Hz, 1H), 1.62 (t, J = 8.4 Hz, 1H), 1.59 – 1.40 (m, 4H), 1.27 (s, 4H), 1.14 – 1.06 
(m, 3H), 1.02 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 216.72, 171.26, 170.11, 169.37, 159.85, 141.76, 132.78, 129.81, 
127.88, 114.60, 102.37, 76.36, 74.04, 73.34, 71.59, 53.36, 50.79, 40.61, 39.63, 39.59, 38.53, 
31.18, 29.80, 28.90, 28.85, 27.38, 23.46, 21.76, 20.59, 19.57, 18.70, 16.46, 12.36 





























































































































































































































































































5.7.6 Preparation of 5.25 
 
 To a solution of maleimide 5.10 (1.9 mg, 1.42 µmol, 1 eq.) in DMF (0.15 mL) was added 
a solution of thiol 5.23 (1.2 mg, 1.85 µmol, 1.3 eq.) in DMF (0.15 mL) at room temperature. To 
the resulting solution was added DIPEA (1 µL, 1.42 µmol, 1 eq.), and the solution was stirred at 
room temperature for 40 min. The reaction mixture was concentrated under reduced pressure, and 
the resulting residue was purified by preparative HPLC, eluting with 1:20 MeOH:CH2Cl2 and 
washing with the same solvent mixture. The wash was concentrated to afford octreotide-epothilone 
B conjugate 5.24 (2.0 mg, 0.994 µmol, 70% yield) as a film. The product was carried to the next 




































 To a solution of octreotide-epothilone B conjugate 5.24 (2.0 mg, 0.994 µmol, 1 eq.) in 
CH2Cl2 (0.2 mL) was added TFA (0.1 mL) at room temperature. The resulting solution was stirred 
at room temperature for 30 minutes and then concentrated to afford octreotide-epothilone B 
conjugate 5.25 (quantitative yield) as crude product. 







































5.7.7 Preparation of 5.27 
 
 To a vial containing maleimide 5.13 (4.6 mg, 1.92 mmol, 1 eq.) was added a solution of 
thiol 5.23 (4.0 mg, 5.95 µmol, 3.10 eq.) in DMF (0.3 mL). To the resulting solution was added 
DIPEA (0.5 µL, 2.88 µmol, 1.5 eq.) at room temperature, and the mixture was stirred for 1 hour. 
The reaction mixture was concentrated under reduced pressure, and the resulting residue was 
purified by preparative TLC, eluting with 1:20 MeOH:CH2Cl2 and washing with the same solvent 
combination. The wash was concentrated to afford octreotide-iso-fludelone conjugate 5.26 (1.3 
mg, 0.424 mmol, 22% yield) as a film. 







































 To a solution of octreotide-iso-fludelone conjugate 5.26 (1.3 mg, 0.424 µmol, 1 eq.) in 
CH2Cl2 (0.2 mL) was added TFA (0.1 mL) at room temperature. The resulting solution was stirred 
at room temperature for 20 min., and then concentrated under reduced pressure to afford 
octreotide-iso-fludelone conjugate 5.27 (quantitative yield) as a crude product. 











































5.7.8. Preparation of 5.30 
 
 To a room temperature solution of 5.21 (3.2 mg, 5.47 µmol) and cleavable linker 5.3 (8.1 
mg, 10.95 µmol) in DMF (0.25 mL) was added TEA (1.5 µL 10.95 µmol). The resulting mixture 
was stirred at room temperature for 12 hours. The mixture was concentrated under reduced 
pressure, and the resulting residue was purified by preparative TLC, eluting with 1:10 
MeOH:CH2Cl2 to give 5.28 as a white solid (3 mg, 2.54 µmol, 46%). 
















































































 To a solution of 5.28 (3 mg, 2.54 µmol) and and NHS ester 5.17 (0.62 mg, 3.05 µmol) in 
DMF (0.25 mL) was added DIPEA (0.5 µL). The resulting mixture was stirred at room 
temperature for 20 minutes, then concentrated under reduced pressure. To the resulting residue 
was added a solution of Fmoc octreotide 5.18 (3.46 mg, 2.79 µmol) in DMF (0.25 mL), and the 
resulting mixture was stirred at room temperature for 12 hours. The mixture was concentrated 
under reduced pressure, and the resulting residue was purified by preparative TLC, eluting with 
1:10 MeOH:CH2Cl2 to give 5.29 as a white solid (2.5 mg, 0.99 µmol, 39%). 









































1) DIPEA, DMF, r.t., 20 min.












































 To a room temperature solution of 5.29 (2.5 mg, 0.99 µmol) in DMF (0.1 mL) was added 
piperidine (10 µL). The resulting mixture was stirred for 30 seconds, then concentrated under 
reduced pressure to give crude 5.30 as film (quantitative yield). The biological activity was 
evaluated without further purification.  

























































































5.7.9 Preparation of 5.36 
 
 A mixture of alcohol 5.31 (41 mg, 0,156 mmol), boronic ester 5.30 (125 mg, 0.375 mmol), 
K3PO4 (199 mg, 0.936 mmol), and Pd(PPh3)4 (18 mg, 0.0156 mmol) was dissolved in DMF (3 
ml), and stirred at 80 °C for 12 hours. The mixture was cooled to room temperature, and most of 
the DMF was removed under reduced pressure. The resulting residue was partitioned between 
EtOAc (20 mL) and H2O (10 mL), and the resulting aqueous layer was extracted with EtOAc (2 x 
5 mL). The organic extracts were combined, dried over Na2SO4, and concentrated. The resulting 
residue was purified by silica gel chromatography, eluting with 30:70 → 50:60 → 50:50 
EtOAc:hexanes to give 5.33 as a yellow oil (55 mg, 106 mmol, 61 %). 
IR (thin film, cm-1) 3340, 2977, 2930, 2246, 1912, 1687, 1600, 1511, 1452, 1390, 1365, 1273, 
1249, 1163, 1044, 1022, 909, 864, 817, 784, 730, 647, 616, 556, 497 
1H NMR (400 MHz, CDCl3) δ 7.68 (t, J = 1.7 Hz, 1H), 7.60 (d, J = 8.3 Hz, 4H), 7.55 (d, J = 1.7 
Hz, 2H), 7.36 (d, J = 7.9 Hz, 4H), 4.90 (s, 2H), 4.82 (s, 2H), 4.36 (d, J = 5.9 Hz, 4H), 2.00 (s, 
1H), 1.48 (s, 18H) 
13C NMR (126 MHz, CDCl3) δ 156.13, 142.35, 141.68, 140.04, 138.36, 128.00, 127.49, 125.11, 
124.66, 79.70, 65.17, 44.42, 28.52 




































































































































 To a 0 °C solution of PPh3 (91 mg, 0.347 mmol) in THF (0.75 mL) was added DIAD (70 
mg, 0.347 mmol) dropwise over 10 minutes. The resulting mixture was stirred at 0 °C for 20 
minutes, at which point AcSH (26 mg, 0.347 mmol) was added dropwise. To the resulting 
mixture was added dropwise a solution of 5.33 (45 mg, 0.0868 mmol) in THF (0.75 mL), 
followed by stirring at 0 °C for 1 hour and 1 hour at room temperature. The mixture was 
concentrated, and the resulting residue was purified by silica gel plug, washing with 1:20 
EtOAc:CH2Cl2 to give 5.34 as a yellow oil (28 mg, 0.0493 mmol, 56 %). 
IR (thin film, cm-1) 3352, 2976, 2929, 2248, 1914, 1688, 1598, 1509, 1451, 1412, 1390, 1365, 
1268, 1247, 1163, 1133, 1047, 1020, 954, 931, 910, 864, 816, 784, 729, 627, 556, 498, 465 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 2.1 Hz, 1H), 7.61 – 7.56 (m, 4H), 7.47 (d, J = 1.6 Hz, 
2H), 7.37 (d, J = 7.8 Hz, 4H), 4.87 (s, 2H), 4.37 (d, J = 5.9 Hz, 4H), 4.23 (s, 2H), 2.37 (s, 3H), 
1.48 (s, 18H) 
13C NMR (126 MHz, CDCl3) δ 195.15, 156.04, 141.94, 139.92, 138.88, 138.52, 128.07, 127.58, 
126.65, 125.07, 79.68, 44.49, 33.62, 30.49, 28.55 























































































































































 To a room temperature suspension of thioester 5.34 (25 mg, 0.433 mmol) in dioxane 
(0.25 mL) and water (0.25 mL) was added LiOH•H2O (4.8 mg). The reaction was stirred at room 
temperature for 3 hours, then neutralized with 5% citric acid, diluted with H2O (5 mL), and 
extracted with EtOAc (4 x 2 mL). The organic extracts were combined and, dried over Na2SO4, 
and concentrated. The resulting residue was purified by preparative TLC, eluting with 40:60 
EtOAc:hexanes, and washing with 50:50 EtOAc:hexanes to give 5.35 as a white solid (14.6 mg, 
0.0137 mmol, 63%). 
IR (thin film, cm-1) 3344, 2976, 2928, 2248, 1689, 1597, 1509, 1451, 1391, 1365, 1271, 1248, 
1162, 1047, 1020, 908, 864, 815, 784, 729, 646, 612, 556, 495, 465 
1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 1.8 Hz, 1H), 7.55 – 7.48 (m, 4H), 7.39 (d, J = 1.7 Hz, 
2H), 7.30 (d, J = 8.0 Hz, 4H), 5.13 (s, 2H), 4.35 (d, J = 6.1 Hz, 4H), 3.69 (s, 2H), 1.48 (s, 18H) 
13C NMR (126 MHz, CDCl3) δ 156.17, 141.74, 139.66, 138.64, 138.42, 127.97, 127.44, 127.15, 
125.10, 79.65, 44.37, 43.14, 28.58 







































































































































 To a solution of disulfide 5.35 (5 mg, 4.68 µmol) in 1:1 EtOAc:MeOH (1.75 mL) was 
added K3PO4 pH 7.5 buffer (290 µL) and Cleland’s reagent (0.72 mg, 5.68 µmol), and the 
resulting mixture was stirred at room temperature for 4 hours. Three additional 0.72 mg portions 
of Cleland’s reagent were added over this time period. The mixture was concentrated in vacuo 
and resususpended in EtOAc (7 mL). The mixture was washed with NH4Cl sat. solution (4 mL), 
and the resulting aqueous layer was extracted with EtOAc (2 x 3 mL). The organic extracts were 
combined, dried over Na2SO4, and concentrated. The resulting residue was purified by 
preparative TLC, eluting with 50:50 EtOAc:hexanes to give 5.36 as a white solid (4.1 mg, 2.81 
µL, 82%). 
IR (thin film, cm-1) 3346, 2976, 2928, 1690, 1597, 1510, 1452, 1391, 1365, 1270, 1248, 1164, 
1047, 1020, 932, 912, 864, 817, 783, 732, 646, 612, 556, 494 
1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 1.8 Hz, 1H), 7.62 – 7.57 (m, 4H), 7.51 (d, J = 1.7 Hz, 
2H), 7.37 (d, J = 7.8 Hz, 4H), 4.91 (s, 2H), 4.37 (d, J = 6.1 Hz, 4H), 3.86 (d, J = 7.6 Hz, 2H), 
1.86 (t, J = 7.6 Hz, 1H), 1.48 (s, 18H) 
13C NMR (126 MHz, CDCl3) δ 156.06, 142.33, 142.01, 140.03, 138.52, 128.10, 127.60, 125.94, 
124.89, 79.72, 44.52, 29.21, 28.57 





































































































































5.7.10 Preparation of 5.43 
 
 To a solution of 5.18 (2.2 mg, 1.77 µmol) and 5.1 (1.18 mg, 3.54 µmol) in DMF (0.3 mL) 
was added DIPEA (0.5 µL, 2.66 µmol). The resulting mixture was stirred for 12 hours, then 
concentrated under reduced pressure. The resulting residue was purified by preparative TLC 
(1:10) MeOH:CH2Cl2 to afford 5.37 (2.5 mg, 96%) as a film. 




























 To a room temperature solution of 5.37 (4 mg, 2.74 µmol) and thiol 5.36 (3 mg, 5.48 
µmmol) in DMF (0.4 mL) was added DIPEA (0.5 µL, 2.74 µmol). The resulting solution was 
stirred at room temperature for 1 hour, then concentrated under reduced pressure. The resulting 
residue was purified by preparative TLC, eluting with 1:12 MeOH:CH2Cl2 to give 5.38 as a film 
(2.7 mg, 1.35 µmol, 49%). 




































 To a room temperature solution of 5.38 (2.7 mg, 1.35 µmol) in CH2Cl2 (0.25 mL) was 
added TFA (25 µL). The resulting mixture was stirred at room temperature for 20 minutes, then 
concentrated under reduced pressure. The resulting product 5.39 was carried through to the next 
step without further purification. 



































 To a room temperature solution of 5.39 (1.35 µmol) and 5.40 (4.7 mg, 5.40 µmol) in 
DMF (0.3 mL) was added DIPEA (0.7 µL, 4.05 µmol). The resulting solution was stirred at 
room temperature for 12 hours. The mixture was concentrated under reduced pressure, and the 
resulting residue was purified by preparative TLC, eluting with 1:8 MeOH:CH2Cl2 to give 5.41 
as a film (3 mg, 0.910 µmol, 67%). 































































 To a room temperature solution of 5.41 (12.21 mg, 3.70 µmol) and DM1 (6.01 mg, 8.14 
µmol) in DMF (0.36 mL) was added DIPEA (1.3 µL, 7.40 µmol). The resulting mixture was 
stirred at room temperature for 3 hours, then concentrated under reduced pressure. The resulting 
residue was purified by preparative TLC, eluting with 1:10 MeOH:CH2Cl2 to give 5.42 as a film 
(8 mg, 1.68 µmol, 45%). 














































































 To a room temperature solution of 5.42 (8 mg, 1.68 µmol) in DMF (0.3 mL) was added 
piperidine (15 µL). The resulting solution was stirred at room temperature for 20 min, then 
concentrated under reduced pressure. The resulting was product 5.43 (quantitative yield) was 
evaluated without further purification. 
















































































5.7.11 Preparation of 5.4 
 
 To a mixture of NiCl2•6H2O (19 mg, 0.0800 mmol, 5 mol%) and CuI (15 mg, 0.790 mmol, 
5 mol%) suspended in THF (1.1 mL) was added TMEDA (48 µL, 0.32 mmol, 0.2 eq.), and the 
resulting mixture was stirred at room temperature for 2 minutes. To the mixture was added 
phenylacetylene (0.145 mL, 1.32 mmol, 5 eq.), followed immediately by addition of ester 5.44 (46 
mg, 0.264 mmol, 1 eq.). The resulting mixture was capped and stirred under ambient atmosphere 
at room temperature for 12 hours. The reaction mixture was concentrated, and the resulting residue 
was purified by silica gel plug, eluting with 10:90 EtOAc:hexanes to afford ester 5.45 (32 mg, 
0.117 mmol, 44%) as a white solid. 
IR (thin film, cm-1) 2950, 2921, 2850, 2215, 2146, 1736, 1596, 1509, 1488, 1436, 1414, 1338, 
1300, 1254, 1222, 1158, 1069, 1016, 917, 896, 840, 817, 756, 689, 583, 529 
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.51 (m, 2H), 7.49 (d, J = 8.2 Hz, 2H), 7.40 – 7.31 (m, 
3H), 7.26 (d, 2H), 3.70 (s, 3H), 3.64 (s, 2H) 
13C NMR (100 MHz, CDCl3) δ 171.52, 135.38, 132.84, 132.65, 129.59, 129.36, 128.58, 121.93, 
120.82, 81.76, 81.42, 74.22, 74.06, 52.32, 41.24 

























































































































 To a solution of ester 5.45 (32 mg, 0.117 mmol, 1 eq.) in THF (0.140 mL) and MeOH 
(0.140 mL) was added.a 1 M solution of NaOH in H2O (131 µL). The resulting mixture was stirred 
at room temperature for 12 hours. The reaction mixture was acidified to pH 1 with 1 N HCl, and 
the resulting precipitate was collected by vacuum filtration and dried under high vacuum overnight 
at 35 °C to afford carboxylic acid 5.46 (15.5 mg, 0.0595 mmol, 51% yield) as a reddish solid. 
IR (thin film, cm-1) 3849, 3034, 2923, 2853, 2734, 2654, 2558, 2146, 1713, 1510, 1487, 1441, 
1407, 1336, 1240, 1197, 1107, 1069, 1022, 908, 858, 816, 756, 734, 687, 676, 645, 531 
1H NMR (400 MHz, CDCl3) δ 7.59 – 7.44 (m, 4H), 7.42 – 7.30 (m, 3H), 7.30 – 7.21 (m, 2H), 
3.67 (s, 2H) 
13C NMR (100 MHz, CDCl3) δ 176.87, 134.54, 132.89, 132.66, 129.71, 129.39, 128.59, 121.89, 
121.12, 81.84, 81.28, 74.35, 74.01, 41.00 













































































































 To a 0 °C solution of acid 5.46 (10.7 mg, 0.0411 mmol), N-hydroxysuccinimide (6 mg, 
0.0993 mmol), and DMAP (one crystal) in DMF (0.3 mL) was added EDCI (8 mg, 0.0493 mmol). 
The resulting solution was stirred at 0 °C for 2 hours, then warmed to room temperature and stirred 
for 12 hours. The mixture was concentrated under reduced pressure, and the resulting residue was 
purified by silica gel chromatography, eluting with 30:70 → 50:50 EtOAc:hexanes to give 5.4 (9.1 
mg, 0.035 mmol, 85% yield) as an off-white solid. 
IR (thin film, cm-1) 2925, 2853, 2216, 2147, 1814, 1785, 1737, 1569, 1511, 1489, 1441, 1427, 
1414, 1362, 1297, 1205, 1069, 1021, 993, 898, 842, 819, 757, 689, 646, 594, 557, 528 
1H NMR (500 MHz, CDCl3) δ 7.57 – 7.48 (m, 4H), 7.42 – 7.29 (m, 5H), 3.95 (s, 2H), 3.08 – 
2.63 (m, 4H) 
13C NMR (126 MHz, CDCl3) δ 169.00, 166.37, 133.07, 132.67, 132.63, 129.60, 129.41, 128.59, 
121.85, 121.61, 81.94, 81.10, 74.58, 73.96, 37.68, 25.72 




























































































































5.7.12 Preparation of 5.49 
 
 To a mixture of 5.47 (2.3 mg, 6.44 µmol) and 5.18 (4 mg, 3.22 µmol) was added DMF 
(0.25 mL). The resulting mixture was stirred for 12 hours, then concentrated under reduced 
pressure. The resulting residue was purified by preparative TLC, eluting with 1:10 
MeOH:CH2Cl2 to afford 5.48 (3.1 mg, 2.09, 65%) as a film. 
HRMS (MALDI+) calculated for C82H86N10O13S2Na [M+Na]+: 1505.5715; found 1505.7249 
 
 
To a solution of 5.48 (3.1 mg, 2.09 µmol) in DMF (0.2 mL) was added piperidine (20 µL). 
The resulting mixture was stirred for 1 minute, then concentrated under reduced pressure to afford 
crude 5.49 (quantitative yield). 
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